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Abstract 
 
Targeting beta Amyloid (Aβ) peptide, in relation to the degenerative processes of 
Alzheimer Disease (AD), and studying the mechanisms of Aβ misfolding, 
oligomerization and aggregation are currently two hot-topics in AD research. Both these 
aspects can be preferentially approached by the use of anti-Aβ antibodies, in particular of 
those which are conformation specific, as demonstrated by in vitro studies and by in vivo 
immunotherapy. 
Here, we describe the generation of a large panel of anti-Aβ scFvs recombinant 
antibodies, exploiting a novel in vivo, yeast two hybrid-based, approach developed in our 
laboratory: the “Intracellular Antibody Capture Technology” (IACT). In this way, we 
have selected and characterized a panel of 18 different anti-Aβ scFvs, which show 
interesting features in vitro and in cells. 
IACT-selected anti-Aβ scFvs are conformation specific versus Aβ oligomers and show 
peculiar immunoreactivity pattern versus the in vivo produced Aβ deposits in human AD 
brains. Moreover, our anti-Aβ scFvs, being in vivo selected in the yeast cytoplasm, can be 
readily expressed as intracellular antibodies in mammalian cells, targeted to different 
cellular compartments, allowing new promising strategies to study the emerging role of 
intracellular Aβ processing and oligomerization in AD pathology.  
The panel of IACT-selected scFvs under study represents a new tool in the survey of 
existing anti-Aβ antibodies, and the unique characteristics of the selection strategy used 
for their isolation appear to be particularly suited for the selection of oligomeric specific 
anti-Aβ antibodies. Furthermore, the recombinant nature of the antibodies makes them 
ideally suited for extracellular and for intracellular delivery, in vitro as well as in vivo.  
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1. Alzheimer’s Disease and Beta Amyolid peptide 
  
1.1 Alzheimer’s Disease: a Protein Misfolding Disorder 
In several neurological and systemic disorders, specific proteins can accumulate within 
cells and tissues as a result of changes in protein conformation (misfolding) that render 
the molecules prone to self-aggregation and resistant to clearance. These conformational 
diseases, or Protein Misfolding Disorders (PMDs), comprise systemic amyloidoses, in 
addition to neurodegenerative conditions that are marked by the buildup of characteristic 
proteins in the brain, such as Alzheimer’s disease (AD), Parkinson’s disease (PD), 
Huntington’s disease (HD), and prion diseases. (Walker, 2006) 
Although the proteins involved in different PMDs do not share sequence or structural 
identity, all of them can adopt at least two different conformations without requiring 
changes in their amino acid sequence. The misfolded form of the protein usually contains 
stacks of β sheets organized in a polymeric arrangement known as a ‘cross-β’ structure. 
Because β-sheets can be stabilized by intermolecular interactions, misfolded proteins 
have a high tendency to form oligomers and larger polymers. 
Two main mechanisms of AD pathology are based on the involvement of two 
aggregation-prone proteins: amyloid-β (Aβ) and tau. Αβ is the main constituent of senile 
plaques, one of the key pathological characteristics of AD. Tau, a microtubule-associated 
protein, is the main component of neurofibrillary tangles, the other hallmark lesion of 
AD. 
Plaques and tangles in AD pathology are present mainly in brain regions involved in 
learning and memory and emotional behaviours such as the entorhinal cortex, 
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hippocampus, basal forebrain and amygdala. Brain regions with plaques typically exhibit 
reduced numbers of synapses, and damaged neurites of cholinergic and glutamatergic 
neurons.  
The accumulation of misfolded proteins is also a hallmark of ageing; as cells age they 
lose their ability to correct the misfolding through chaperone proteins and the “stress 
response” machinery. So neurodegenerative diseases, such as AD and PD, may be 
considered a manifestation of ageing, with mutations in particular gene products 
accelerating the process. In addition, as with other age-related diseases, there are likely to 
be behavioural, dietary and other environmental factors that may affect the risk of AD. 
Currently, it is estimated that 50% of people older than age 85 years are afflicted with 
AD. The risk of AD, the most common cause of dementia today, dramatically increases 
in individuals beyond the age of 70 and it is predicted that the incidence of AD will 
increase threefold within the next 50 years. 
The vast majority of cases of AD are sporadic - they do not run in families. Nevertheless, 
molecular genetic analyses suggest that there are likely to be many genes that influence 
one’s susceptibility to AD; these genes are primarily related to the ‘metabolism’ of Aβ 
peptide, as, for instance, the genes coding for Amyloid Precursor Protein, Presenilin1 and 
2, Apolipoprotein E (Mattson, 2004). 
 
1.2 Beta Amyloid in Alzheimer’s Disease 
In the 1980s, biochemists focused on the isolation of the amyloid deposits from AD 
brains to identify its principal component. Glenner and Wong purified microvascular 
amyloid deposits from the meninges of AD brains and provided a partial sequence of a 
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protein of ~4-kDa that they named amyloid β-protein (Aβ). Shortly thereafter, Masters, 
Beyreuther and co-workers identified the same protein as the subunit of amyloid plaque 
cores that were isolated from post-mortem AD cortices. 
Numerous pieces of evidence indicate that Aβ is the principal misfolded protein involved 
in AD pathogenesis, leading to the formulation of the following ‘Aβ hypothesis’: a 
chronic imbalance between the production and clearance of this small hydrophobic 
peptide with a tendency to misfold and aggregate leads gradually to synaptic and neuritic 
compromise and glial activation (Selkoe 1991, Hardy 1992, Hardy & Selkoe 2002, 
Selkoe 2004). 
 
1.3 Aβ generation: the processing of Amyloid Precursor Protein (APP) 
Aβ is generated by proteolytic processing of β-amyloid precursor protein (APP), through 
sequential cleavages by β-secretase and γ-secretase.  
APP is an extremely complex protein that may be a functionally important molecule in its 
full-length configuration, as well as being the source of numerous fragments with varying 
effects on neural function.  
APP is a single transmembrane polypeptide that is cotranslationally translocated into the 
endoplasmic reticulum and then posttranslationally modified (“matured”) through the 
secretory pathway. Both during and after the trafficking of APP through the secretory 
pathway, it can undergo a variety of proteolytic cleavages to release secreted derivatives 
into vesicle lumens and the extracellular space (Selkoe, 2001). 
The processing of APP at the cell surface is one example of a general physiological 
mechanism now known as “regulated intramembrane proteolysis” (RIP). Aβ is released 
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from APP through sequential cleavages by β-secretase (also called BACE-1), a 
membrane-spanning aspartyl protease with its active site in the lumen, and γ-secretase, an 
unusual intramembrane aspartyl protease containing presenilin at its catalytic site 
complexed with three other membrane proteins, nicastrin, Aph-1 and Pen-2 (fig.1). 
 
 
 
Fig. 1. Regulated Intramembrane Proteolisis (RIP) of APP (from Haass & Selkoe, 2007) 
 
The γ-cleavage is variable and occurs after Aβ amino acids 38, 40 or 42 (Fig.1 and fig.2). 
The precise sites of these γ-cleavages have an important influence on the self-aggregating 
potential and resulting pathogenicity of Aβ, as the Aβ42 peptide has a strong propensity 
to oligomerize in vivo. 
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Fig.2 Cleavage sites on the ‘Aβ-generating’ region of APP (from Selkoe, Nat Cell Biol 
2004) 
 
As mentioned above, during its trafficking through the secretory pathway, APP can 
undergo proteolytic cleavages, and Aβ can be produced at multiple intracellular sites. In 
neurons, APP undergoes fast anterograde transport to nerve terminals (Koo et al., 1990; 
Ferreira et al., 1993; Buxbaum et al., 1998), and is metabolized within axonal or 
presynaptic vesicles into Aβ peptides that are released and deposited as amyloid plaques 
around nerve terminals (Lazarov et al., 2002; Sheng et al., 2002). Furthermore, synaptic 
activity increases Aβ secretion, indicating that the presynaptic terminal is an important 
regulatory site for Aβ generation (Kamenetz et al., 2003; Cirrito et al., 2005). Thus, the 
axonal/synaptic fractions of APP appear particularly important in the generation of Aβ 
species that are ultimately deposited in amyloid plaques. However, Lee E.B. and 
coworkers (2005) highlight the importance of perikaryal versus axonal APP proteolysis 
in the development of Aβ amyloid pathology in AD (Lee et al., 2005). 
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1.4 Interactions between the cholinergic system, neurotrophins and APP metabolism 
The regulation of APP metabolism is a very complex process modulated by a lot of 
mechanisms, most of which are under investigation including cholinergic mechanisms 
and neurotrophin receptor signaling (Fig.3).  
The deprivation of Neurotrophic Growth Factor (NGF) leads to the formation and 
deposition of Aβ in AD11 mice (Capsoni et al, 2000, 2002), as well as to the activation of 
the amyloidogenic pathway with overproduction and accumulation of Aβ in PC12 
differentiated cells (Matrone et al, submitted paper), suggesting a direct link between 
NGF signaling and abnormal APP processing.  
APP expression and processing have been shown to be under the direct regulatory control 
of NGF, via independent and potentially conflicting signaling through p75 and TrkA 
receptors (Roßner, et al., 1998). Thus, an imbalance in this two-receptor system (Chao 
and Hempstead, 1995), determined by a variety of different causes, may have direct 
effects on APP processing and on the homeostatic mechanisms regulating hippocampal 
and cortical NGF, APP, and cholinergic activity. 
 15
 
 
Fig.3 Interactions between the cholinergic system, neurotrophins and amyloid precursor 
protein metabolism. 
Cholinergic neurons of the basal forebrain are vulnerable to amyloid toxicity. Lack of 
stimulation of M1/M3 mAChR in neocortical cholinoceptive target areas or impaired 
mAChR signaling may favor the amyloidogenic pathway of APP processing. NGF plays 
a role in maintaining cholinergic function, but also controls expression and processing of 
APP (from Roßner, et al., 1998). 
 
 
1.5 Aβ aggregation 
The misfolded Aβ usually contains stacks of β sheets organized in an arrangement known 
as a ‘cross-β’ structure. Because β-sheets can be stabilized by intermolecular interactions, 
Aβ have a high tendency to form oligomers and larger polymers (Soto, 2006). 
It has been demonstrated by a number of studies that both synthetic Aβ and its analogs, 
and also isolated senile plaque proteins, spontaneously assemble into amyloid protofibrils 
and fibrils exhibiting a β-pleated sheet conformation consistent with native AD amyloid-
β-proteins (Antzutkin, 2004). 
The pathway of aggregation, extending from Aβ monomers, to Aβ oligomers and finally 
to Aβ fibrils, can be studied using several experimental methods: nuclear magnetic 
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resonance (NMR) spectroscopy, circular dichroism (CD) spectroscopy, transmission 
electron microscopy (TEM), Atomic Force Microscopy (AFM) (Antzutkin, 2004). 
Petkova and coworkers (2002) showed a structural model for amyloid fibrils of Aβ1-40 
peptide, based on a set of experimental constraints from solid state NMR spectroscopy 
(fig.4). 
Approximately the first 10 residues of Aβ1–40 are structurally disordered in the fibrils. 
The monomer unit has a hairpin geometry with two anti-parallel β-strands. Residues 12–
24 and 30–40 adopt β-strand conformations and form parallel β-sheets through 
intermolecular hydrogen bonding. Residues 25–29 contain a bend of the peptide 
backbone that brings the two β-sheets in contact through sidechain-sidechain interactions. 
A single cross-β unit is then a double-layered β-sheet structure with a hydrophobic core 
and one hydrophobic face. The only charged sidechains in the core are those of D23 and 
K28, which form salt bridges. Fibrils with minimum mass-per-length and diameter 
consist of two cross-β units with their hydrophobic faces juxtaposed. 
 
  
Fig.4 Structural model for Aβ1–40 fibrils, consistent with solid state NMR constraints on 
the molecular conformation and intermolecular distances and incorporating the cross-β 
motif common to all amyloid fibrils (a). Detail of the monomeric unit (b). Residues 1–8 
are considered fully disordered and are omitted. Residues are color-coded according to 
their sidechains as hydrophobic (green), polar (magenta), positive (blue), or negative 
(red). (from Petkova et al., 2002) 
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Recently, Mastrangelo and coworkers (2006) investigating the formation and structure of 
earliest formed oligomers of Aβ42 using the high resolution AFM, suggest different 
possible structures (fig.5), sharing with other models the hairpin structure of monomeric 
unit. 
 
 
Fig.5 A model showing the sequence of assembly and possible structures of Aβ42 
monomers, low molecular weight (LMM) oligomers, high molecular weight (HMM) 
oligomers, unit-protofibrils, and protofibrils/fibrils (from Mastrangelo et al., 2006) 
 
 
It is evident that Aβ40 and Aβ42 peptides form in vitro, but reasonably also in vivo, a 
variety of structures, including multiple monomer conformers, different types of 
oligomers, protofibrils and  fibrils. 
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1.6 Aβ oligomers 
A large and confusing body of literature describes many types of intermediate oligomeric 
forms of synthetic and natural Aβ, including protofibrils (PFs), annular structures, 
paranuclei, Aβ-derived diffusible ligands (ADDLs), globulomers (Haass & Selkoe, 
2007). 
Some different types of recognized Aβ oligomers are summarized in the following table: 
 
 
from Haass & Selkoe, Nat. Mol.Cell Biol. 2007 
 
A critical question is whether soluble oligomers are transient or relative stable structures, 
and if they represent only intermediate building blocks in the assembly of the mature 
fibrils. Stable oligomeric aggregates of Aβ can exist in vivo, as demonstrated by the 
isolation of Aβ*56 (probably a dodecamer of Aβ) from brains of APP transgenic mice 
Tg2576 (Lesnè et al., 2006). Moreover, Stine and coworkers (2003) have characterized 
chemical-physical conditions in vitro (time, concentration, temperature, pH, ionic 
strength) able to influence selectivily the aggregation of Aβ monomers in oligomers or 
fibrils. Finally, the oligomeric and mature fibrillar structures are distinct on the basis of 
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their mutually exclusive reactivity towards antibodies specific for generic fibrils and 
oligomer conformations (Kayed et al., 2003; Glabe, 2004). 
1.7 Soluble oligomers in AD pathogenesis 
 
Prior to the last decade, insoluble Aβ fibrils were considered the aggregated species with 
a significant role in the pathogenesis of AD. Over the last years, an increasing body of 
evidence has been produced, that supports a fundamental shift in our view of the 
pathogenic mechanism of AD. The original ‘Aβ hypothesis’ shifted essentially in ‘Aβ 
synaptic hypothesis’, attaching importance to soluble oligomers targeting the synapses.  
Synaptic dysfunction occurs early in Alzheimer’s Disease (AD) and is considered the 
best pathological correlate of cognitive decline (Masliah et al., 2001). Recent studies 
suggest that Aβ oligomers are the most synaptotoxic Aβ species in the human brain 
(Gong et al., 2003), and in transgenic mice AD models (Klyubin et al, 2005; Lesnè et al, 
2006). Soluble oligomers correlate much better with the presence and degree of cognitive 
deficits than do simple plaque counts. However, it must also be pointed out that the large 
plaques areas of fibrillar Aβ, often intimately surrounded by a number of smaller 
assemblies (probably oligomers), in AD brains typically show dystrophic neurites, 
indicating that insoluble aggregates might contribute to neuronal injury. At the current 
stage of research, one should not conclude that either large, insoluble deposits or small, 
soluble oligomers represent the sole neurotoxic entity; indeed, a continuous dynamic 
exchange between these forms might well be detrimental (Haass & Selkoe, 2007). 
In vitro studies have demonstrated differential mechanisms of toxicity mediated by Aβ 
fibrils or by Aβ oligomers. The latter (in a concentration range of nM) cause a fast and 
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massive toxic effect, whereas Aβ fibrils (in a range of μM) induce progressive dystrophy 
and modest cell death in human cortical neurons (Desphande et al, 2006).  
Several lines of evidence suggest that Aβ oligomers (both natural and synthetic) can 
inhibit the maintenance of hippocampal Long Term Potentiation (LTP), altering memory 
function, by both in vivo microinjection in living rats (Walsh et al., 2002) and by 
treatment of hippocampal slices (Towsend et al., 2006). In addition, the effects of the 
natural oligomers on LTP are specifically neutralized by anti-Aβ antibodies in vivo, either 
through active vaccination or passive infusion (Klyubin et al., 2005). 
The biochemical mechanism by which soluble oligomers bind to synaptic plasma-
membranes and interfere with the complex system of receptor and/or channel proteins 
and signalling pathways that are required for synaptic plasticity is under intensive study. 
Recent studies show that Aβ oligomers bind to NMDA receptors triggering reactive 
oxygen species (ROS) production (De Felice et al., 2007) and spine density reduction 
(Lacor et al., 2007). Shankar and coworkers (2007) have observed also the involvement 
of NMDA receptors in the induction of reversible synapse loss mediated by natural 
oligomers.  
Other evidences suggest that Aβ oligomers can physically intercalate into and penetrate 
membranes, leading to permeabilization; the concomitant increase in intracellular 
calcium may be the proximate initiator of several pathogenic pathways, including 
reactive oxygen species (ROS) production, altered signaling pathways and mitochondrial 
dysfunction (Glabe et al., 2006). 
In conclusion, the involvement of Aβ oligomers in AD pathogenesis is under intense 
investigation suggesting that early-stages of the disease might be due to specific impact 
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on the signaling biochemistry required for synaptic plasticity. If so, new treatments such 
as oligomers-targeting drugs may not only stop AD’s inexorable course, but may actually 
reverse the dysfunction in mild cognitive impairment and early-stage AD. 
 
1.8 Intracellular oligomerization 
As discussed above, Aβ peptide can be produced intracellularly in different sites. 
Increasing evidence supports also the role of intracellular Aβ oligomerization and 
accumulation as an early event in AD pathogenesis in humans and in transgenic mice. 
Accumulation of Aβ42, occurs intracellularly in AD (Gouras et al., 2000; D’Andrea et 
al., 2001) and in transgenic mice that develop Aβ plaques (Oddo et al., 2003; Sheng et al., 
2003). In Tg2576 (mice harboring the Swedish mutant human APP (Hsiao et al.,1996)) 
and human AD brain, but also in aged cultured Tg2576 primary neurons, accumulation of 
Aβ42 oligomers within neuronal processes and synaptic profiles is associated with 
pathological alterations and with synaptic degeneration (Takahashi et al., 2004). 
Finally, the reduction of intracellular Aβ in triple transgenic mice by passive 
immunization (Oddo et al., 2004) was the best correlate of their cognitive improvement 
(Billings et al., 2004). 
To conclude, synaptic alterations can be induced by extracellular as well as by 
intracellular Aβ oligomers. Increasing evidence supports an as yet poorly understood 
dynamic relationship between extracellular and intracellular Aβ, modulation of which 
might be especially important also in Aβ antibody induced therapeutic effects (Oddo et 
al, Am J Pathol 2006). 
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2. Targeting Beta Amyloid through antibodies 
 
2.1 Targeting Aβ pathological assemblies through antibodies: from in vitro studies to 
in vivo applications 
Antibodies (Abs) are an important tool for analyzing protein misfolding and aggregation, 
as well as for targeting degenerative processes that are caused by protein misfolding.  
Several in vitro studies showed that monoclonal antibodies (MAbs), raised against the N-
terminal of Aβ, can inhibit synthetic Aβ fibrillogenesis and can even disrupt pre-existing 
fibrils. In addition, the disassembly of fibrils is accompanied by strongly reduced 
neurotoxicity in culture (Solomon, 1996, 1997; Frenkel, 1998, 1999). Moreover, also 
several anti-Aβ single-chain Fv (scFv) antibody fragments, developed from phage display 
libraries (Liu et al., 2004) or from MAbs, exhibit anti-aggregating properties and prevent 
the toxic effect of Aβ fibrillar aggregates (Frenkel et al., 2000).  
The anti-Aβ MAb ‘m266.2’ directed against amino acid residues 13–28 has been shown 
to act as an Aβ “sink” in an in vitro dialysis system; when administered peripherally into 
PDAPP transgenic mice, ‘m266.2’ promotes clearance of Aβ via the plasma and prevents 
Aβ plaque accumulation, acting also in vivo as a “peripheral sink” (DeMattos et al., 2001, 
2002). Another MAb directed against the N terminus (amino acid residues 1–5) of Aβ, 
‘m3D6’, has also been shown to decrease Aβ deposition when administered parenterally 
(Bard et al., 2000). 
Recent in vitro studies suggested a new mechanism of action of anti-Aβ antibodies (N-
terminal and mid-domain specific) through cell membrane surface binding, at the 
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extracellular Aβ-domain of APP, reducing intracellular Aβ and protecting against 
synaptic alterations in APP mutant (Tg2576) neurons (Tampellini et al., 2007).  
 
The identification of conformational epitopes in Aβ fibrils and in Aβ oligomers in recent 
studies gives uniqueness to the antibody-approach in Aβ targeting studies. Early 
experiments with rabbit polyclonal sera suggested that amyloid fibrils possess a non-
native structure and that antibodies can be generated that are specific for the 
amyloidogenic conformation (Linke et al., 1973). Recently, a new class of antibodies 
associated with a fundamental amyloid-folding motif recognizing common 
conformational epitopes independently of aminoacid sequence, has been specifically 
elaborated against fibrils (O’Nuallain & Wetzel, 2002) and against oligomers (Kayed et 
al, 2003). Subsequently, both monoclonal (Lambert et al., 2006) and polyclonal (Lambert 
et al., 2003; Barghorn et al., 2005) anti-Aβ oligomer antibodies have been specifically 
developed.  
Significantly, anti-oligomer antibodies have been found to block the toxicity when tested 
in vitro (Kayed et al., 2003; Lambert et al., 2003, 2006) but also in vivo (Barghorn et al., 
2005). Oddo and colleagues found that passive immunization prevented tau pathology but 
did not affect phosphorylated tau aggregates that existed prior to antibody treatment 
(Oddo et al., 2006 a, b).  
In conclusion, in vitro and in vivo studies show that the relevance of the antibody-
approach to target Aβ pathological assemblies, in particular Aβ oligomers.  
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2.2 Immunotherapy 
Immunotherapy is a new and promising approach for AD treatment, through either active 
Aβ-peptide vaccination or passive infusion of anti-Aβ monoclonal antibodies, attempting 
to target the toxic forms of Aβ directly without perturbing the enzymatic activities of the 
secretases (classic targets of actual pharmacological therapy, through secretases 
inhibitors), which process many important substrates.   
Active immunization 
Improvements in pathology and cognition in mouse models of AD after treatment with 
Aβ1–42 (Schenk et al., 1999) and Aβ1–40 (Lemere et al., 2000; Weiner et al., 2000), 
together with the observed safety characteristics in a broad range of animal species, led to 
the initiation of Phase 1 and Phase 2 clinical studies in AD patients. Unfortunately, the 
Phase 2 clinical trial of an Aβ1–42 vaccine (using aggregated Aβ1–42 (AN1792) in 
combination with QS21 adjuvant) in AD patients was associated with the development of 
a T-cell-mediated (Nicoll et al., 2003; Ferrer et al., 2004), autoimmune 
meningoencephalitis in 6% of patients, leading to cessation of dosing. Despite this self-
limited reaction, patients who subsequently developed anti-Aβ antibodies had reduced 
cerebrospinal levels of tau and showed a slower cognitive decline (Gilman et al., 2005; 
Masliah et al., 2005). 
T-cell infiltrates were present in the brains of two patients with encephalitis, suggesting a 
T-cell-mediated immune response as a reason for the adverse events (Nicoll et al., 2003; 
Ferrer et al., 2004). 
Active immunization induces both a humoral (antibody mediated) and cellular immune 
response (via T lymphocytes). After immunization with Aβ, the peptide is processed by 
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antigen-presenting cells in the periphery and then presented to T and B cells. Epitope 
mapping of these events following Aβ immunization in AD patients indicates that the 
predominant T-cell epitopes are in the carboxyl terminus of Aβ. By contrast, most of the 
B-cell or antibody producing epitopes detected from immunized patients reside in the 
amino-terminal region of the peptide (Schenk, 2004).  
Also in mice (Lemere et al., 2000; Town et al., 2001; McLaurin et al., 2002; Cribbs et al., 
2003) and in monkeys (Lemere et al., 2004), the majority of anti-Aβ antibodies 
generated, from active Aβ immunization, recognize an epitope located within the amino 
terminus of Aβ protein (e.g., Aβ1–15).  
These observations have been used to design alternative immunogens, which encompass 
the N-terminal antibody epitope of Aβ  but lack the more C-terminal T-cell reactive sites 
for immunization in AD animal models. Such shorter Aβ fragments have been shown to 
lead to an immune response when conjugated to T-helper (Th) cell epitopes (Monsonego 
et al., 2001) and/or have been used on a branched peptide framework (Agadjanyan et al., 
2005). Recently, Maier and coworkers (2006) demonstrated that four alternative Aβ 1–
15-containing immunogens reduce cerebral Aβ load and learning deficits in J20 mouse, 
an AD model (hAPPFAD), in the absence of an Aβ-specific cellular immune response. 
Interestingly, Moretto and coworkers (2007) found that conformation-sensitive antibodies 
against Aβ (recognizing preferentially oligomers and fibrils, but not monomers) are 
elicited by immunization with a thioredoxin-constrained-Aβ1-15.  
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Passive immunization 
Passive immunization eliminate a cellular response to Aβ. In AD mouse models, 
peripheral injection of Aβ-specific antibodies reduced cerebral Aβ levels (Bard et al., 
2000; DeMattos et al., 2001) and improved cognitive function (Dodart et al., 2002); anti-
Aβ antibodies are also in clinical trial in humans (Schenk, 2004; Morgan, 2006). 
Proposed mechanisms of action for anti-Aβ immunotherapy include local microglia-
mediated plaque phagocytosis (through an Fc receptor-mediated mechanism), systemic 
sequestration of Aβ in plasma that results in its efflux from the brain (peripheral sink) 
and/or the inhibition of Aβ oligomerization and cytotoxicity. 
Interestingly, Bacskai and coworkers (2002) found a plaque clearance by a direct 
administration to the brains of APP transgenic mice, not only of anti-Aβ antibodies but 
also of Fab fragments, raising questions as to whether Fc receptor-mediated phagocytosis 
was required for plaque clearance, as originally reported. Wilcock and coworkers (2003), 
have demonstrated a two-phase mechanism of anti-Aβ antibody-mediated plaque 
clearance: the first phase is fairly rapid and involves clearance of diffuse Aβ without 
microglial activation; the second is slower, involving clearance of compact Aβ through 
activation of microglial Fc receptors and phagocytosis of pre-existing plaques.  
Fukuchi (2006) and Levites (2006) have recently tested a novel gene therapy modality 
where adeno-associated virus (AAV) encoding anti-Aβ single-chain antibodies (scFvs) 
are intracranial injected of AD mouse models. AD mouse models subjected to AAV 
injection showed a significant reduction of amyloid deposits. Because the scFv lacks the 
Fc portion of the immunoglobulin molecule, this modality may be a feasible solution for 
 27
AD without eliciting inflammation, and possibly confirming the mechanism non-Fc 
receptor mediated. 
 
 
3. From recombinant antibodies to their in vivo selection  
 
3.1 Recombinant antibodies 
Recombinant DNA technology and antibody engineering have supplemented, and in 
some instances, replaced hybridoma technology in the production of antibodies (Hudson 
and Souriau, 2001). Antibody genes from animals can be amplified by PCR and 
expressed in different expression systems in various formats, such as the Fab, Fv, single 
domain (VH), single chain Fv (scFv) and the variable fragment (VHH) of single-domain 
heavy chain antibodies (HCAb) from camelids (fig.6). Different recombinant antibody 
fragments, e.g. Fab, scFv and VHH have been synthesized and found to possess binding 
characteristics comparable to their respective parent polyclonal and/or monoclonal 
antibodies (Yau et al, 2003).  
 
Fig.6 Schematic diagram illustrating the structures of conventional antibody molecule 
(IgG) and its different recombinant formats.  
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The major advantage of these antibody fragments is that they are smaller in size and 
therefore easier to manipulate genetically and express in bacterial systems. Furthermore, 
these antibody fragments can be expressed and anchored on bacteriophage surfaces as 
fusion proteins. Displayed antibody fragments remain functional for the purpose of 
affinity selection. As a result, specific antibody fragments and their coding sequences can 
be selected simultaneously from a diverse library of displayed antibodies. Antibody 
fragments can either be displayed on the surfaces of a bacterium or yeast, or as a fusion to 
viral coat proteins. The common feature among the various display technologies is that a 
direct link is created between the genotype and phenotype of the antibody being 
displayed. By having easy access to the genotype, display technologies allow antibodies 
to be rapidly evolved to suit specific applications by protein engineering methods 
(Hoogenboom et al, 1992; Winter and Milstein, 1991; Winter et al, 1994).  
 
The format of recombinant antibodies discussed in this thesis is the single-chain Fv 
(scFv) fragment, which comprises H- and L-chain variable (VH and VL) segments held 
together by a short, flexible, linker sequence (Fig.7) (Bird et al., 1988). ScFv carry the 
variability inherent in the antibody combining site, namely the three hypervariable 
complementarity-determining regions (CDRs) of each V region (Fig.7), which together 
constitute the antigen-binding region of the antibody. A single domain alone can also 
serve for antigen recognition. The CDRs are close to each other in the tertiary structure, 
forming an antigen-binding pocket (Fig.7). However, the scFv and single-domain formats 
do not carry any effector functions, because the variable V regions are normally 
associated with the constant (C) region of the antibody.   
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Fig.7 The single-chain Fv (scFv) antibody fragment consists of a VH (blue) and a VL 
(pink) domain, connected by a flexible linker peptide (total weight, ~30 kDa). The N-
terminal (N) parts of both domains are responsible for binding antigen. Tertiary structure 
of a single VH or VL domain of scFv, showing the three complementarity-determining 
regions (CDRs) that form the antibody combining site. VL–VH might also be a suitable 
format, the one used in our system. (modified from Lobato & Rabbitts, 2003). 
 
 
The availability of recombinant antibodies and the possibility to express them in different 
formats is the prerequisite for the use of antibodies as genes, rather than as proteins, 
which allows expressing them in different cells and in different compartments, an 
approach pioneered by our group (Biocca & Cattaneo, 1995; Cattaneo & Biocca, 1997; 
Piccioli et al., 1995). 
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3.2 From the principle of intracellular antibodies to the development of 
new strategies of antibody selection 
 
On the basis of their pioneering studies, in the nineties, Cattaneo and coworkers 
developed the idea of intracellular immunization and its feasibility through the ectopic 
expression of recombinant single chain Fv fragments (scFvs) antibodies inside the cells 
(Biocca & Cattaneo, 1995). They demonstrated that intracellularly expressed scFvs can 
function in antigen recognition in eukaryotic cells and that this interaction can inhibit the 
function of proteins in the cytoplasm, the nucleus, or the secretory pathway (for a review, 
Cattaneo & Biocca 1997).  
A major hindrance for this interesting approach was the paucity of scFvs antibodies, 
normally functioning “in vitro”, that maintain this ability also “in vivo” in eukaryotic 
cells, presumably because not all antibodies fold correctly in the cytoplasm. To overcome 
this problem, in our group was developed an in vivo assay for functional intracellular 
antibodies using a two-hybrid approach (Visintin et al., 1999). 
Visintin and coworkers (1999) adapted the eukaryotic two-hybrid assay to monitor the 
interaction of scFv fragments with their corresponding antigens, under conditions of 
intracellular expression. These studies were the ‘proof of principle’ of the following 
developments of yeast two hybrid-based selection strategies, for de novo selection of 
intracellular antibodies (Intracellular Antibody Capture Technology, IACT) (Visintin et 
al., 2002, 2004). 
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From the yeast two-hybrid to the intrabody selection 
The yeast two-hybrid system was a logical extension of studies that demonstrated the 
modular nature of transcriptional activators. Site-specific transcription factors often have 
discrete, separable DNA-binding domains (DBDs) and transcriptional activation domains 
(ADs). In the original two-hybrid system, two putative interacting proteins X and Y are 
respectively fused to the DBD and AD of a yeast transcriptional activator. An interaction 
between X and Y can reconstitutes the activator (DBD-AD) and leads to transcription of 
‘reporter’ genes, resulting in an easily detectable phenotype (Fields & Song, 1989). 
Visintin and coworkers (1999) exploited the two-hybrid system to monitor intracellular 
antigen-antibody interactions via reporter gene activation.  
Through the cotransfection of two specific expression vectors in yeast cells, the target 
antigen can be expressed as a (C-terminal) fusion of the DNA binding domain (DBD) of 
the E. coli protein LexA, and the specific scFv fragment can be expressed as a (N-
terminal) fusion of the activation domain (AD) of the herpes virus 1 VP16 transcription 
factor (Fig.8). 
The system exploited the L40 yeast strain, lacking histidine production (not growing in 
the absence of histidine) but that carry the HIS3 gene and the lacZ gene under the control 
of a minimal promoter with LexA DNA recognition site (Fig.8). Thus, HIS3 and lacZ 
represents the two ‘reporter genes’. If the scFv antibody fragment binds to the antigen 
target in vivo, a complex is formed that can bind to the HIS3 and lacZ promoters and 
activate transcription, as above described in the classic two-hybrid system. This activity 
restore histidine independent growth of the yeast or the β-gal production (measured by 
activation of β-galactosidase and blue colonies) (Fig.8).  
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Fig.8 Scheme of antibody-antigen interaction in vivo, based on the two-hybrid system. 
(modified from Visintin et al., 1999) 
 
The authors showed also that most scFvs selected from phage display libraries do not 
bind to antigen in the cytoplasm of yeast cells (Visintin et al., 1999), confirming that not 
all antibodies are able to bind antigens under conditions of intracellular expression. The 
low number of scFvs that can bind in vivo is probably the result of the lack of disulfide 
bonding in the reducing environment of the cell cytoplasm (Biocca et al, 1995). The 
folding stability of antibody domains is contributed by many residues in the frameworks 
(Proba et al., 1998), with different scFv fragments having different overall stabilities. 
Therefore, those scFv fragments that are intrinsically more stable will tolerate the loss of 
intrachain disulfide bond and remain folded, whereas others will not. In addition, good 
intracellular expression is related to additional parameters such as solubility versus 
propensity to aggregate, cellular half-life, and others (Visintin et al., 1999). 
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Intracellular Antibody Capture Technology (IACT) 
The first studies performed in the field of antigen-antibody two-hybrid system provided a 
‘proof of principle’ for the Intracellular Antibody Capture Technology (IACT), an in vivo 
selection strategy for functional intracellular antibodies (ICAbs) (Visintin et al., 2002). 
IACT is a procedure that allows the isolation of specific ICAbs from complex mixtures 
(i.e., libraries of recombinant antibodies). In a few words, the antigen fused to the DNA 
binding domain can be used as “bait” to screen a library of recombinant antibodies cDNA 
clones that are fused to an activation domain. The selected or ‘captured’ antibody 
represents the “prey”.  
Diverse scFv libraries, cloned in the two-hybrid Activation Domain vector, can be used 
for IACT selections, starting from different V repertoire sources: naïve or immunized 
phage display libraries, hybridomas, immunized splenocytes, and peripheral blood 
lymphocytes (PBLs) (Visintin et al., 2004b). 
The first examples of IACT selections used phage display libraries of scFvs. In this way, 
in our laboratory, Visintin and coworkers demonstrated that IACT can be effectively 
applied to the de novo selection of panels of functional ICAbs against diverse protein 
antigens and report the full characterization of a set of ICAbs selected against the 
microtubule associated protein Tau, involved in Alzheimer's disease (Visintin et al., 
2002). 
The authors demonstrated that antibodies suitable for intracellular expression are present 
in natural repertoires, which have been incorporated into phage libraries and can be 
readily isolated with IACT, avoiding the need for any rational mutation strategy or 
molecular evolution approaches (Visintin et al., 2002). 
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They also demonstrated that a rapid preselection of phage antibody libraries may 
represent one possibility to provide an antigen specific enriched input library in yeast, 
allowing the subsequent selection of several functional antibodies readily suitable for 
intracellular expression. 
However, the enrichment step of phage display scFv libraries requires the antigen as 
purified protein in coating, not exploiting one relevant and real potential of IACT: its 
ability to select recombinant antibodies directly from the gene sequence of the antigen 
(‘‘from gene to intrabody’’).  
The use of libraries enriched at the source in ‘‘good intracellular antibodies’’, for instance 
ad hoc engineered libraries exploiting intracellular consensus sequences (ICS) (Visintin 
et al., 2002), would represent a solution to avoid the antigen-based enrichment step. 
Recently, we explored also the possibility of exploiting naïve repertoires of natural V 
regions, superseding the need for framework consensus engineering, with the 
development of Single Pot Libraries of INTrabodies (SPLINT) (Visintin et al., 2004a).  
 
Single Pot Libraries of INTrabodies (SPLINT) 
SPLINT libraries represented a significant improvement of the IACT genetic selection 
strategy (Visintin et al., 2004a).  
In order to explore the probability of isolating intrabodies directly from primary (mouse) 
antibody repertoires, we have engineered a single pot antibody library in an activation 
domain vector and tested it in a two-hybrid selection strategy by using a wide panel of 
different antigens. The results obtained from all the different selections performed have 
indicated that the SPLINT library is a good source of antibody fragments, able to bind 
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proteins intracellularly. In fact, it was possible to select several scFv against each antigen 
challenged with the IAC technology. For most of the target antigens, it was possible to 
isolate several antibodies, thus indicating that, although this proof of principle SPLINT 
library has a complexity of ~107, the diversity obtained is still sufficient to isolate 
antibody binders that recognize particular antigens as, for example, proteins that are 
highly conserved between species. It is very well reported that the probability to find 
antibodies of a given affinity in a library has a direct relationship with the size of the 
library itself, in such a way that higher affinity antibodies can be selected from highly 
diverse libraries of greater complexity (Perelson and Oster, 1979). The required diversity 
for the selection of high affinity antigen-specific antibodies from an immune library is 
much lower than that required for such selection from a non-immune library. On the 
other hand, the conditions of intracellular expression allow antigen–antibody pairs to 
achieve higher local concentrations, making affinity as would be determined in vitro not 
the most important parameter for being a good, functional intrabody. 
We have demonstrated that a relatively small library (with a diversity of 107) derived 
from a natural repertoire, contains functional ICAbs against all antigens against which it 
was challenged, and can therefore provide a good source of antibodies suitable, not only 
for intracellular expression (Visintin et al., 2004a), but also as conventional antibodies.  
This certainly contrasts with the well-established observation (Visintin et al., 2002; Tse et 
al., 2002) that a very high proportion of ELISA-positive antigen-specific scFv fragments 
isolated from phage display libraries fail to pass the in vivo IACT selection against the 
same antigen. Several reasons may explain this finding.  
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First of all, it is possible (although unlikely) that phage display selects antibodies that are 
particularly unsuitable for intracellular expression, as opposed to antibodies that are 
directly derived from natural repertoires, with no intermediate selection.  
Second, unfolded or aggregating antibodies certainly provide a growth disadvantage to 
cells, and this is likely to contribute a background of antigen independent selection that 
provides an enrichment for functional intrabodies in the SPLINT library, which are then 
selected in an antigen-dependent way.  
Third, the relatively lower affinity requirement for intrabodies reduce the size of the 
library necessary to isolate intracellular binders.  
Last but not least, it is possible that the effective diversity of the library is actually higher 
than the initial number of yeast transformants, if more than one scFv is expressed in any 
given yeast cell, and this may or may not result in further recombination events and in 
segregation of different scFvs in daughter cells.  
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3.3 IACT and SPLINT: novel approaches to select recombinant 
antibodies targeting Aβ oligomers  
 
Antibodies, in particular the conformation specific ones, are important tools for analyzing 
Aβ misfolding and aggregation, as well as for targeting Aβ-related degenerative 
processes of Alzheimer Disease (AD). In addition, the precise intracellular targeting of 
recombinant antibodies to specific cellular locations (Cattaneo & Biocca, 1997, 1999), 
where post translationally modified pathological forms of proteins, such as Aβ oligomers, 
are formed is a promising strategy (the intrabody approach for protein knock-out) in AD 
studies. 
In this work, we describe a novel generation of anti-Aβ scFvs recombinant antibodies, 
exploiting a revolutionary approach developed in our laboratory, called “Intracellular 
Antibody Capture Technology” (IACT) (Visintin et al., 1999, 2002, 2004a, 2004b). 
Current evidences obtained from the characterization of the IACT-selected anti-Aβ scFvs 
under study, demonstrated their interesting binding properties in vitro, with conformation 
specificity for Aβ oligomers; in addition, being in vivo selected in the yeast cytoplasm, 
scFvs are highly stable and readily folded to be intracellularly expressed also in 
mammalian cells.  
Moreover, we discuss for the first time a comparative approach of selection from two 
different Single Pot Libraries of INTrabodies (SPLINT): one naïve and the other derived 
from Aβ-immunized mice. SPLINT are specialized libraries for subsequent IACT 
selection. We demonstrated that the SPLINT immune in comparison to that naïve, is a 
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source of scFv fragments with specific binding properties, biased towards N-terminal 
epitopes of Aβ. 
The IACT-selected scFvs under study represent a new strategic tool in the survey of anti-
Aβ antibodies, and for the peculiar characteristics of the selection strategy they can be 
used both for extracellular and for intracellular purposes, in vitro as well as in vivo.  
Several anti-oligomer specific antibodies have been developed as monoclonal or 
polyclonal antibodies, but not as intrabodies. On the other hand, several single-chain Fv 
(scFv) fragments anti-Aβ, but not conformation specific, have been developed:  
i) from phage display libraries (Manoutcharian K., et al., 2003, 2004; Liu et al., 
2004),  
ii) from monoclonal Abs (MAbs) (Frenkel et al., 2000).  
These anti-Aβ scFvs exhibit anti-aggregating properties and prevent the toxic effect of 
Aβ fibrillar aggregates. Moreover, a recent experimental report showed that a scFv 
intrabody targeting the β-secretase cleavage site of APP can reduce the generation of Aβ 
(Paganetti et al., 2005), supporting our proposed intrabody-based approach to investigate 
intracellular Aβ processing and oligomerization. 
For intracellular studies, scFvs intrabodies, targeted to specific intracellular 
compartments, can act as specific functional knock-out tools (Cattaneo & Biocca, 1997). 
This stage-specific, “protein interference” approach could not be pursued with the now 
standard RNA interference (RNAi) methods (Wall et al., 2003), because Aβ is a 
proteolitic fragment deriving from its APP (Amyloid Precursor Protein) precursor. RNAi 
based approaches could not be pursued to specifically target intracellular Aβ, or even 
more difficult, Aβ oligomers, as appeared to target the whole APP precursor. Even tough 
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targeting β-secretase BACE I with small interfering RNAs (siRNAs) reduce Aβ 
production and ameliorates neuropathology in an AD mouse model (Singer et al., 2005), 
the selective targeting versus oligomeric forms of Aβ peptide is only possible with 
antibody-based strategies and this is the peculiar and unique feature of our scFvs panel 
and of our experimental strategy.  
In an in vivo perspective, anti-Aβ scFvs represent an attractive alternative to more 
conventional antibody-based therapeutics for AD, since they are smaller, and therefore 
have a facilitated access/diffusion in the brain parenchyma and since they do not contain 
the antibody Fc region, responsible for activating the complement response in brain 
inflammation. For gene or cell therapy purposes, scFv are ideal, since there is only one 
gene to be expressed, instead of the two antibody chains.  
Recent studies showed that an anti-Aβ scFv based gene delivery, by intraventricular 
administration of adeno-associated virus in the brain of transgenic AD model mice, elicits 
a decrease in Aβ deposition and a rescue of pathological phenotype (Fukuchi et al., 2006; 
Levites et al., 2006). These data support the hypothesis to develop our Aβ conformation-
specific scFvs as in vivo therapeutics in animal models, exploiting different approaches, 
from the passive immunization using scFvs as recombinant purified proteins, to gene-
therapy approaches using specialized viral vectors, to an “ex vivo” cell therapy, in which 
genetically engineered cells can express and secrete our neutralizing the SPLINT-selected 
anti-Aβ scFvs.  
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Aim of the work 
 
In this thesis, we discuss the selection of a panel of recombinant scFv antibodies against 
the ‘neurologically relevant’ antigen β-amyloid peptide, from a SPLINT naïve library and 
from an ad hoc created SPLINT Aβ-immune library. 
The in vivo strategy of antibody selection here proposed was favorably supported by 
previous studies on Aβ-Aβ interaction (Hughes et al., 1996; Festy et al., 2001) and Aβ 
interactors selections (Yan et al., 1997; Hughes et al., 1998) performed in the yeast two 
hybrid systems. 
The aim of the thesis work was: 
- the creation of immune library 
- the selection of anti-Aβ antibodies from the immune and the naïve SPLINT 
libraries and their sequence characterization  
- the expression of selected antibodies for their subsequent characterization in vitro 
and in vivo  
- the biochemical, immunohistochemical and cellular characterization of the panel 
of selected antibodies 
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MATERIALS AND METHODS 
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1. Immunization of mice 
 
Three mice Balb-C (6-8 weeks old) were used for immunization.  
Human Aβ1-42 peptide (Biosource) was diluted at 2 mg/ml in phosphate buffer saline 
(PBS). The aggregation status of Aβ peptide was not checked before immunization, but 
we can assume that it was mainly constituted of aggregated in forms of oligomers and 
protofibrils, because the antigen was incubated at 37°C before the administration. 
Preimmune serum was taken on day 0. A total of four subcutaneous injections were 
performed (100μg antigen per animal per injection). For the first immunization, equal 
parts antigen and complete Freund's adjuvant were used, while for the subsequent 3 
injections the antigen was mixed with incomplete Freund’s adjuvant and injected at 3-
week intervals. The mice were killed five days after the last injection. 
The mice sera (diluted down to 1:10000) have been tested for antibodies titer by ELISA 
assay against Aβ peptide coating (mostly monomeric; 10μg/ml in PBS), and unrelated 
antigen Bovine Serum Albumin (BSA). As general procedure of ELISA assay, see the 
below-discussed section 7a.  
Immunization of mice was entirely and kindly performed by Dr. M. Stebel (University of 
Trieste) in the Animal Facility of the University of Trieste.  
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2. Construction of the immune SPLINT library 
 
Mouse spleens (extracted from freshly sacrificed immunized mice) were washed and 
cleaned in PBS and the lymphocytes released by pressing the spleen with a hypodermic 
needle and a sterile spatula. The cell suspension was then transferred to a sterile tube and 
left to deposit for 5 min. The supernatant was then removed and the cells washed twice in 
PBS and H2O to remove the red blood cells. The cells were then immediately used for 
total RNA extraction.  
The total RNA was extracted using a kit (Rneasy Mini Kit, Qiagen) according to the 
manufacturer’s protocols. 
 
2a. cDNA synthesis  
After extraction, the RNA was quantified (about 30 µg from 10 mg of original tissue) and 
used for cDNA synthesis using random primers (GIBCO Brl). The synthesis of the DNA 
complementary to individual RNA filaments was obtained by using Superscript II Rnase 
H- Reverse Transcriptase enzyme (GIBCO Brl). 
 
Random primers   1μl (100 ng);  
RNA total    5 μl;  
dNTP mix (10mM each)  1μl;  
H2O DEPC    5 μl.  
 
The mix is heated to 65° C for 5 min, then rapidly cooled on ice. The content of the tube 
is collected after brief centrifugation and were added: 
 
First-strand buffer 5 x  4 µl,  
DTT 0.1M    2 µl  
 
The tube content is mixed and then incubated for 2 min at 42° C, after which 1 µl (200U) 
of Superscript II is added and incubated for 50 min at 42° C. The reaction is inactivated at 
70° C for 15 min. 1 µl (2U) of RNAseH is added to remove the residual RNA bound to 
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the formed DNA and is left for 20 min at 37° C. The cDNA can then be used to amplify 
the variable chains. 
 
2b. VL and VH regions amplifications 
To obtain cDNA from the immunoglobulin variable regions, the V regions were 
amplified by PCR using degenerated 5’ and 3’ primers that permit the amplification of a 
greater number of variable chains. 
The immunoglobulin variable regions were amplified using V-region PCR (Orlandi et al., 
1992), using the following degenerated primers: 
VH mouse BACK: 
TTA TCC TCG AGC GGT ACC GAK GTR MAG CTT CAG GAG TC HB1 
TTA TCC TCG AGC GGT ACC GAG GTB CAG CTB CAG CAG TC HB2 
TTA TCC TCG AGC GGT ACC CAG GTG CAG CTG AAG SAS TC HB3 
TTA TCC TCG AGC GGT ACC GAG GTC CAR CTG CAA CAR TC HB4 
TTA TCC TCG AGC GGT ACC CAG GTY CAG CTB CAG CAR TC HB5 
TTA TCC TCG AGC GGT ACC CAG GTY CAR CTG CAG CAG TC HB6 
TTA TCC TCG AGC GGT ACC CAG GTC CAC GTG AAG CAG  HB7 
TTA TCC TCG AGC GGT ACC GAG GTG AAS STG GTG GAA T  HB8 
TTA TCC TCG AGC GGT ACC GAV GTG AWG YTG GTG GAG TC HB9 
TTA TCC TCG AGC GGT ACC GAG GTG CAG SKG GTG GAG TC HB10 
TTA TCC TCG AGC GGT ACC GAK GTG CAM CTG GTG GAG TC HB11 
TTA TCC TCG AGC GGT ACC GAG GTG AAG CTG ATG GAR TC HB12 
TTA TCC TCG AGC GGT ACC GAG GTG CAR CTT GTT GAG TC HB13 
TTA TCC TCG AGC GGT ACC GAR GTR AAG CTT CTC GAG TC HB14 
TTA TCC TCG AGC GGT ACC GAA GTG AAR STT GAG GAG TC HB15 
TTA TCC TCG AGC GGT ACC CAG GTT ACT CTR AAA GWG TST G  HB16 
TTA TCC TCG AGC GGT ACC CAG GTC CAA CTV CAG CAR CC HB17 
TTA TCC TCG AGC GGT ACC GAT GTG AAC TTG GAA GTG TC HB18 
TTA TCC TCG AGC GGT ACC GAG GTG AAG GTC ATC GAG TC HB19 
VH mouse FOR: 
GAT TGG TTT GCC GCT AGC TGA GGA GAC GGT GAC CGT GGT    HF1 
GAT TGG TTT GCC GCT AGC TGA GGA GAC TGT GAG AGT GGT    HF2 
GAT TGG TTT GCC GCT AGC TGC AGA GAC AGT GAC CAG AGT    HF3 
GAT TGG TTT GCC GCT AGC TGA GGA GAC GGT GAC TGA GGT    HF4 
 
 
 48 
VL mouse BACK: 
AGC AAG CGG CGC GCA TGC CGA YAT CCA GCT GAC TCA GCC     LB1 
AGC AAG CGG CGC GCA TGC CGA YAT TGT TCT CWC CCA GTC     LB2 
AGC AAG CGG CGC GCA TGC CGA YAT TKT GMT VAC TCA GTC     LB3 
AGC AAG CGG CGC GCA TGC CGA YAT TGT GYT RAC ACA GTC     LB4 
AGC AAG CGG CGC GCA TGC CGA YAT TGT RAT GAC MCA GTC     LB5 
AGC AAG CGG CGC GCA TGC CGA YAT TMA GAT RAM CCA GTC    LB6 
AGC AAG CGG CGC GCA TGC CGA YAT TCA GAT GAY DCA GTC     LB7 
AGC AAG CGG CGC GCA TGC CGA YAT YCA GAT GAC ACA GA       LB8 
AGC AAG CGG CGC GCA TGC CGA YAT TGT TCT CAW CCA GTC     LB9 
AGC AAG CGG CGC GCA TGC CGA YAT TGW GCT SAC CCA ATC    LB10 
AGC AAG CGG CGC GCA TGC CGA YAT TST RAT GAC CCA RTC     LB11 
AGC AAG CGG CGC GCA TGC CGA YRT TKT GAT GAC CCA RAC    LB12 
AGC AAG CGG CGC GCA TGC CGA YAT TGT GAT GAC BCA GKC    LB13 
AGC AAG CGG CGC GCA TGC CGA YAT TGT GAT AAC YCA GGA    LB14 
AGC AAG CGG CGC GCA TGC CGA YAT TGT GAT GAC CCA GWT    LB15 
AGC AAG CGG CGC GCA TGC CGA YAT TGT GAT GAC ACA ACC    LB16 
AGC AAG CGG CGC GCA TGC CGA CAG GCT GTT GTG ACT CAG GAA TC  LBL 
VL mouse FOR: 
GAA GTT ATG GTC GAC CCT CCG GAA CGT TTK ATT TCC AGC TTG G   LF1/2 
GAA GTT ATG GTC GAC CCT CCG GAA CGT TTT ATT TCC AAC TTT G LF4 
GAA GTT ATG GTC GAC CCT CCG GAA CGT TTC AGC TCC AGC TTG G   LF5 
GAA GTT ATG GTC GAC CCT CCG GAA CCT AGG ACA GTC AGT TTG G  LFL 
 
The primers were kindly provided by Dr. Visintin (LayLineGenomics, Trieste) 
 
To create the library that is as representative as possible, single amplifications were 
performed using each oligonucleotide described above according to the following 
schemes: 
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 HB1 HB2 HB3 HB4 HB5 HB6 HB7 HB8 HB9 HB10 HB11 HB12 HB13 HB14 
HF1 x X x x x x x x x x x x x x 
HF2 x X x x x x x x x x x x x x 
HF3 x X x x x x x x x x x x x x 
HF4 x X x x x x x x x x x x x x 
 HB15 HB16 HB17 HB18 HB19
HF1 X x x x x 
HF2 X x x x x 
HF3 X x x x x 
HF4 X x x x x 
 
 LB1 LB2 LB3 LB4 LB5 LB6 LB7 LB8 LB9 LB10 LB11 LB12 LB13 LB14 LB15 LB16 LBL
LF1/2 x x x x x x x x x x x x x x x x  
HF3 x x x x x x x x x x x x x x x x  
HF4 x x x x x x x x x x x x x x x x  
HF5 x x x x x x x x x x x x x x x x  
LFL                 x 
 
This procedure allows verification of the library quality, without having to introduce a 
prevalence of determinate variable regions that are more easily amplified than others. In 
this specific case, 141 individual amplifications are carried out, starting from the cDNA 
obtained from the total RNA extracted from the immunized mouse spleen. The conditions 
used to amplify the variable chains were: 
 
PCR reaction mix 
cDNA   0.5 μl;   
H2O    30.5μl;  
10X PCR buffer  5μl;  
dNTP 2.5mM each  5μl;  
MgCl2 25mM  3 μl;  
Oligo1 (10pmol/μl)  2.5 μl;  
Oligo 2 (10pmol/μl);  2.5μl 
Taq polymerase 1μl  
Mineral oil (50-100μl) is added to prevent evaporation in the test tube containing the 
reaction mixture. The tube is then placed in a thermocycler programmed as follows:  
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PCR amplification cycles 
94°C, 5’,  
(94°C, 1’ 60°C , 1’ 72°C, 1’) for 30 cycles;  
72°C, 10’;  
4°C  
 
After the variable regions have been amplified, they are analyzed on a 1.5% agarose gel 
and quantified. The same quantity of DNA for each amplified products is then used for 
cloning. A total of 10μg of a variable chain is then used for each cloning.  
 
2c. PULL THROUGH 
After all the VL and the VH variable regions have been amplified from the cDNA, they 
are reamplified to increase the quantity of DNA for cloning and to add extra sites to each 
terminus of the variable region previously amplified with the degenerated primers. After 
the variable chains (PTVL and PTVH) have undergone pull through, the amplified 
products are purified with gels. After purification, the PTVL and the PTVH are used for 
in vitro assembly. The pull through is used to insert a small polypeptide chain (called 
linker) that, after in vitro assembly, is in turn needed to reconstruct the single chain 
sequence. The assembly was done in a single step. 
 
The primers used for pull through were: 
 
VH PTL 220 BACK 
GGA GGG TCG ACC AGC GGT TCT GGG AAA CCA GGT TCC GGT GAA GGC TCG AGC GGTA 
 
VH PTMIC FOR 
CCA GGC CCA GCA GTG GGT TTG GGA TTG GTT TGC CGC TA 
 
VL PTL 220 FOR 
ACC GCT CGA GCC TTC ACC GGA ACC TGG TTT CCC AGA ACC GCT GGT CGA CCC TCC 
VL PTMIC BACK 
CGC TGG ATT GTT ATT ACT CGC AGC AAG CGG CGC GCA TGC C 
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The pull-through protocol was:  
VL 5μl (~100 ng); 
VL PTL 220 FOR 5 μl;   
VL PTMIC BACK 5 μl;  
MgCl2 2 μl;  
dNTPs 10 μl;  
buffer 10X 10 μl;  
Taq polymerase 2 μl;  
H2O 61 μl;  
 
VH 5 μl (~100 ng);  
VH PTL 220 BACK 5 μl;  
VH PTMIC FOR 5 μl;  
MgCl2 2 μl;  
dNTPs 10 μl;  
buffer 10X 10 μl;   
Taq polymerase 2 μl;  
H2O 61 μl. 
 
Mineral oil (50-100μl) is added to prevent evaporation in the test tube containing the 
reaction mixture.  
The tube is then placed in a thermocycler programmed as follows: 
 
94°C –5’; (94°C –30”, 60°C –30”, 72°C –30”) for 20 cycles;  72°C –10’;   
4°C   –24h. 
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2d. ASSEMBLY 
After the pull-though band for the VH and VL is isolated, the chains are purified with gel 
and the amplified products are used for in vitro assembly. In all, about 200 ng of DNA is 
used for the reaction (100 ng of PTVL and 100 ng of PTVH). 
The assembly reaction primers are: 
 
VH PT2 FOR 
TGG TGA TGG TGA GTA CTA TCC AGG CCC AGC AGT GGG TTT G 
 
VL PT2 BACK 
TAC CTA TTG CCT ACG GCA GCC GCT GGA TTG TTA TTA CTC 
 
The reaction is:  
 
PTVL 100 ng;  
PTVH 100 ng;  
VL PT2 BACK (100μM) 0.5 μl;  
VH PT2 FOR (100μM) 0.5 μl;  
dNTPs 10 μl;  
Buffer 10X 10 μl;  
MgCl2 2 μl;  
Taq polymerase2 μl;  
H20 to 100 μl.  
 
Mineral oil (50-100μl) is added to prevent evaporation in the test tube containing the 
reaction mixture. The tube is then placed in a thermocycler programmed as follows: 94°C 
–5’; (94°C –30”, 68°C –30”, 72°C –30” ) for 8 cycles without primers and 12 cycles with 
primers; 72°C –10’; 4°C   –24h.  
After assembly of the VH and the VL, the assembled scFv library is purified with gel as 
described above.  
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After purification, the DNA is digested with enzymes NheI and BssH2 in the following 
way:  
DNA mix 10μg;  
NheI (NEB 20 U/μl) 1.5μl;   
Buffer 2 (NEB)10μl 
BSA (10mg/ml)1μl;  
H2O  Q.S. (final V=100μl) , 
 and left to digest for 4 h at 37°C. 
 
After digestion and purification with gel, the DNA is cut with BssHII:  
DNA mix 10μg  
BssHII (NEB 20 U/μl) 1.5μl;  
Buffer 3 (NEB) 10μl; 
H2O  Q.S. (final V=100μl). 
The reaction mixture is incubated at 50°C for 4 h.  
 
The digested chains are then purified with 1.5% gel using a purification kit (Gel 
extraction kit, Qiagen). After purification, the DNA is quantified on 1.5% agarose using 
spectrophotometry at a wavelength of 260 nm. 
 
2e. LARGE SCALE LIGATION FOR LIBRARY 
The library is then ligated in the vector pMV1: about 300ng of vector were used  for this 
step; ligation was performed in gradient to optimize the reaction. The reaction mix is: 
pMV1:  80 μl (320ng);   
VL-VH assembly: 20 μl (200 ng);  
Ligase:10μl (400U/μl);  
Buffer: 40μl;  
H2O: 240μl;  
The reaction mixture is placed in 8 Eppendorf tubes and incubated  overnight at 16° C, in 
PCR thermocycler. The next day, the reaction is inactivated at 65° C for 10 min. After 
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incubation, the reaction mix is purified with QIAGEN PCR purification columns, eluited 
in final 45 µl of EB buffer QIAGEN, and then electroporated in DH5αF’. 
For each electroporation, 30 µl of bacteria plus 1 µl of ligase mix is used (max. 100 ng 
per electroporation). After transformation, the bacteria are resuspended in 1 ml of SOC 
medium + 10 nM MgCl2 and incubated for 1 h at 37° C, after which they are seeded on 
LB+ ampicillin plates. The next day, the efficiency of the transformation is evaluated. 
The library thus obtained was estimated to be about 1.7X106 CFU. 
At this point, the SPLINT library was used for the control test such as PCR-fingerprinting 
to test library diversity, antibody sequences taken randomly, western blot analysis to 
check the expression of the individual chains in yeast and screening on a panel of known 
antigens. 
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3. Aβ BAITS CONSTRUCTS 
 
All DNA encoding Aβ baits were cloned into pMICBD1, kindly provided by Dr. Visintin, 
(LayLineGenomics, Trieste) (see the “Results section” for the description of the vector) in 
the same reading frame of LexA, between BamHI-PstI restriction sites of the polylinker.  
 
lexA   MIC sense 
CTT CGT CAG CAG AGC TTC ACC ATT GAA GGG CTG GCG GTT GGG GTT ATT CGC AAC GGC GAC  
        polylinker       MIC antisense 
TGG CTG GAA TTC CCG GGG ATC CGT CGA CCT GCA GCC AAG CTA ATT CCG GGC GAA TTT CTT  
       EcoRI         SmaI    BamHI         SalI            PstI 
 
Aβ baits inserts preparation: 
DNA coding for human and murine Aβ42 were obtained by PCR amplification using two 
overlapping oligonucleotides. The DNA of all the other baits were obtained by annealing 
of complementary oligonucleotides.  
 
Human Aβ42 
 
Oligonucleotides 
hAβ (1-42) BamHI sense 
5’ GAA TTC CCG GGG ATC CTC GAT GCA GAA TTC CGA CAT GAC TCA GGA TAT GAA GTT 
CAT CAT CAA AAA TTG GTG TTC TTT GCA GAA GAT GTG GGT TCA 3’ 
hAβ (1-42) PstI antisense 
5’ TAG GCA TTA CTG CAG CTA CGC TAT GAC AAC ACC GCC CAC CAT GAG TCC AAT GAT 
TGC ACC TTT GTT TGA ACC CAC ATC TTC TGC AAA GAA CAC CAA 3’ 
 
Obtained amplimer 
hAβ42 (BamHI-PstI)  
GAATTCCCGGGGATCCTCGATGCAGAATTCCGACATGACTCAGGATATGAAGTTCATCATC
AAAAATTGGTGTTCTTTGCAGAAGATGTGGGTTCAAACAAAGGTGCAATCATTGGACTC
ATGGTGGGCGGTGTTGTCATAGCGTAGCTGCAGTAATGCCTA 
 
Note: in bold highlighted the coding sequence of hAβ42; underlined restriction sites BamHI and PstI . 
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PCR reaction mix for hAβ42 amplification 
Oligo BamHI sense  3μl (1μg) 
Oligo PstI antisense  3μl (1μg) 
dNTPs 2.5mM each  0.5μl 
Buffer 10X   5 μl 
Pfu Polymerase  1μl 
H2O    35.5μl 
PCR reaction cycles 
95°C , 5min  
(95°C, 1 min; 65°C, 30 sec; 72°C, 1min) x 15 cycles 
72°C, 10min 
4°C 
 
Mouse Aβ42 
 
Oligonucleotides 
Aβ(1-42) mouse BamHI sense 
GAA TTC CCG GGG ATC CTC GAT GCA GAA TTC GGA CAT GAT TCA GGA TTT GAA GTC 
CGC CAT CAA AAA CTG GTG TTC TTT GCT GAA GAT GTG GGT TCG  
Aβ (1-42) mouse PstI antisense 
TAG GCA TTA CTG CAG CTA CGC TAT GAC AAC GCC GCC CAC CAT GAG TCC GAT GAT 
GGC GCC TTT GTT CGA ACC CAC ATC TTC AGC AAA GAA CAC CAG 
 
Obtained amplimer 
Mouse Aβ42 (BamHI-PstI) 
GAA TTC CCG GGG ATC CTC GAT GCA GAA TTC GGA CAT GAT TCA GGA TTT GAA GTC 
CGC CAT CAA AAA CTG GTG TTC TTT GCT GAA GAT GTG GGT TCG AAC AAA GGC 
GCC ATC ATC GGA CTC ATG GTG GGC GGC GTT GTC ATA GCTAGCTGCAGTAATGCCTA 
 
Notes: highlighted in yellow only coding mutations in comparison to human sequence. PCR reaction 
similar to human Aβ42 (see above). 
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DNA sequences of Aβ baits inserts (BamHI-PstI) 
 
1. human Aβ42 
GAATTCCCGGGGATCCTCGATGCAGAATTCCGACATGACTCAGGATATGAAGTTCATC
ATCAAAAATTGGTGTTCTTTGCAGAAGATGTGGGTTCAAACAAAGGTGCAATCATTG
GACTCATGGTGGGCGGTGTTGTCATAGCGTAGCTGCAGTAATGCCT 
 
2. human Aβ40 
GAATTCCCGGGGATCCTCGATGCAGAATTCCGACATGACTCAGGATATGAAGTTCATC
ATCAAAAATTGGTGTTCTTTGCAGAAGATGTGGGTTCAAACAAAGGTGCAATCATTG
GACTCATGGTGGGCGGTGTTGTCTAGCTGCAGTAATGCCT 
 
3. mouse Aβ42 
GAATTCCCGGGGATCCTCGATGCAGAATTCGGACATGATTCAGGATTTGAAGTCCGCC
ATCAAAAACTGGTGTTCTTTGCTGAAGATGTGGGTTCGAACAAAGGCGCCATCATCG
GACTCATGGTGGGCGGCGTTGTCATAGCTAGCTGCAGTAATGCCTA 
 
4. human Aβ28 
GAATTCCCGGGGATCCTCGATGCAGAATTCCGACATGACTCAGGATATGAAGTTCATC
ATCAAAAATTGGTGTTCTTTGCAGAAGATGTGGGTTCAAACAAATAGCTGCAGTAATG
CCTA 
 
5. mouse Aβ28 
GAATTCCCGGGGATCCTCGATGCAGAATTCGGACATGATTCAGGATTTGAAGTCCGCC
ATCAAAAACTGGTGTTCTTTGCTGAAGATGTGGGTTCGATAGCGTAGCTGCAGTAATG
CCTA 
 
6. human Aβ17 
GAATTCCCGGGGATCCTCGATGCAGAATTCCGACATGACTCAGGATATGAAGTTCATC
ATCAAAAATTGTAGCTGCAGTAATGCCTA 
 
7. mouse Aβ17 
GAATTCCCGGGGATCCTCGATGCAGAATTCGGACATGATTCAGGATTTGAAGTCCGCC
ATCAAAAACTGTAGCTGCAGTAATGCCTA 
 
 
 
8. human Aβ10 
GAATTCCCGGGGATCCTCGATGCAGAATTCCGACATGACTCAGGATATTAGCTGCAGTA
ATGCCTA 
 
9. mouse Aβ10 
GAATTCCCGGGGATCCTCGATGCAGAATTCGGACATGATTCAGGATTTTAGCTGCAGTA
ATGCCTA 
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DNA inserts and pMICBD1 vector were digested BamHI-PstI (in Buffer3 NEB +BSA, 
37°C, 1h) 
 
The digested vector was dephoshorylated with CIAP prior to ligating to the insert DNA.  
 
For ligation, the ideal ratio of insert-to-vector DNA is variable; however, a reasonable 
starting point is 1:3 (vector-to-insert molar ratio), measured in available picomole ends. 
This is calculated as follows: 
 
Picomole ends/microgram of DNA=  2x106 ________ 
   n.of base pairs x 650 
 
MW of a double-stranded DNA molecule=(#of base pairs) x (650daltons/base pair) 
Average weight of a DNA basepair (sodium salt)= 650 daltons 
 
 pMICBD1 + insert 
1:3 
pMICBD1 + 
insert 1:5 
pMICBD1 + 
ligase 
pMICBD1 
prepared vector 
Prepared  
pMICBD1 vector 1 μl 1μl 1μl 1μl 
Prepared insert 3X 5X / / 
T4 DNA ligase 1U 1U 1U / 
10X ligase buffer 1 1 1 1μl 
H2O MQ to 10 μl to 10 μl to 10 μl to 10 μl 
 
Ligate overnight at 16°C.  
Performed a standard transformation of the vector construct into E.coli competent cells. 
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4. IACT selection method using SPLINT libraries 
 
 
 
 
 
 
 
 
 
 
 
List of abbreviations 
 
Two-Hybrid Terminology 
AD vector   Plasmid encoding the VP16 activation domain (AD) 
DNA-BD vector   Plasmid encoding the lexA DNA-binding domain (DNA-BD) 
scFv-VP16 A hybrid protein comprised of the single chain fv fragment (scFv) 
previously cloned to the VP16 activation domain 
SPLINT Mouse scFv library naïve or immune (iperimmune anti-Aβ) constructed 
in AD vector such that the scFv is fused to the VP16 activation domain 
DNA-BD/target protein A hybrid protein (the “bait”) comprised of the lexA DNA-BD fused 
with your target protein 
DNA-BD/target plasmid Plasmid encoding the “bait” (i.e., the DNA-BD/target protein) 
 
Yeast Phenotypes 
Trp- Requires tryptophan (Trp = W) in the medium to grow, i.e., is a Trp 
auxotroph 
Leu- Requires leucine (Leu = L) in the medium to grow, i.e., is a Leu 
auxotroph 
His- Requires histidine (His = H) in the medium to grow, i.e., is a His 
auxotroph 
LacZ+ Express the lacZ reporter gene, i.e., is positive for β galactosidase 
activity 
His+ Express the HIS3 reporter gene, i.e., does not require HIS in the 
medium to grow 
 
Yeast Selection Media 
YC Synthetical minimal medium 
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MATERIALS 
 
vectors 
pMICBD1 vector (bait plasmid)  
pVP16 vector (negative control) 
plexA-lamin (negative control) 
plinker220 and pMV1 (prey plasmids) represented by SPLINT libraries  
 
primers 
MIC sense 5’ CAg AgC TTC ACC ATT gAA 3’ 
MIC antisense 5’ gAA ATT CgC CCg gAA TT 3’ 
BssH2 sense 5’ gTg gCC CAg CCg AgC gCg CAT gCC 3’ 
NheI antisense 5’ CCg CTT CTT CTT ggg TgC CAT ggC 3’ 
SalI antisense 5’ TTT CCC AgA ACC gCT ggT CgA CCC 3’ 
linker 220 sense 5’ AAA CCA ggT TCC ggT gAA ggC TCg 3’ 
linker 220 antisense 5’ gCT CgA gCC TTC ACC ggA ACC Tgg 3’ 
VP16 antisense 5’ TCg AgC TCg gTA CAC CTg gg 3’ 
 
Host strain 
L40 S.cerevisiae strain (Invitrogen, # C830-00) 
Mata his3Δ200 trp1-901leu2-3,112ade2LYS2::(lexAop)4-HIS3 URA3::(lexAop)8-lacZ GAL4 
 
Antibodies 
Anti-lexA polyclonal antibody (Invitrogen, #R990-25) 
Anti-VP16 polyclonal antibody (BD-Clontech, #3844-1) 
 
 
All the materials were kindly provided by Dr. Visintin (LayLineGenomics, Trieste) 
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REAGENTS AND SOLUTIONS 
• Yeast Nitrogen Base without amino acids and ammonium sulfate (SIGMA #Y-1251) 
• Bacto Agar (BD # 214010) 
• NaOH (Riedel-deHaen #30620) 
• Adenine hemisulfate salts (SIGMA #A-9126) 
• L-arginine HCl (SIGMA #A-5131) 
• L-cysteine (SIGMA #C-6852) 
• L-threonine (SIGMA #T-8652) 
• L-aspartic acid (SIGMA #A-4534) 
• L-isoleucine (SIGMA #I-2752) 
• L-methionine (SIGMA #M-9625) 
• L-phenylalanine (SIGMA #P-2126) 
• L-proline (SIGMA #P-0380) 
• L-serine (SIGMA #S-4500) 
• L-tyrosine (SIGMA #T-3754) 
• L-histidine (SIGMA #H-8125) 
• Uracil (SIGMA #U-0750) 
• L-leucine (SIGMA #L-8912) 
• L-lysine HCl (SIGMA #L-5626) 
• L-tryptophan (SIGMA #T-0254) 
• Ammonium sulfate (Fluka #09980) 
• Polyethylene glycol 4’000 (Fluka #95904) 
• D-(+) Glucose anhydrous (SIGMA #G-7021) 
• Lithium Acetate dihydrate (SIGMA #L-6883) 
• Succinic acid (SIGMA #S-7501) 
• Dimethyl sulfoxide –DMSO (Fluka #41639) 
• Glass beads 425-600 microns acid washed (SIGMA #G-8772) 
• Yeast extract (BD # 211931) 
• Bacto peptone (BD #211840)  
• Colony lifts, Protran BA85 (Schleicher & Schuell #10 401116) 
• 3-amino-1,2,4-triazole (SIGMA #8056) 
• 5-bromo-4-chloro-3 indolyl-β -D-galactosidase –X-gal (Eppendorf #0032006.400) 
• N-N-dimethylformamide (Fluka #34903) 
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4a. Preparation of the Yeast host strain 
 
The interaction system that we have used requires the yeast strain L40 (Hollenberg et al., 
1995) which contains lexA operator-responsive reporters chromosomally integrated; the 
genotype of L40 is: 
Mata his3Δ200 trp1-901 leu2-3,112 ade2 LYS2::(lexAop)4-HIS3 URA3::(lexAop)8-lacZ 
GAL4 
The expression of HIS3 gives a growth selection for interaction while the expression of 
lacZ, which encodes the enzyme β-galactosidase, can be monitored using a colorimetric 
assay based on the activity of β -galactosidase: the lacZ+ yeasts form blue colonies in the 
presence of the chromogenic substrate 5-bromo-4-chloro-3-indolyl- β -D galactoside (X-
gal). 
This strain is deficient for TRP and LEU (auxotrophic phenotype) and cannot grow on 
minimal medium lacking those nutrients unless functional TRP1 and LEU2 genes are 
introduced. Moreover, this strain carries the ade2 mutation, which confers a red color 
(due to a red pigment accumulation) on medium containing limiting amounts of adenine 
that turns darker as the colony age. 
 
Yeast Strain Maintenance 
1. Yeast strain can be maintained as stock in YPD medium with 30% glycerol and 
can be stored indefinitely at -80°C.  
2. To recover frozen strains and prepare working stock plates:  
a) streak a small portion of the frozen stock onto YPD agar plate.  
b) Incubate the plate at 30°C until yeast colonies reach ~ 2mm in Ø (this takes ~3 
days) 
c) Seal plates with Parafilm and store at 4°C for up to 2 weeks 
 
Preparation of stock cultures of new yeast strain 
1. Use a sterile inoculation loop to scrape an isolated colony from the agar plate 
2. Thoroughly resuspend the cells in 200 μl of YPD medium. Add sterile 50% 
glycerol to a final concentration of 30%. 
3. Tightly close the cap. Vortex the vial before freezing at -80°C. 
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Phenotype Verification 
Yeast colonies should appear slightly pink or red (because of the ade2-101) mutation and 
grow to > 2 mm in Ø. However, small white colonies will form at the rate of 1-2% due to 
spontaneous mutations that eliminate mitochondrial function. The strain turns darker as 
the colony ages. 
 
Test of the strain 
L40 yeast strain should not grow in these media: 
 
Yeast strain YC selection media phenotype 
L40 -W No growth 
L40 -L No growth 
L40 -H No growth 
L40 -U Growth 
L40 -K Growth 
 
 
L40 strain is deficient for TRP and LEU and cannot grow on minimal medium lacking 
those nutrients unless functional TRP1 and LEU2 genes are introduced.  
L40 can grow onto –U and –K media because the lexA operator is integrated into URA 
and LYS markers. Using media with Ura and Lys dropped out, results in minimal 
background.  
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4b. Preparation of Media and Reagents 
 
Yeast strains, which employ auxotrophic mutations as markers, are grown on nutrient-
rich media at 30°C to minimize selections for revertants.  
Strains to be preserved are grown to logarithmic phase on YPD plates; the yeast is then 
scraped up with sterile inoculation loop and suspended in a 15-30% (v/v) glycerol-YPD 
medium; yeast can be stored now indefinitely at -70°C (the vials should be vortex briefly 
before freezing at -70°C to avoid cells settling to the bottom of the tube). 
When needed, the yeast strain can be revived by transferring a small portion of the frozen 
sample onto YPD plates (yeast L40 colonies should appear slightly pink onto YPD plates 
and grow to >2 mm in diameter); yeast can be also stored at 4°C on YPD plates for up to 
2 months. To verify the phenotype of the yeast strain provided, the streaking of few 
colonies from the working stock onto separate YC plates is performed (see table); 
phenotype will appear after 3-4 days of incubation at 30°C. 
 
YPD medium  
10 g yeast extract (BD # 211931)  
20 g bacto peptone (BD # 211840 )      
20 g bacto-agar (BD # 214010)       
2% glucose (SIGMA # G-7021)  
Add H2O to 950 ml. Adjust pH to 5.8 then adjust to 1 liter. Autoclave 121°C for 15 min. 
 
YPA medium 
10 g yeast extract (BD # 211931) 
20 g bacto peptone (BD # 211840 ) 
20g bacto-agar (BD # 214010) 
0.1g Adenine hemisulfate salt (SIGMA # A-9126) 
Add H2O to 950 ml. Adjust pH to 5.8 then adjust to 1 liter. Autoclave 121°C for 15 min. 
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YC medium 
 
1. YNB w/o aa & (NH4)2SO4: 
1.2 g yeast nitrogen base, w/o amino acids and ammonium sulfate (SIGMA # Y-1251) 
20 g bacto-agar (BD # 214010) 
Add H2O to 800 ml. Autoclave  121°C for 15 min. 
 
 
2. SALTS: 
5.4g NaOH (Riedel-de Haen #30620) 
10g succinic acid (SIGMA # S-7501) 
5g ammonium sulfate (Fluka # 09980) 
 
3. Glucose:
22g D-glucose
(SIGMA # G-7021)
Dissolve in 16 ml H2O
 
Add H2O to 100 ml and dissolve all components one by one. Add glucose (3.) and H2O to 
solution 2. to obtain a final volume of 150 ml.  
 
4. amino acids MIX:  
5.8 g NaOH (Riedel-de Haen #30620) 
1 g Adenine hemisulfate salts (SIGMA#A-9126) 
1 g L-Arginine HCl (SIGMA # A-5131) 
1 g L-Cysteine (SIGMA #  C-6852) 
1 g L-Threonine (SIGMA #  T-8625)  
0.5 g L-Aspartic acid (SIGMA # A-4534) 
0.5 g L-Isoleucine (SIGMA # I-2752) 
0.5 g L-Methionine (SIGMA #  M-9625) 
0.5 g L-Phenylalanine (SIGMA # P-2126) 
0.5 g L-Proline (SIGMA # P-0380) 
0.5 g L-Serine (SIGMA # S-4500) 
 
Dissolve in 80 ml H2O 
5. L-Tyrosine: 
0.5 g L-Tyrosine (Sigma # T-3754) 
0.2 g NaOH (Riedel-de Haen #30620) 
Dissolve in 10 ml by heating 
Add to aa MIX (4.) the L-Tyrosine solution (5.) and H2O to make a final volume of 100 
ml. Filter –sterilize, aliquot and store at -20°C for up to 1 year.  
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6. Omitted aminoacid solutions: 
 
L-Histidine (SIGMA # H-8125): 
• 5 g/l H2O 
Uracil (SIGMA # U-0750) : 
• 10 g/l H2O (+2 pellets NaOH) 
L-Leucine (SIGMA # L-8912): 
• 10 g/l H2O 
L-Lysine HCl (SIGMA # L-5626): 
• 10 g/l H2O 
L-Tryptophan (SIGMA # T-0254): 
• 10g/lH2O 
Filter-sterilize and aliquot individually omitted amino acids (aa) solutions (H, W, L, K, 
U) and store at -20°C for up to 1 year. 
Before preparing YC plates or media by mixing appropriate solutions, media must be 
adjusted to pH 5.8 and sterilized by filtering salts + aa final mix. All the components 
must be mixed as suggested in the following Table : 
 
 YNB w/o aa 
& (NH4)2SO4 
 
Salts aaMIX W H U L K H2O 
-UKW 800 150 10  10  10  20 
-UKL 800 150 10 10 10    20 
-UKWL 800 150 10  10    30 
-WHUK 800 150 10    10  30 
-WHULK 800 150 10      40 
 
Table: mix of salts and aa to prepare selective media 
 Note: All the suggested volumes are expressed in ml. 
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4c. LiAc transformation (small-scale) 
A number of specialized media and reagents are required for the protocols in this section.  
This protocol is a modification of published methods (Gietz et al., 1992), (Hill et al., 
1991), (Schiestl and Gietz, 1989), made by Clontech laboratories. The expected 
transformation efficiency is 103-104 / μg plasmid DNA. 
Materials 
• 10X LiAc buffer: 1M LiAc, pH 7.5 adjusted with diluted glacial acetic acid 
autoclave-sterilized (lithium acetate dehydrate –SIGMA # L-6883)  
• 50% (w/v) autoclave-sterilized PEG 4000: polyethylene glycol, avg. mol. wt.=3350-
Fluka # 95904. (Solution must be kept in a tightly sealed glass bottle to avoid 
evaporation) 
• 10X TE buffer: 100mM Tris, 10mM EDTA, pH7.5, autoclave-sterilized 
• 100% DMSO: dimethyl sulfoxide (Fluka #41639) 
• 10 mg/ml denatured carrier DNA from fish sperm (Roche # 1467140) 
Procedure 
Day 1: Inoculate few colonies of L40 in 50 ml of YPD and incubate for 16-18 hr with 
shaking at 250 rpm at 30°C to place the culture at mid log phase the next day (OD600 > 
1.5). Note. Use only glass flasks carefully washed with ultra pure, pyrogen-free water 
and sterilized by autoclaving 15 min at 121°C. 
Day 2: 
1) Dilute the overnight culture to OD600 0.2-0.3 in 300 ml of YPD prewarmed to 30°C. 
Grow at 30°C for 3 hours with shaking (230 rpm) 
2) Pellet the cells by centrifugation (1000 X g for 5 min) at room temperature, discard the 
supernatant and resuspend the pellet in 50 ml of H2O. 
3) Centrifuge the cells again as in 2), decant the supernatant 
4) Resuspend the pellet in 1.5 ml of freshly prepared 1X TE/LiAc (10mM TE, 0.1M 
LiAc) 
5) Prepare in a tube a mixture of:  
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9 0.1 µg lexA-Ag vector construct 
9 0.1 µg scFv-VP16 vector construct (if you need to test specific antigen-antibody 
partners) 
9 0.1 mg denatured carrier DNA from fish sperm 
9 100 μl freshly prepared yeast cells 
6) Add 0.6 ml of a sterile PEG/LiAc (0.1 M LiAc, 10mM TE, PEG 4000 40%) to the 
tube and vortex to mix 
7) Incubate 30 minutes at 30°C with shaking (230 rpm) 
8) Add 70 µl of DMSO, mix gently by inversion and heat shock for 15 min in a 42°C 
water bath. 
9) Chill cells on ice 
10) Pellet cells by centrifugation (20 sec at maximum speed) 
11) Remove supernatant and resuspend cells in 0.5 ml of sterile 1X TE; spread 100 µl for 
single transformation or 250 µl for a co-transformation on each 100 mm plate. 
The competent cells can be stored at 4°C for 1 week without a significant reduction in 
competency. 
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4d. Characterization of the “Aβ baits”  
A series of control experiments must be performed to establish whether the fusion 
proteins LexA-Aβ  were suitable as such or whether it must be modified; the verifications 
of well-behaved bait are:  
 
a) testing for activity  
b) testing for expression 
c) testing for toxicity 
 
a) activity 
A well-behaved bait should not transactivate in a non-specific way the reporter genes in 
the L40 strain and should not interact with either the nuclear localization signals or with 
the VP16 activation domain. Therefore, the L40 strain transformed with the bait alone or 
together with VP16 plasmid should not grow in the absence of histidine and should not 
contain any detectable β-galactosidase activity. Note: the bait must be modified by using 
a particular domain or a deletion mutant of the same protein in frame to lexA if it does 
not fulfill all the proposed features. 
Test the extent of non specific activation of the reporter construct by the bait plasmid 
with the following protocol: 
1) transform the bait plasmid into L40 strain using the small-scale yeast transformation 
protocol 
2) select for transformants on appropriate YC plates as described in Table 2.2 
3) assay the bait construct for activation of HIS3 reporter gene as described in Table 2.2 
and for activation of the lacZ reporter gene using the β-galactosidase colony-filter 
assay as described below 
Growth of the bait Ag MUST be kept low.  
If growth on –H plates occurs background growth can be suppressed with 3AT: pick 
transformants from YC-UKW plates and restreak them in duplicate onto YC-UKWH 
plates with a range in 3AT concentrations from 0 to 150mM in 5mM increments. 
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Transformation controls for well-behaved “bait” 
To test for the possibility of transactivation by the lexA fusion Ag the transformants must 
be plated onto diagnostic media (see the following Table.). It is very important that His 
gene does not switched on by intrinsic transactivation of the lexA fusion protein, as this 
would lead to growth on selective media.  
 
„bait“ „AD“ YC selection medium HIS3 phenotype lacZ phenotype 
lexA-Aβ   -UKW + white 
lexA-Aβ   -WHUK /  
lexA-Aβ  VP16 -UKWL + white 
lexA-Aβ  VP16 -WHULK /  
 
 
b) expression 
• Preparation of Crude Yeast Lysate for SDS-PAGE analysis 
To verify that the bait fusion protein is properly synthesized, an SDS-PAGE and 
immunoblot analysis on crude yeast lysate must be performed. 
Materials 
9 master plate with bait-containing positive and control yeasts 
9 antibody to lexA (Invitrogen) or monoclonal/polyclonal to fusion protein 
9 Laemmli sample buffer 2x 
Procedure 
Day 1: 
Incubate overnight at 30°C a 5-ml culture of the bait being tested and relative controls in 
the appropriate YC medium. 
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Day 2: 
1) From each overnight culture start a new 5-ml culture at OD600= 0.15. Incubate at 
30°C until the culture has reached OD600= 0.5-0.7. 
2) Remove 1.5 ml from the tube and centrifuge cells 3 min at maximum speed 
3) Remove the supernatant and working rapidly resuspend in 50 μl of 2x Laemmli 
sample buffer. 
4) Vortex and place immediately the tube on dry ice.  
5) Boil 5 min and centrifuge 1 min at maximum speed the sample before loading it on 
SDS-PAGE. 
 
c) toxicity 
A high level expression of the fusion protein could be toxic to the reporter strain and this 
could lead the transformant cells to be unable to grow. To alleviate this detrimental effect 
the truncation of the toxic protein or a conditional promoter on hybrid plasmid could be 
used. 
 
After the scoring of His+ yeast colonies, a X-Gal lift assay is performed as described 
below (Visintin and Cattaneo, 2001).  
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β-galactosidase filter assay 
 (Breeden and Nasmyth, 1985) 
Materials 
9 Nitrocellulose filter circles (Scheicher and Schuell BA85) 
9 Buffer Z (60 mM Na2HPO4, 40 mM NaH2PO4, 10 mM KCl, 1mM MgSO4, pH 7.0. 
Store at room temperature for up 1 year) 
9 50 mg/ml  5-bromo-4-chloro-3-indolyl-β-D-galactoside (Eppendorf # 0032006.400) 
9 Whatman filter circles 
9 Liquid nitrogen 
Procedure 
1) Prepare 5-bromo-4-chloro-3-indolyl-β-D-galactoside (Eppendorf # 0032006.400) in 
N,N-dimethylformamide (DMF) at a concentration of 50 mg/ml. Store in dark at -
20°C. 
2) Patch yeast colonies to a nitrocellulose filter circle 
3) Lift filter and place colony side up on a pre-cooled aluminum boat floating upon a sea 
of liquid nitrogen 
4) After 20 seconds, immerse boat and filter for 5 seconds 
5) Allow the filter to come to room temperature and place on top of Whatman filter 
circle that had been prewet in 3 ml of Z buffer containing 30 μl of X-gal  
6) Incubate the filter for up to 5 hours. Blue coloration is indicative of  β-gal activity. 
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4e. SPLINT TRANSFORMATION AND SELECTION 
 
When screening a SPLINT library the bait plasmid and the SPLINT library can be 
introduced sequentially into L40 strain. The flowchart of the SPLINT transformation and 
selection is below outlined. 
Screening of SPLINT: 
1) Construct the “Aβ bait”: a fusion of the gene encoding the target protein 
and the sequences encoding the lexA DNA-BD in pMICBD1. The target 
gene should be inserted in the correct reading frame and orientation so that 
a hybrid consisting of the target protein fused to the lexA DNA-BD will 
be expressed from this vector. 
2) Verify the bait construction by restriction digestion and sequencing. If 
sequencing, use the MIC back and MIC for junction primers  
3) Test the lexA-Aβ target bait for transcriptional activation function in the 
L40 reporter strain before using it in a two-hybrid screening 
4) Transform the hybrid construct into L40. Use the small-scale yeast 
transformation protocol. Plate transformants onto YC-UKW selection 
medium. 
5) Assay transformants on YC-UKWH and for β-galactosidase activity using 
the colony-lift filter assay. 
6) Introduce sequentially the lexA-Aβ and SPLINT library into L40 strain: 
use the SPLINT scale transformation protocol. 
7) Screen the His+, Trp+, Leu+, transformants for β-galactosidase activity 
using the colony-lift filter assay. Individual blue colonies are isolated by 
restreaking and again assayed for β-galactosidase activity. 
8) Perform colony-PCR and BstNI fingerprinting analysis onto His+ and 
lacZ+ colonies. Use Lyse-N-Go PCR reagent (Pierce, # 78882) to lyse 
colonies prior to use them for PCR. 
9) Select those His+ , lacZ+ and different fingerprinting pattern colonies and 
isolate the plasmid scFv-VP16 DNA. 
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10) Transform plasmid into E.coli and plate bacterial transformant onto LB + 
Amp. 
11) Isolate plasmid DNA from bacteria and sequence insert in the putative true 
positive hybrid plasmids using the VP16 antisense primer. This is 
primarily to confirm that the sequence you have isolated encodes a scFv 
cDNA. 
12) Verify positive interactions by a secondary screening and finally by an 
independent method, such as ELISA, immunoprecipitation, 
immunofluorescence etc. 
 
SPLINT SCREENING 
Transformation of lexA-Aβ construct into L40 yeast strain 
↓ 
Select on YC-UKW plates at 30°C 
3 days 
↓ 
Grow the bait culture in a 10 ml YC-UKW media overnight at 30°C 
↓ 
Inoculate 100 ml of YC-UKW overnight at 30°C 
↓ 
SPLINT transformation 
↓ 
Select on YC-WHULK plates at 30°C  
3 days 
↓ 
X-gal assay 
↓ 
«positive» interaction clones selected 
↓ 
PCR-BstNI fingerprinting analysis 
↓ 
Isolate scFv-VP16 yeast target DNA 
↓ 
Transform in E.coli 
↓ 
Isolate scFv-VP16 bacterial target DNA 
↓ 
Co-transform scFv-VP16 plasmid DNA with lexA-Aβ bait and controls 
↓ 
Further analysis 
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4f. LiAc transformation (SPLINT-scale) 
This protocol should allow a higher efficiency of transformation (≅ 106/μg DNA).  
Materials 
9 1 aliquot of SPLINT/carrier 
9 150 ml YC-UKW  
9 2 l YPAD 
9 1 l YPA 
9 1.5 l YC-UKWL + 10 YC-UKWL plates (100mm) 
9 1.5 l YC-WHULK + 100 YC-WHULK plates (100mm) 
9 100 ml 10X TE 
9 20 ml 10X LiAc 
9 150 ml 50% PEG 4000 
9 20 ml DMSO 
Procedure 
1. Day1: grow L40 yeast containing bait plasmid in YC-UKW O/N 
2. Day2: inoculate 100 ml of YC-UKW with an aliquot of the overnight culture in 
order to find a dilution that places the 100 ml culture to logarithmic phase the next 
day 
3. Day3: transfer enough overnight culture in 1 L of prewarmed to 30°C YPAD to 
produce an OD600 = 0.3 
4. Grow at 30°C for 3 hours 
5. Centrifuge the cells at 1500 X g for 5 min at room temperature 
6. Wash pellet in 500 ml of 1X TE then centrifuge again the cells at 1500 X g for 5 
min at room temperature 
7. Resuspend pellet in 20 ml 1X LiAc, 0.5X TE and transfer to a new flask 
8. Add the pretowed and mixed SPLINT/carrier DNA aliquot 
9. Add 140 ml of 1X LiAc, 40% PEG 3350, 1X TE; mix and incubate for 30 min at 
30ºC with gently shaking 
10. Add 17.6 ml of DMSO; swirl to mix 
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11. Heat shock for 15 minutes at 42ºC in a water bath swirl occasionally to mix 
12. Rapidly cool at room temperature cells in a water bath diluting with 400 ml YPA 
13. Pellet cells by centrifugation and wash with 500 ml YPA 
14. After centrifugation resuspend pellet in 1 L of prewarmed YPAD 
15. Incubate for 1 hour at 30°C with gently shaking 
16. Pellet cells from 1 ml; resuspend in 1 ml YC-UKWL; spread 100 μl of a 1:1000, 
1:100, 1: 10 dilutions for transformation efficiency controls.  
17. Pellet cells from the remaining culture 
18. Wash pellet with 500 ml YC-UKWL 
19. Resuspend in 1L of prewarmed YC-UKWL and incubate O/N at 30°C with gently 
shaking 
20. Day4: pellet cells and wash twice with 500 ml of YC-WHULK 
21. Resuspend final pellet in 10 ml of YC-WHULK 
22. Spread dilutions of the total on YC-UKWL plates to compare to the number of 
primary transformants. This allows to calculate the number of doublings and the 
number of his+ colonies which should be screened to roughly cover the number of 
primary transformants. 
23. Spread part of the remaining transformation suspension on YC-WHULK plate. 
Store in 30% glycerol /YC-WHULK the cotransformed library at -80◦C. 
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4g. Plasmid isolation from yeast 
 
1) Inoculate single, well isolated yeast transformant colonies into 5 ml of appropriate 
selective media at 30°C, shaking at 250 rpm until the culture is saturated (16-24 
hours) 
2) Spin down the culture by centrifuging at 5000 x g and resuspend cells in 250 μl of 
Buffer 1 containing 0.1 mg/ml RNase A; transfer the cell suspension in a 1.5 ml 
microfuge tube 
3) Add 0.3 g of acid-washed glass beads and vortex for 5 min at room temperature 
4) Spin at maximum speed for 5 min and transfer the supernatant to a new 1.5 ml 
microfuge tube 
5) Add 250 μl lysis buffer P2 to the supernatant and invert gently 4-6 times to mix. 
Incubate at room temperature for 5 min. 
6) Add 350 μl neutralization buffer N3 to the tube and immediately invert 4-6 times the 
tube 
7) Centrifuge at maximum speed for 10 min  
8) Transfer the cleared lysate to QIAprep spin column placed in a 2 ml collection tube 
by pipetting 
9) Centrifuge for 1 min at maximum speed; discard the flow-through 
10) Wash QIAprep spin column by adding 0.75 ml of Buffer PE and centrifuging for 1 
min 
11) Discard the flow-through and centrifuge for an additional 1 min to remove residual 
ethanol from wash buffer 
12) Place QIAprep spin column in a clean 1.5 ml microfuge tube.  
13) Add 25 μl of H2O to the center of each QIAprep spin column; let stand for 1 min, and 
centrifuge for 1 min at maximum speed 
 
Then transform the 1µl of extracted DNA into bacteria using electroporation and plate on 
LB with 100µg/ml ampicillin. 
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Incubate the plate overnight at 37°C. Pick several bacterial colonies and inoculate 
individually into 5 ml of LB containing100µg/ml ampicillin. Grow overnight at 37°C 
with shaking. Extract plasmid DNA from each bacterial overnight culture using QIAprep 
Spin Miniprep Kit according to manufacturer’s instruction. Elute DNA with 50µl of 
elution buffer. A quick comparison of the various scFv-VP16 clones can be achieved by a 
gel-DNA fingerprinting method of the product on 2% agarose gels.  
 
4h. Fingerprinting PCR bands 
 
Each individual V region of scFv gives an own “fingerprint”. Fingerprinting carried out 
on V genes will give a number of discrete bands. They can be carried out on V regions 
amplified from cDNA from individual clones. 
If the fingerprinting is performed onto E.coli clones, pick one clone with a toothpick and 
dissolve it in 100 μl ddH2O. Use 1 μl in PCR reaction mix. Alternatively, if the 
fingerprinting is performed onto yeast clones, use Lyse-N-Go PCR reagent (Pierce, # 
78882) to lyse colonies prior to use them for PCR. 
 
DNA clone  1μl 
PCR buffer  2μl 
dNTP 2mM  2μl 
Taq   1μl 
BssH2 sense  1μl   
NheI antisense 1μl   
ddH2O  12μl 
 
 
 
94°C –1 min  ⏐ 
58°C –1 min  ⏐ 30 cycles 
72°C –1 min  ⏐ 
72°C-10 min 
4°C-24h 
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Check PCR amplifications on a 1.5% agarose gel, using 3 μl each PCR reaction mix. 
After verification, use the other 17 μl of reaction mix for digestion: 
DNAmix   17μl 
BstNI (20U/μl)  0.2μl 
NEB buffer 2   4μl 
BSA    0.4μl 
ddH2O   18.4μl 
 
Incubate at 60°C for 2 hours. Add 5 μl 6X gel loading buffer to each tube and load on 4% 
Metaphor/Nusieve TBE gel. Run 60V-120 min. A definitive comparison of the isolated 
scFv is obtained from DNA sequence. 
 
The isolated AD-fusion scFv plasmids must then undergo a secondary screening, for final 
validation, by cotransformation with the antigen bait and, in parallel, with a control 
unrelated antigen vector into L40 yeast strain (Visintin, 2002, 2004). The final validation 
for a positive interaction is assessed testing the co-transformed yeast colonies for His and 
lacZ gene activation.  
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4i. Verification of a positive Aβ-scFv two-hybrid interaction 
SECONDARY SCREENING 
 
The final validation for a positive interaction is assessed testing the co-transformed yeast 
colonies for His and lacZ gene activation.  
LexA-lamin encodes a lexA DNA-BD/human Lamin C hybrid and provides a control for 
fortuitous interaction between an unrelated Ag hybrid protein and your own scFv-VP16 
selected from SPLINT. 
If a positive interaction occurs between your target protein Aβ and the scFv-VP16 
selected from SPLINT the results you should obtain are shown in the table below: 
 
„bait“ „scFv-VP16“ YC selection medium HIS3 phenotype lacZ phenotype 
lexA-Aβ  scFv-VP16 -UKWL + blue 
lexA-Aβ  scFv-VP16 -WHULK + blue 
lexA-lamin scFv-VP16 -UKWL + white 
lexA-lamin scFv-VP16 -WHULK / / 
 
 
 
4j. Western blot analysis of scFv-VP16 
 
In order to verify that your selected scFv-VP16 should not contain a stop codon or a 
deletion, a western blot analysis on protein extract must be performed. 
Yeast protein extracts were prepared as described before; 20μl of sample are subjected to 
SDS-PAGE (12% acrylamide gels), in the presence of β-mercaptoethanol, and gels are 
subsequently blotted onto nitrocellulose membranes (Schleicher & Schuell). For 
immunodetection, the monoclonal antibody anti-VP16 (BD-Clontech, #3844-1) (in 2% 
MPBS) is used, followed by incubation with a polyclonal anti-mouse-peroxidase 
conjugate (DAKO) (1:2000 in 2% MPBS). 
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5. Expression of scFvs anti-Aβ in bacteria 
for protein preparation and purification 
 
 
5a. Cloning and expression of scFvs anti-Aβ for periplasmic preparation 
 
The anti-Aβ SPLINT-selected scFvs were cloned by restriction with the enzymes 
BssHII/NheI into the pDAN3 vector for periplasmic expression of proteins (kindly 
provided by prof. Sblattero, University of Trieste). The vector allows the expression 
with two tags at the C-terminus: an SV5 tag and a His tag. A specific suppressor 
strain HB2151 E.coli [K12, ara Δ(lac-pro), thi/F’ proA+B+, lackIq ZΔM15] 
(Invitrogen) was transformed with pDAN3-scFvs constructs, and positive clones were 
grown in the following conditions. 
 
Periplasmic expression of scFvs anti-Aβ  
400 mL of 2*YT medium + Ampicillin were inoculated with an overnight culture 
at 1:100 ratio. The cultures were grown at 37°C until an OD600=0.5-0.6 and then 
induced with IPTG 1 mM for 4.5 hours at 30°C. 
The cells were harvested at 5000 rpm (Beckman). The pellet was resuspended in 
10 mL of cold PPB buffer (200mg/mL sucrose, 1mM EDTA, 30mM Tris-HCl 
pH8), and incubated on ice for 20 minutes. Then, the sample was centrifuged at 
5000 rpm for 15 minutes and the supernatant was transferred in a new tube. The 
pellet was resuspended in 10 mL of 5 mM MgSO4 buffer and incubated on ice for 
20 minutes. Then, both preparation were centrifuged at 10000 rpm for 15 minutes, 
the supernatant was collected and dialyzed against PBS.  
 
Purification of the scFv from periplasm 
The purification of the scFv expressed in the periplasm of E. coli was achieved 
through affinity purification on the Ni-NTA resin (QIagen). The procedure was 
the one indicated by the manufacturer.  
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Purified scFv proteins were analyzed by SDS-PAGE and by the following Blue-
Comassie staining. 
For the SDS-PAGE, the discontinuous system was composed by a 6 % (w/v) 
stacking and a 12 % or 15 % running. The samples in Laemly sample buffer with 
reducing agents were boiled for 3 minutes and loaded, on the gel. The gel was run 
at 15 mA for 2 hours. 
Gels were stained with Coomassie blue [solution: 40% (v/v) EtOH, 10% (v/v) 
CH3COOH, 0.1% (w/v) Coomassie blue R250] for 2-3 hours and then destained 
for several hours [destaining solution for protein gels: 40% (v/v) EtOH, 10% (v/v) 
CH3COOH]. 
All the analitical Superdex-75 gel filtration chromatographic analyses were 
performed in collaboration with Dr. Covaceuszach, (Lay Line Genomics, Trieste). 
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5b. Cloning and expression of the scFv in the cytoplasm of E. coli 
 
Cloning of the scFv 
The scFvs anti-Aβ selected from SPLINT were sub-cloned into the vector pGIO1 
for cytoplasmic expression in BL21(DE3)pLysS E.coli (Novagen). The vector 
pGIO1 described in the “Results section” is derived from pETM13 kindly 
provided by Dr. Covaceuszach, (Lay Line Genomics, Trieste). 
ScFvs were cloned by restriction with the enzymes BssHII/NheI into the pGIO1, 
and transformed in BL21(DE3)pLysS E.coli. 
 
The following protocols were kindly provided by Dr. Paoletti (EBRI, Roma) and 
discussed in her PhD thesis (SISSA, 2006). 
Experimental procedures of cytoplasmic expression and purification of scFvs 
anti-Aβ were kindly performed by Dr. Visintin (LayLineGenomics, Trieste). 
 
Expression of the scFv in the cytoplasm of E. coli 
400 mL of 2*YT medium + Kanamycin were inoculated with an overnight culture 
at 1:100 ratio. The cultures were grown at 37°C until an OD600=0.7-0.8 and then 
induced with IPTG 0.5 mM for 4.5 hours at 37°C. 
The cells were harvested at 5000 rpm (Beckman) and the pellets were saved at -
80°C. 
 
Extraction, purification and refolding of scFvs anti-Aβ from cytoplasmic 
inclusion bodies  
Buffers composition 
− IB-resuspension buffer: 100 mM Tris/HCl, pH 7; 1 mM EDTA 
− IB-washing buffer (Triton-IB): 60 mM EDTA; 6% (v/v) Triton X-100; 1.5 M 
NaCl 
− IB-washing buffer: 100 mM Tris/HCl, pH 7,0; 20 mM EDTA 
− IB-solubilization buffer: 100 mM Tris/HCl, pH 8; 6 M GdmCl; 10 mM 
EDTA; 100 mM DTT 
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− IB-dialysis buffer: 6 M GdmCl, pH 4; 10 mM EDTA 
− refolding buffer: Tris 100mM pH 8.5, 400mM Arg, 375uM GSSG, 5mM 
EDTA. 
The cell pellet was resuspended with resuspension buffer at 5 mL/g. Then, 
lysozyme was added at 1.5 mg/g, together with 3mM MgCl2 and DNaseI 
50μg/mL and the sample was incubated at 4°C for 30 minutes. Finally, the cell 
disruption was performed via sonication (three pulses of 45 seconds each at 13000 
micron, followed by 1 minute incubation on ice). Then, 0.5 times the volume of 
buffer Triton-IB was added, and the sample was incubated at room temperature 
for 30 minutes on a stirring plate, to disrupt the membrane elements. 
The IB were then centrifuged for 10 minutes  at 4°C at 10000 rpm, resuspended in 
20 mL of resuspension buffer + 10 mL of Buffer Triton-IB and incubated at room 
temperature for 30 minutes on a stirring plate.  
The IB were then centrifuged for 10 minutes  at 4°C at 10000 rpm and 
subsequently washed three other times, each one with 40 mL of washing buffer 
IB. The IB pellet was then stored at -20°C or immediately solubilized. 
 
IB solubilization  
The IB pellet was resuspended with solubilization buffer at a ratio of 5 mL/g and 
incubated for 2 h at RT on rocking platform. Then, the pH was lowered to 3-4 by 
dropwise addition of HCl 1M or concentrated CH3COOH, to avoid the oxidation 
of Cysteins to disulfide bridges in denaturing conditions. 
The insoluble cellular elements were then removed by centrifugation at 10000 
rpm and 4°C for 30 minutes.  
Subsequently, the DTT was removed through a triple dialysis each one against 
300 mL of Buffer Dialysis IB, each for twelve hours at 4°C.  
The protein concentration was estimated with the Protein Assay from BIO-RAD 
(Lowry system). The solute was immediately used for renaturation or stored at -
80°C. 
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Refolding of scFvs anti-Aβ  
The pulsed renaturation was performed in 1 L of refolding buffer, at 6°C at a 
protein concentration of 50 μg/mL. Every hour 35 μg/mL of new protein were 
added to the buffer under vigorous stirring and then the stirrer was switched off. 
The maximum sustainable concentration of GdmHCl was of 500 mM, to avoid 
loss of product. After 16-48 hours after the last addition, the sample was 
concentrated to a volume of approximately 200-300 mL, using a cross-flow 
filtration system or, alternatively, with an ultrafiltration device. Finally, the 
sample was dialyzed for 16 hours at 4°C against Tris 20mM pH8 buffer. Smaller 
volumes were dialyzed, covered with PEG 35000 and left at 6°C until the desired 
volume was reached. 
 
Purification of refolded scFvs anti-Aβ  
The purification of the refolded scFvs anti-Aβ were achieved through two 
subsequent steps: an anion exchange chromatography and a size-exclusion 
chromatography. 
The anion exchange chromatography was performed on a HiTrap Q column (5 
mL – Amersham Pharmacia), equilibrated with 20 mM Tris, pH 8 as A buffer. 
The elution of the sample was achieved with a linear gradient from 0 to 70 % of B 
buffer (A buffer + 1 M NaCl). 
The sample was then dialyzed against PBS and purified on a size exclusion 
chromatography column, a Superdex 75 (Amersham Pharmacia), equilibrated 
with PBS.  
 
The purification of the refolded scFvs were achieved through a ion exchange 
chromatography.  
The cation exchange chromatography for A13 was performed on HiTrap SP 
column (5 mL – Amersham Pharmacia), equilibrated with 20mM sodium 
phosphate buffer, pH 7 as A buffer. The elution of the sample was achieved with 
a linear gradient from 0 to 70 % of B buffer (A buffer + 1 M NaCl). 
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The cation exchange chromatography for scFvs A1, A18, Im8, B2, A19 was 
performed on HiTrap SP column (5 mL – Amersham Pharmacia), equilibrated 
with 20mM sodium phosphate buffer, pH 6.5 as A buffer. The elution of the 
sample was achieved with a linear gradient from 0 to 70 % of B buffer (A buffer 
+ 1 M NaCl). 
The anion exchange chromatography for Im1 was performed on HiTrap Q column 
(5 mL – Amersham Pharmacia), equilibrated with 20 mM Tris, pH 8.5 as A 
buffer. The elution of the sample was achieved with a linear gradient from 0 to 70 
% of B buffer (A buffer + 1 M NaCl). The sample was then dialyzed against PBS. 
The anion exchange chromatography for Im47 was performed on HiTrap Q 
column (5 mL – Amersham Pharmacia), equilibrated with 20 mM Tris, pH 8.5 as 
A buffer. The elution of the sample was achieved with a linear gradient from 0 to 
70 % of B buffer (A buffer + 1 M NaCl). The sample was then dialyzed against 
PBS. 
The cation exchange chromatography for scFvs Im3 and Im18 was performed on 
HiTrap SP column (5 mL – Amersham Pharmacia), equilibrated with 20mM 
sodium phosphate buffer, pH 6.5 as A buffer. The elution of the sample was 
achieved with a linear gradient from 0 to 70 % of B buffer (A buffer + 1 M NaCl). 
The anion exchange chromatography for Im32 was performed on HiTrap Q 
column (5 mL – Amersham Pharmacia), equilibrated with 20 mM Tris, pH 8.5 as 
A buffer. The elution of the sample was achieved with a linear gradient from 0 to 
70 % of B buffer (A buffer + 1 M NaCl). The sample was then dialyzed against 
PBS. 
 
Purified scFv proteins were also analyzed by SDS-PAGE and by the following 
Blue-Comassie staining, as indicated for periplasmic purified proteins (see 
above). 
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6. Cloning of scFvs anti-Aβ into scFv-cyto-SV5 vector and 
expression in mammalian cells 
 
The cDNA of the scFvs anti-Aβ were subcloned by restriction with enzymes 
BssHII/NheI into the vector scFv-cyto-SV5 (kindly provided by Dr. Visintin, 
LayLineGenomics, Trieste) for mammalian cells transfection, cut with the same 
enzymes.  
The subsequent transfection of the NIH 3T3 cells was performed with standards 
methods, using FuGene 6 (Roche) to transfect the cells, according to manufacturers 
instructions.  
Immunofluorescence 
3T3 cells were grown in D-MEM complete 10% FBS. For immunofluorescence 
purposes were grown on coverslips. The cells were fixed in 4 % paraformaldheyde 
for 20 minutes at room temperature and then washed 3-4 times with PBS. Then, they 
were permeabilized for 5 minutes in 0.1 % NP40 in PBS and washed three times with 
PBS. A blocking step in 10 % Fetal Calf Serum (FCS) was then performed for 20 
minutes at room temperature. Then, the primary antibody anti-V5 (MAb Invitrogen) 
was applied, at a 1:1000 dilution in 10 % FCS, for 60 minutes at room temperature.  
After rinsing three times with 5 % FCS, the secondary antibody, anti-mouse 
AlexaFluor 488 conjugated was applied, at a 1:500 dilution in 10 % FCS for 30 
minutes at room temperature. Then, the cells were washed and the DAPI (Boehringer) 
was applied at 1:1000 in PBS (from a stock solution of 2 mg/mL) for 5 minutes at 
room temperature. Finally, the cells were rinsed in PBS and the coverslips mounted in 
Vecta-shield (Vector laboratories). The Immunofluorescence was observed with a 
Zeiss Axioplan microscope. Images were acquired with Nikon Coolpix 990 digital 
camera.  
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7. IN VITRO ASSAYS 
 
7a. ELISA with coating of different aggregated forms of synthetic Aβ 
peptide 
 
Wells of PVC (Corning) were coated with monomeric, fibrillar and oligomeric forms (see 
below note 1) of human Aβ42 peptide (Biosource) in Phosphate-buffered saline (PBS) 
buffer (pH 7.4) and incubated at 10μg/ml over night at 4°C.  
After removing the coating solution, the wells were incubated with the primary 
antibodies: MAb 4G8 (1μg/ml=~6.7nM) (Signet), immune sera of mice (1:10000), scFvs 
anti-Aβ (25μg/ml=0.8μM) or unrelated scFv (25μg/ml=0.8μM) in 2% non-fat dry 
milk/PBS, for 2hrs at room temperature. Recombinant purified scFvs present a C-
terminal SV5 tag, that allows to detect them using a MAb anti-SV5 (1μg/ml) 
(Invitrogen). Anti-mouse HRP-conjugated secondary antibody (Dako) was incubated in 
2% non-fat dry milk/PBS, for 1hrs at room temperature. 
Between all the incubations steps the plate was washed with T-PBS (a PBS solution 
containing 0.05 % of Tween-20 detergent) and PBS for three times each. 
The colorimetric reaction was detected using Tetramethylbenzidine (TMB) (Pierce) after 
stopping with H2SO4 1M. The intensity of the colorimetric signals were analysed with a 
spectrophotometer at 450 nm using an ELISA Reader. 
 
Notes.  
1) Monomeric and fibrillar Aβ42 were prepared as described (Stine et al., 2003); Aβ42 
oligomers in format of ADDLs were kindly provided by Dr. Westlind-Danielsson 
(University of Stockholm) and prepared following the above-mentioned protocol (Stine et 
al.,2003).  
All the Aβ species were checked by Western Blot analysis, using NuPAGE bis-tris 4-
12% (Invitrogen) or Criterion XT bis-tris 4-12% (BioRad). Electrophoresis was 
performed in MES buffer (Invitrogen, BioRad), at 200V for ~30min. Samples, in non-
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reducing LDS sample buffer, were not boiled before loading. Semi-dry blotting was then 
performed using appropriate transfer buffer on nitrocellulose membrane 0.2μm, for ~1h. 
After blotting, the membrane was incubated for 1 hour at room temperature in 5 % 
blocking solution of non-fat dry milk in TBS-T (0.05 % of Tween-20). Then, the 
membrane was incubated with the primary antibody MAb 4G8 (Signet) (1:1000) in 3 % 
M-TBST, for 16 hours at 4°C. After washing with TBS-T and TBS, the membrane was 
incubated with the secondary antibody anti-mouse HRP-conjugated (Dako).  
After washing again with TBS-T and TBS, the developing was carried out with the ECL 
chemiluminescent system. The membrane was briefly dried and incubated for 1 minute 
with the developing solution (mix solution A and B of the Amersham kit) and the films 
were exposed for different time frames. 
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7b. ELISA Protocol using NeutrAvidin™ Coated Plates (Pierce) 
 
A. Materials  
• Wash Buffer: PBS-T (PBS, 0.05% Tween®-20) 
• Incubation Buffer: PBS, 0.05% Tween®-20, 0.1% BSA,  
• Biotinylated Aβ40/42 (Bachem) (see below, note 1) diluted in Incubation Buffer 
• Primary antibodies (see below, note 2) diluted in Incubation Buffer  
• HRP-labeled secondary antibody  
• TMB Substrate Kit (pierce) for horseradish peroxidase  
B. Method 
1. Wash each well three times with 200 μl of Wash Buffer. 
2. Add 100 μl of the biotinylated Aβ to each well and incubate for 2 hours at 
room temperature. 
3. Wash each well three times with 200 μl of Wash Buffer.  
4. Add 100 μl of the primary antibody to each well and incubate plate for 2 
hours at room temperature. 
5. Wash each well three times with 200 μl of Wash Buffer.  
6. Add 100 μl of the HRP-labeled secondary antibody to each well. Incubate 
plate for 1hour at room temperature. 
7. Wash each well three times with 200 μl of Wash Buffer. 
8. The colorimetric reaction was detected using 70 μl of 
Tetramethylbenzidine (TMB) (Pierce) after stopping with 70μl of H2SO4 
1M. The intensity of the colorimetric signals were analysed with a 
spectrophotometer at 450 nm using an ELISA reader 
Notes 
1) Lyophilized amyloid peptides hAβ40-biot and hAβ42-biot (Bachem) according to the 
manufacturer’s instructions were solubilized 1mg/ml in NH4OH 2%. For standard 
NeutrAvidin assays were diluted in Incubation Buffer (see above) at different 
concentrations (see “Results section”). For Oligomerization Assay in NeutrAvidin plates 
hAβ42was solubilized in Ham F12 (without phenol red) (Biosource): details of this assay 
are in the “Results section”.  
 
2) Anti-Aβ scFvs SPLINT selected were tested at different concentrations. For details of 
these and other primary antibodies, see the “Results section”.  
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7c. IMMUNOPRECIPITATION (IP) 
 
Materials 
• RIPA buffer for immunoprecipitation: 50 mM Tris, pH 7.4, 150 mM NaCl, 1 
% Triton X-100, 1 % Deoxycholate, 10 mM EDTA 
• PBS: 173 mM NaCl, 27 mM KCl, 4.3 mM Na2HPO4, 1.4 mM KH2PO4 
• Protein G Sepharose (Amersham) 
• PAb anti-V5 (Sigma) 
• MAb anti-V5 (Invitrogen) 
• MAb anti-Aβ 4G8 (Signet) 
• PAb anti-Aβ42 (Chemicon) 
• humanAβ42 monomer (Biosource) and hAβ42 ADDLs (kindly provided by 
Dr. Westlind-Danielsson, University of Stockholm) (see materials in “ELISA 
section”) 
 
Methods 
 
IP scFv A1+hADDLs (protocol n.1) 
scFv A1:  
• concentration 160ng/μl ≈ 5μM = 5 pmoles/μl 
• volume  80μl =12.8μg = 400pmoles 
 
hADDLs: 
• concentration: 0.45 μg/μl = 100μM monomer Aβ = 100pmoles/μl 
• volume  10μl=4.5μg= 1000pmoles  
 
Protocol: 
- coincubation A1+ADDLs for 2hrs 30min 4ºC; 
- coincubation ProtG (30μl) + PAb antiV5(1μl=4μg) for 1h; 
- centrifuge protG, eliminate supernatant, and resuspend in 800μl RIPA  
- add to protG in RIPA, in two different eppendorf: 1) (A1+ADDLs); 2) (ADDLs) 
- coincubation for1h 30 min 4ºC; 
- centrifuge at 6000rpm 
- wash 3 times with 500μl RIPA buffer 
- Western Blot with final pellets and first supernatant (primary antibody MAb anti-Aβ 
4G8)  
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IP scFv B2+hAβ monomer (protocol n.1) 
IP scFv B2+hADDLs (protocol n.1) 
 
scFv B2:  
• concentration 160ng/μl ≈ 5μM = 5 pmoles/μl 
• volume  70μl =11.2μg = 350pmoles 
 
hAβ monomer  
• concentration: 0.45 μg/μl = 100μM of monomer Aβ = 100pmoles/μl 
• volume 10μl=4.5μg= 1000pmoles 
 
hADDLs: 
• concentration: 0.45 μg/μl = 100μM of monomer Aβ = 100pmoles/μl 
• volume 1μl=0.45μg= 100pmoles  
 
Protocol: 
- coincubation (B2+hAβ monomer) and (B2+ADDLs) for 3hrs 4ºC; 
- coincubation ProtG (30μl) + PAb antiV5(1μl=4μg) in 500μlfor 1h 30min;  
- centrifuge protG, elimin sup, and resusp in 800μl RIPA  
- add to protG in RIPA, in four different eppendorf: 1) (B2+ Aβ monom); 2) (Aβ 
monom); 3) (B2+ADDLs); 4) (ADDLs) 
- coincubation for1h 30 min 4ºC; 
- centrifuge at 6000rpm 
- wash 5 times with 500μl RIPA buffer 
- Western Blot with final pellets and first supernatant (primary antibody MAb anti-Aβ 
4G8)  
 
 
IP scFvB2+hADDLs (protocol n.2) 
 
scFv B2:  
• concentration 160ng/μl ≈ 5μM = 5 pmoles/μl 
• volume  60μl =11.2μg = 350pmoles 
 
MAb anti-V5  
• concentration 1.3μg/μl ≈  100μM = 100 pmoles/μl 
• volume  2.5μl =3.25μg = 250 pmoles (bivalent Æ binding: 1Ig:2scFvs) 
 
hADDLs: 
• concentration: 0.45 μg/μl = 100μM of monomer Aβ = 100pmoles/μl 
• volume 1μl=0.45μg= 100pmoles  
 
Protocol: 
- coincubation (B2+MAb antiV5) for 1h30min 4ºC; 
- add protG in 400μl RIPA, incubation for 4h 4ºC; 
 93
- wash (1x), resuspend in 400μl RIPA 
- incubation 1h ice; 
- add ADDLs 1μl (100pmoles)   
- coincubation for1h 4ºC; 
- centrifuge at 6000rpm 
- wash 6 times with 400μl RIPA buffer 
- Western Blot with final pellets and first supernatant (primary antibody PAb anti-Aβ42) 
 
 
Note: for Western Blot analysis, see details above on 7a. section of  “Materials and 
Methods”, and also on the ‘Results section’.
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7d. IMMUNOHISTOCHEMISTRY (IHC) on human brains 
 
Sections of 40μm were prepared from Temporal Cortex of post-mortem human AD 
brains (Braak stage V-VI) and control (Braak 0-I), fixed for 24 h in 4% 
paraformaldehyde, then cryoprotected in sucrose 30%. 
Anatomical pieces were available in SISSA laboratories at -80°C, coming from the 
‘Netherland Human Brain Bank’. Free-floating sections were obtained using a microtome 
system and stored in 0.02% sodium azide in phosphate-buffered saline. The endogenous 
peroxidase activity was quenched for 30 min in 3% H2O2. Slices were incubated in 
blocking-permeabilization buffer (TBS, 0.3%TritonX100, 10%FBS) for 30 min. The 
appropriate primary antibody (in blocking solution) was applied overnight at 4 °C, at the 
following concentrations: MAb 4G8 (Signet): ~2μg/ml, (dilution 1:500 of initial stock 
1μg/μl); PAb anti-Aβ42 (Chemicon): ~8μg/ml (dilution 1:150 of initial stock ~1μg/μl); 
scFvs anti-Aβ ~50μg/ml. 
Sections were washed with PBS and incubated with the appropriate secondary antibody 
for 1 h.  
When scFvs were used as primary antibodies, the signal were detected via a sandwich of 
antibodies using an intermediate MAb anti-V5 (Invitrogen, 1.3μg/μl, 1:1500), or PAb 
anti-V5 (Sigma, 4μg/μl, 1:800) and after the appropriate secondary for IHC. 
Staining was revealed with the Vector ABC peroxidase standard kit and 
diaminobenzidine (DAB) (0.05% or 1:500 in Tris buffer for 2 min) (kit ELITE pK6100 
Vector Laboratories).  
 
 
7e. IMMUNOFLUORESCENCE (IF) on human brains 
 
For fluorescence microscopy, sections were incubated in 90% formic acid for 7 min to 
expose the Aβ epitope. The steps of blocking-permeabilization are similar to the IHC 
protocol; the sections were then incubated in the appropriate primary antibody (see IHC 
for concentrations) overnight at 4 °C. After the incubation (~2h) with MAb or PAb anti-
V5 only for scFvs (see IHC), suitable Alexa Fluor secondary antibody (Molecular 
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Probes) was applied. The reduction of autofluorescence was performed by treatment with 
Sudan Black solution 0.8% in EtOH70%. Subsequently, sections were washed in H2O 
and phosphate buffered saline, mounted on slide and coverslip with Vectashield (Vector 
Laboratories).  
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8. CELL BIOLOGY ASSAYS 
 
8a. SHSY5Y cell cultures: neuroprotection assay 
 
Cell Culture and Treatments  
Human neuroblastoma SHSY5Y cells were maintained in Dulbecco’s modified Eagles 
medium (DMEM) (GIBCO) supplemented with 2 mM L-glutamine and 10% (v/v) fetal 
bovine serum (FBS). Cells were plated at low density and grown to 80% confluency on 
96-well plates at 37ºC in a humidified 5% CO2 atmosphere incubator.  
Before treatment with anti-Aβ scFvs (E.coli purified proteins), cells were rinsed once 
with serum-free DMEM media (without phenol red).  
In the chronic toxicity neutralization protocol scFvs anti-Aβ, (1.5nM to 600nM), and 
serum-free DMEM media (without phenol red) were added to cells simultaneously for 2 
hrs, followed by addition of 600 nM Aβ oligomers hADDLs directly to cells and 
incubation for up to 46 hr at 37ºC. 
In the acute toxicity neutralization protocol, Aβ oligomers hADDLs (2.5μM) were 
preincubated or not with scFvs anti-Aβ (550nM) in serum-free DMEM media (without 
phenol red) for 2 hrs with gentle shaking at 37ºC, followed by their addition to cells 
simultaneously and incubation for up to 16 hr at 37ºC. 
In both protocols, cells were also treated with “vehicle solutions” and with scFvs alone as 
internal controls. 
 
Cell viability assays 
Cell viability was determined by DNA-binding fluorochrome Hoechst 33342 (5μg/ml) 
(Molecular probes); cells were incubated with the dye for 10min at 37ºC in the dark, 
rinsed with PBS and examined with Nikon Diaphot inverted epifluorescence microscope 
with 20X and 40X objectives. Cells showing condensed nuclei were identified from an 
average of ~300 cells per treatment and cell bacht. We evaluated 1500-2100 cells per 
treatment. See other details in the “Results section”. 
Cell viability was also measured by the MTT tetrazolium salt assay (Mosmann, 1983); 
MTT (Sigma) solution was added to cell cultures (0.5mg/ml) and was incubated for 1-
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2hrs. Medium was then removed and the cells were solubized with DMSO (Applichem). 
The intensity of the colorimetric signals were analysed with a spectrophotometer at 570 
nm (with the subtraction of 650nm measured background) using an ELISA Reader 
(BioRad).  
 
Statistical analysis 
Values are expressed as mean ± SE. Statistical analysis was performed with Anova 
followed by Newman-Keuls test, using the software SigmaStat™. Statistical significance 
was accepted at the 95% confidence level (P<0.05). 
 
 
8b. Synaptic binding assay 
Cell Culture  
Hippocampal cells were kindly prepared from embryonic day 18 (E18) rat pups by M.T. 
Ciotti (Institute of Neurobiology and Molecular Medicine, CNR, Roma), coated on poly-
L-lysine (0.002%) coated coverslips, and maintained in Neurobasal with B27 
supplements and L-glutamine (2.5 μM), at least 21 days in vitro (DIV). 
When ADDLs were added, medium was changed to F12 medium (phenol-red free) with 
300 nM synthetic ADDLs; in the synaptic binding blocking assay, ADDLs (300nM) were 
previously incubated with scFvs anti-Aβ (300-600nM), for 2hrs at 37ºC. ADDLs or 
ADDLs-scFvs solutions were incubated for 20min, and then gently rinsed with PBS.  
Immunocytochemistry  
Cells were fixed at room temperature in 1.88% formaldehyde for 5 min, followed by a 
post-fix for 10 min in 3.7% formaldehyde.  
The coverslips were washed, permeabilized with 0.1% Triton X-100 in 10% normal goat 
serum and PBS (NGS:PBS) for 60 min at room temperature. Bound ADDLs were 
identified by incubation with the polyclonal anti-oligomer PAb A11 (Biosource) 
(1:1000); MAb anti-PSD95 (Chemicon) (1:700) was co-incubated overnight at 4°C. 
Alexa Fluor (molecular Probes) anti-rabbit and anti-mouse were used as secondary 
antibodies (incubation ~2 hrs at room temperature). The cells were rinsed, mounted with 
Vecta-Shield (Vector Laboratories) and analyzed by fluorescence microscopy (Nikon). 
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8c. PC12 model 
 
Cell culture 
 
PC12 cells were maintained in RPMI medium containing 10% horse serum and 5% foetal 
bovine serum (GIBCO). Differentiation was achieved by placing PC12 in Petri dishes in 
the presence of 10% horse serum and 5% foetal bovine serum (GIBCO) and NGF 
(50ng/ml) for 10-12 days. To ensure maximum bioavailability, NGF and serum were 
replaced every 2 days.  
To induce apoptosis, cells were washed three times with PBS and one in serum free 
medium. Subsequently, cells were placed in serum-free media with NGF (50 ng/ml) 
(+NGF) or without NGF (-NGF).  
 
Treatment with γ and β secretase inhibitors and anti-Aβ antibodies 
 
γ (L-685,458, Calbiochem) and β-secretase (MBL) inhibitors, anti-Aβ antibodies 
MAb4G8 (Chemicon) and scFv A13 (E.coli purified recombinant protein) were tested in 
PC12 cells deprived of serum (+NGF) and in PC12 cells deprived of serum and NGF (-
NGF) for 48 hrs with the aim of evaluating the highest non toxic concentration of each 
drug. γ inhibitor was used at concentrations ranging from 50 to 70nM, β-secretase 
inhibitor from 0,2 to 2,4 μM, Mab4G8 was used at 6.7 nM and scFv A13 in the range 
from 1nM to 2 nM 
 
Treatment with TrK-a (K-252a)  
A 2mM stock solution of K-252a (Calbiochem) was prepared in dimethylsulfoxide 
(Me2SO) and stored in the dark at 4 °C, according to the manufacturer. For each 
experiment, PC12 cells were deprived of serum for 2 hrs using a serum free RPMI 
containing either the K-252a stock solution in appropriate dilution (ranging from 50nM to 
200nM) or similar amounts of Me2SO as control. In dose-response experiments, after a 2 
hrs K-252a incubation, cells were washed three times and re-exposed to NGF (50ng/ml) 
for 48 hrs when the cell viability and extent of ThT binding release were measured.  
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Western blotting 
 
Equal amounts (10-20μg) of proteins were separated on 4-12% Bis-Tris SDS-PAGE gels 
or 16% Tricine gels (Invitrogen), blotted onto PVDF membranes (Millipore) and 
incubated overnight with the appropriate primary antibody. The antibodies used was 
mouse monoclonal anti Aβ (6E10) from Chemicon, and anti-β-actin antibody from 
Sigma.  
 
Fibrils purification procedure 
 
Beta sheets aggregates were isolated from media of cultured cells deprived of serum and 
NGF for 48 hrs, following the methods previously described and adapted to the 
experimental conditions of this study (Matrone et al., submitted paper). 
Briefly, the culture medium was centrifuged at 10.000xg for 30 min in order to remove 
cell debris and the supernatant was further centrifuged at 100000xg for 2h at 4°C. The 
resulting small pellet was first dissolved in 100 μl of 70% glass-distilled formic acid and 
the volume was reduced by a vacuum concentrator (speed vac) to 10μl. Finally, 90μl of 
Tris 2M, containing protease inhibitors, were added to the samples to a final volume of 
100μl and 10μl of each sample was quantified by Bradford methods. Equal amounts of 
proteins were finally analysed for Aβ1-42 by Elisa assay and by Western Blot. 
 
ELISA 
Wells of PVC were coated with Donkey anti-mouse IgG in carbonate buffer (pH 7.4) and 
incubated over night at 4°C. After removing the coating solution, the wells were 
incubated with the capture mouse anti-Aβ antibody 6E10, recognizing residues 1-17 of 
Aβ (Chemicon) in 5% non-fat dry milk/TBS 0.05% Tween, for 3hrs at room temperature 
and then exposed to 50μl of appropriately diluted samples. The quantification of Aβ was 
done with the polyclonal rabbit antibody Aβ1-40 and Aβ1-42 (Biosource) 0.5μg/ml and 
1μg/ml, respectively. The values of samples were compared against those of standard 
curve which was generated from samples of known concentrations (0.040 to 2.0 ng/ml) 
of Aβ1-40 or Aβ1-42 and then expressed as pg/mg of total protein. To ensure accuracy, 
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standards (duplicate or triplicates), and blank were run with each plate The colorimetric 
reaction was detected using Tetramethylbenzidine (TMB) after stopping with HCl 1M. 
 
Thioflavine T assay 
Fluorescence measurements of thioflavine binding proteins were obtained, at the 
excitation and emission wavelength of 446 and 490nm, respectively, incubating 5 μM 
thioflavin T (ThT, Sigma) in 1 ml of culture medium obtained from PC12. Controls were 
run under the same conditions with fresh, non incubated media and subtracted form 
experimental samples. In preliminary experiments the possible interference of phenol red 
on Th-T binding and absorbance were performed by incubating cells under identical 
experimental conditions with a culture medium devoid of phenol red. We found that 
optical readings did not show any significative difference both in absence and in presence 
of phenol red.  
 
Statistical analysis 
Values are expressed as mean ± SE. Statistical analysis was performed with Anova 
followed by Newman-Keuls test. Statistical significance was accepted at the 95% 
confidence level (P<0.05) 
 
The experiments in the PC12 model were performed in collaboration with Dr. Matrone 
(Institute of Neurobiology and Molecular Medicine, CNR, Roma). 
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Construction of an Aβ immune SPLINT library  
and IACT selections of scFvs anti- Aβ  
Here we describe the design, construction, analysis and selection of a single pot library of 
intrabodies (SPLINT) (Visintin et al., 2004), a library of V regions assembled in the 
format of single chain variable Fragments (scFvs), derived from hyperimmune spleens of 
mice immunized with human Aβ1-42.  
Moreover, we describe the first complete comparative analysis between the selection of 
scFvs from SPLINT immune and SPLINT naïve libraries against the same antigen (Aβ 1-
42), using the Intracellular Antibody Capture Technology (IACT) (Visintin et al., 2002, 
2004a, 2004b).  
 
1. Construction of scFv library from Aβ1-42 immunized mice 
1.1 Immunization of mice and screening of sera 
Three mice Balb-C (6-8 weeks old) were used for immunization. Preimmune serum was 
taken on day 0. A total of four injections were administered (100μg antigen per animal 
per injection). The first injection on day 0 with equal parts (v/v) of complete Freund’s 
adjuvant and human Aβ1-42 (2mg/ml in PBS) was performed to stimulate the production 
of high affinity antibodies against this antigen. The aggregation status of Aβ peptide was 
not checked before immunization, but we can assume that it was mainly constituted of 
aggregated  in forms of oligomers and protofibrils, because the antigen was resuspended 
in PBS and incubated at 37°C before the administration. The following three boosts were 
carried out with equal parts (v/v) incomplete Freund's adjuvant and antigen on days 21 
and 42 with an additional final boost prior to spleen removal. 
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The mice sera have been tested for antibodies titer by ELISA assay against Aβ peptide 
coating (mostly monomeric; 10μg/ml in PBS), and unrelated antigen Bovine Serum 
Albumin (BSA). Mice sera before immunization and sera after the first boost did not 
show specific immunoreactivity against human Aβ1-42: similar ELISA values were 
observed against Aβ and BSA (unrelated antingen) and only at low dilutions (1:1) of sera.  
After different boosts, mice sera have shown high increase of specific immunoreactivity 
against Aβ peptide. After third and fourth boost, the antibodies titer was highly 
significant also at 1:10000 dilutions of sera (fig.1); only one mouse did not show high 
immunoresponse to human Aβ and shows splenomegalic complications.  
 
 
Fig.1 Titers of anti-Aβ Abs in the sera of immunized mice. 
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1.2 Construction and evaluation of scFv repertoire 
The cloning scheme used to create the scFv library SPLINT immune is outlined in fig.2, 
and identical to scheme followed to create naïve library, described by Visintin and 
coworkers (2004a).  
 
 
Fig.2 Construction of SPLINT library: from mice to cloning in two-hybrid vector (from 
Visintin et al, 2004a). 
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Natural V regions were cloned from total RNA extracted from lymphocytes pooled from 
three immunized mouse spleens. 
After cDNA synthesis performed by random hexamer priming, mouse V regions were 
amplified (fig.3) by using a set of partially degenerated 5’and 3’mouse-specific primers 
(Orlandi et al., 1992), suitably re-designed (Sblattero and Bradbury, 2000).  
 
 
Fig.3 results of individual PCR amplifications of VH and VL regions. 
 
V regions from cDNA were subsequently amplified, to add extra restriction sites for their 
assembly into scFv fragments. VH and VL gene mix were assembled together in the scFv 
format by overlap extension PCR (Sheets et al., 1998). 
The scFv assembled library was then subcloned for expression as a VP16 fusion in pMV1 
plasmid (modified version of pLinker220) kindly provided by Dr. Visintin 
(LayLineGenomics, Trieste) (fig.5). This cloning in pMV1 was obtained by large scale 
ligation and large scale transformation in electro-competent DH5αF’ cells.   
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Large scale ligation was performed after several trials of small scale ligations in order to 
obtain the highest cloning efficiency: crucial was obtaining an excellent preparation of 
double-digested BssHII-NheI pMV1 vector, that produce the smallest number of false 
positive transformants carrying “empty” vector after transformation in E.coli. We 
performed large scale ligation following an optimized protocol mixing a total amount of 
~400ng of pMV1 DNA and a total amount of ~250ng of “assembly scFv” cDNA. After a 
purification step of the ligation product, the ligated DNA was transformed in electro-
competent DH5αF’ cells (previously prepared and showing high efficiency of 
transformation: ~6x109 cfu / μg DNA). We obtained a large number of positive clones, 
estimated altogether in 1.7x106. Cloning efficiency close to 99% was confirmed by PCR 
amplification of randomly isolated bacterial clones. The percentage of transformed cells 
with vector pMV1 lacking the insert (scFv) was less than 1%. 
One hundred independent scFvs clones were randomly chosen and analyzed by 
separately amplifying VH and VL genes and fingerprinting them with the restriction 
enzyme BstNI (fig.4); the selected clones were also analyzed by sequencing. All the 
analyzed clones display a different sequence and fingerprinting pattern, confirming the 
diversity of the library. The “diversity” was estimated in 99% (percentage of different 
scFvs). 
 
 
Fig.4 Evaluation of “diversity” of SPLINT Aβ immune library, by BstNI fingerprinting 
analysis. 
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Considering the high “diversity” of library, the total number of positive clones obtained 
from our large scale transformation in E.coli, estimated in 1.7x106, corresponds 
approximately to the “complexity” of the library. The complexity of the library is the 
overall number of different VH and VL combinations that can obtained while 
constructing a scFv library.  
Even if the complexity of SPLINT Aβ-immune library (~106 different scFvs clones per 
μg DNA of original non-amplified library) is lower than the complexity of SPLINT naïve 
library (~107) (Visintin et al., 2004a), it remains compatible with the efficiency of 
transformation threshold of yeast cells (~106 cfu/μg DNA). Moreover, the required 
diversity for selecting high affinity antigen-specific antibodies from an immune library is 
much lower than that required from an non-immune library. 
As discussed by Visintin and coworkers (2004a), the real diversity of the library could be 
higher than the number of yeast transformants: this peculiarity could be achieved by yeast 
that express in any given cell more than one scFv. The final diversity may or may not 
result after further recombination events and after segregation of different scFvs in 
daughter cells. This latter event, could easily contribute to an increase of the real diversity 
by a factor ≥10 therefore, under the selective pressure of IACT, it may lead to the 
selective isolation of one antigen-specific scFv fragment. 
Thus, we expect that immune SPLINT anti-Aβ library could be a good source of specific 
anti-Aβ scFvs. 
The bulk DNA of the immune-library was transformed in L40 yeast cells to generate a 
population of scFvs-VP16 expressing yeast cells; the expression of scFv-VP16 fusion 
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protein and the diversity of the library were verified after selection of clones onto 
selective medium (–Leu = YC−UKL). 
 
 
 
 
 
 
Fig. 5 pMV1, is used for expression of SPLINT library as fusion to the VP16 activation 
domain. The LEU2 gene allow the maintenance of the plasmid and the selection on 
media lacking leucine in yeast strain L40. The bla gene permits the selection of plasmid 
in E.coli. (from Visintin et al., 2004a) 
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2. IACT selections in yeast 
 
2.1 Construction of human Aβ1-42 “bait” 
DNA sequence coding for human Aβ1-42 was cloned (BamHI-PstI) into pMIC-BD1 
(Visintin et al., 2004a, 2004b), specific vector for bait in IACT two-hybrid based system 
(kindly provided by Dr. Visintin, LayLineGenomics, Trieste).  
 
Fig.6 pMIC-BD1 uses the strong alcohol dehydrogenase promoter (ADH1) to express 
bait proteins as fusions to the DNA-binding protein lexA. The plasmid contains the TRP1 
selectable marker and the 2μ origin of replication to allow propagation in yeast, and the 
chloramphenicol resistance gene (Cam) to allow the selection in E. coli. 
 
We first check the expression level of the lexA fusion bait in L40 yeast cells (see Western 
Blot analysis in fig.7). Positive transformants carrying lexA-Aβ42 bait plasmid were 
selected by growth in medium lacking Trp (YC−WUK). 
 
 
Fig.7 Western Blot analysis of LexA-Aβ42 fusion protein and LexA protein under 
denaturing conditions. Anti-LexA polyclonal antibody was used for the detection.  
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The toxicity of LexA-Aβ42 bait protein in terms of L40 viability was evaluated; Aβ42 
bait showed a weak toxicity in L40 expressing cells, observing their growth and 
morphology in comparison with cells expressing only LexA. Finally, we have tested 
lexA-Aβ42 bait for unspecific trans-activation activity of the reporter genes. The Aβ42 
bait plasmid was cotransformed with empty “prey” plasmid, carrying the VP16 activation 
domain (without any scFv). Auto-transactivation was not observed for His3 reporter 
gene: in fact, co-transformants can growth only in medium lacking Trp and Leu (YC 
−WUKL) that select for plasmids. Cotransformed yeast cells cannot growth in medium 
lacking Trp, Leu and His (YC −WHULK) that select for specific protein-protein 
interaction, see table). Unspecific trans-activation activity was not observed for LacZ 
reporter gene too: in fact, Aβ42-bait and VP16-prey cotransformants that grown in 
medium lacking of Trp and Leu were not able to give a positive result in X-gal assay.  
In conclusion, Aβ42 resulted a good bait because it is well expressed, slightly toxic and it 
does not transactivate reporter genes under basal conditions.  
 
2.2 Large scale transformation of SPLINT libraries in L40 
IACT primary and secondary screening 
Two different screenings were performed: one using a naïve SPLINT library and the 
other using the above-discussed Aβ-immune SPLINT library. 
The naïve SPLINT library was previously used in several selection strategies against a 
panel of different antigens (Visintin et al., 2004a). It shows a nominal complexity of ~107 
different scFvs derived from V natural regions of non immunized mice.  
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Naïve and immune SPLINT libraries were separately introduced by maxi scale 
transformation into yeast cells expressing the LexA-Aβ1-42 “bait” and IACT selections 
were performed as described (Visintin et al., 2004a).  
The transformed amount of each library was of ~500μg of plasmid DNA, a huge amount 
of DNA that fully represent the entire libraries (~107 clones for naïve library and ~106 
clones for immune library). 
Following table resumes the growth conditions for the selection of vectors and interaction 
of IACT-SPLINT technology using the yeast strain L40 (genotype: MATa his3D200 
trp1-901 leu2-3112 ade2 LYS2::(4lexAop-HIS3) URA3::(8lexAop-lacZ) GAL4). 
 
Table: selective media for plasmid transformation and for Aβ bait- scFv prey interaction 
 Aβ bait scFv prey Aβ bait + scFv prey 
Selection for plasmid 
transformation 
YC −WUK YC −UKL YC −WULK 
Selection for 
interaction 
  YC −WHULK 
 
Note: L40 can grow onto –U and –K media because the lexA operator is integrated into URA and LYS 
markers. Using media with Ura and Lys dropped out, results in minimal background.  
 
 
In the primary screening (fig.8), double transformants were selected for histidine 
prototropy (grown in selective medium YC −WHULK) and lacZ activity. We have 
analyzed about 50 His+/lacZ+ different clones from the primary screening from naïve 
library and 50 different clones from the Aβ-immune library primary screening.  
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Fig.8 Primary screening: selection for histidine prototropy (in YC −WHULK plates) and 
for lacZ activity of positive clones and characterization of their scFv DNA by PCR-
fingerprinting. 
 
  
Yeast clones selected from the primary screening were characterized for diversity (by 
PCR BstNI-fingerprinting) and for specificity against Aβ by a secondary screening. The 
secondary screening confirmed that true positives could be identified that interact 
specifically with the original bait, but not with other lexA fusions (lexA-lamin) (fig.9). 
 
 
 
Fig.9 Secondary screening of one positive isolated clone selected from the primary 
screening. The plasmid coding the primarily selected scFv clone was co-transfected in 
L40 yeast with the plasmid coding the Aβ42 antigen (bait), or with the plasmid coding 
the unrelated antigen Lamin. Specific scFv clones are expected to interact only with Aβ 
bait. 
 
  
scFv + Aβ1-42 scFv + Lamin
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The following tables 1 and 2, resume the results obtained from SPLINT transformations 
and from primary and secondary screenings of SPLINT selections. 
 
Table 1. SPLINT selections with Aβ42 bait: efficiency of transformation of SPLINT 
naïve and immune libraries in L40 yeast and number of isolated positive clones from the 
primary screening selections (1/10 of total number of transformed yeast cells) 
 
 cfu/μg 
SPLINT-
DNA 
in L40 
 
No. of 
His3+/ lacZ+ 
rescued 
clones 
(I screening) 
Naïve 
Library 
1.2x106 900 
Immune 
Library 
1.3x106 2400 
 
 
Table 2. SPLINT selection with Aβ42 bait: primary and secondary screening results 
 
 No. of 
His3+ / lacZ+ 
analyzed 
clones 
 
 
(I screening) 
No. of 
non specific 
clones 
(Lamin +)  
 
 
(II screening) 
No. of 
true 
positive  
clones (Aβ+)  
His3+ / lacZ+ 
 
(II screening) 
No. of 
uncertain 
positive  
clones (Aβ+) 
His3+ / lacZ− 
 (II screening) 
No. of 
different 
positive 
clones 
 
Naïve 
Library 
50 15 20 15 11 
Immune 
Library 
50 1 25 24 7 
 
Immediate interpretation of SPLINT selections results suggest that Immune Library in 
comparison to Naïve Library allows selection of a larger number of positive clones in 
primary screening. 
ScFvs derived from immune library seems to be more specific because only 1/50 of the 
isolated scFv interacts with unrelated antigen Lamin in the secondary screening; 
moreover, these scFvs show stronger LacZ activation. However, the number of different 
 115
positive clones is higher from naïve SPLINT selection (11 naive scFvs versus 7 immune 
scFvs). In fact, a large number of true positive scFvs are highly redundant among the 
scFvs of the immune library screening: 3 different scFvs clones from the immune library 
(Im1, Im3 and Im47) represent more than 80% (Im3=10/25; Im1=5/25; Im47=5/25) of 
the total true positive clones.  
From Naïve and Immune Libraries we have selected a panel of 18 different scFvs: 11 of 
them from naïve SPLINT library (A1, A2, A5, A7, A9, A13, A18, A19, B2, B15, B21) 
and 7 from immune SPLINT library (Im1, Im3, Im8, Im11, Im18, Im32, Im47).  
Following tables (3 and 4) resume detailed properties of the selected anti-Aβ scFvs on 
differential modulation of reporter genes (His3 and LacZ). 
 
Table 3: differential activation of reporter genes (His3 and LacZ) by naïve scFvs-Aβ bait 
interaction 
 
 A1 A2 A5 A7 A9 A13 A18 A19 B2 B15 B21 
-His  
selectivity 
+ + + + + +++ ++ + + + ++ 
-His 
growth 
++ + + + + +++
+ 
++ + + + ++ 
LacZ 
activation 
++ + + + + ++ ++ + ++ + ++ 
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Table 4: differential activation of reporter genes (His3 and LacZ) by immune scFvs-Aβ 
bait interaction 
 Im1 Im3 Im8 Im11 Im18 Im32 Im47 
-His  
selectivity 
++ +++ +++ ++ + + + 
-His 
growth 
+++ ++++ ++ + ++ +++ +++ 
LacZ 
activation 
+++ ++++ + +++ ++ ++ ++ 
 
The stringency of histidine prototropy is lower than LacZ activation and a basal growth in 
–His is often possible also for unspecific interactors as scFv-lamin. In the table –His 
selectivity indicate the specificity of His3 reporter gene activation by scFv anti-Aβ 
interactors. Some scFvs, as A13, Im3 and Im8, are highly specific showing excellent 
selectivity for Aβ bait.   
Normally, most of the clones that grow in the absence of histidine give a strong reaction 
in the X-Gal assay. ScFvs anti-Aβ determine a differential activation of the reporter 
genes; for instance, Im8 induce a strong and specific His growth activation but it is a 
weak activator of LacZ; in general, naïve scFvs gave a lower and slower reaction in the 
X-Gal assay respect to scFvs isolated from immune library. Further considerations are 
presented in the section regarding In Vivo Epitope Mapping (IVEM) characterization. 
  
In conclusion, primary and secondary screenings of Naïve and Immune SPLINT 
Libraries allowed to select a panel of 18 different scFvs anti-Aβ42. 
Preliminary observations suggested that there is a higher specificity and selectivity of the 
immune library in the in vivo selection against Aβ antigen. In order to obtain a complete 
 117
comparative analysis of scFvs from naïve and immune SPLINT libraries, further 
characterizations such as in vivo epitope mapping, sequence analysis, in vitro binding of 
synthetic and naturally produced antigen and in vitro modulation of Aβ-induced cell 
toxicity will be afterwards discussed in the next chapters. 
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3. In Vivo Epitope Mapping (IVEM) 
 
For most practical purposes, an epitope is easy to define as part of an antigen involved in 
its recognition by an antibody. The term “epitope mapping” is usually applied to protein 
antigens, and is the process of locating the epitope on the protein surface or in the protein 
sequence. It is essential to distinguish between conformational (“discontinuous”, 
“assembled”) epitopes, in which amino acids far apart in the protein sequence are brought 
together by protein folding, and linear (“continuous”, “sequential”) epitopes, which can 
often be mimicked by simple peptide sequences. In order to determine the major sites 
recognized by selected antibodies on the Aβ1-42 surface, we applied the in vivo epitope 
mapping (IVEM) (Visintin et al., 2002). This method allows to produce in a very easy 
way an epitope map of the protein antigen used for the SPLINT selection applying the 
same IACT technology. To this aim we design a ‘linear mapping’ approach using baits 
that are C-terminal deletion mutants of human Aβ1-42: Aβ1-40, Aβ1-28, Aβ1-17 and 
Aβ1-10 (see fig.1).  
 
 
Fig.1 sequences of the C-terminal deletion mutants of human Aβ42 used in IVEM  
 
ScFvs are also tested by IVEM against deletion mutants of rodent baits (Aβ1-42, Aβ1-28, 
Aβ1-17, Aβ1-10): rodent Aβ has three different residues (5R>G, 10Y>F, 13H>R) in the 
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N-terminal portion of the peptide (fig.2); these changes are responsible for different 
biochemical and biophysical properties of the mouse Aβ peptide (Fung J. et al. 2004). 
 
  
Fig.2 Sequence of human and murine Aβ42 with amino acid changes indicated. 
 
 
Fig.3 Schematic colored representation of deletion mutants of human and rodent Aβ42 
tested in IVEM with scFvs anti-human Aβ42. 
 
 
The choice of the above-mentioned deletion mutants has been justified by the processing, 
folding and immunogenic properties of the Aβ peptide. In fact: 
- Aβ1-10 represents the most unstructured portion and the most immunogenic part of Aβ 
peptide in immunizations; it is also involved in packaging and lateral aggregation. 
- Aβ1-17 is naturally generated in the processing of APP by cleavage of α-secretase (C-
term) and β-secretase (N-term); 
-Aβ1-28 is the beginning of the second β-sheet (28-40/42), after the hairpin loop 
connecting with the first β-sheet (1-23) in the β- structured peptide model 
-Aβ1-40 represents the most important alternative product of γ-secretase cleavage. 
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From the panel of the selected 18 scFvs, we have chosen five naïve scFvs (A1, A13, A18, 
A19, B2) and six immune scFvs (Im1, Im3, Im8, Im18, Im32, Im47), for the in vivo 
epitope mapping with the above-mentioned baits. 
 
The results of IVEM are summarized in the following tables: 
 human 
Aβ1-10 
human 
Aβ1-17 
human 
Aβ1-28 
human 
Aβ1-40 
human 
Aβ1-42 
A1 − − ± + + 
A13 − − − + + 
A18 − − − ± + 
A19 − − − + + 
B2 + + + + + 
Im1 + + + + + 
Im3 + + + + + 
Im8 − − − + + 
Im18 − − − ± + 
Im32 + + + + + 
Im47 + + + + + 
 
 rodent 
Aβ1-10 
rodent 
Aβ1-17 
rodent 
Aβ1-28 
rodent 
Aβ1-42 
A1 − − − + 
A13 − − − + 
A18 − − − + 
A19 − − − + 
B2 + + + + 
Im1 + + + + 
Im3 + + + + 
Im8 − − − + 
Im18 − − − + 
Im32 + + + + 
Im47 + + + + 
 
SPLINT-selected anti-Aβ scFvs are able to recognize either human and murine Aβ 
deletion mutants in IVEM format, showing the same pattern of epitopes recognizition for 
both Aβ species. 
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From IVEM analysis, two family of non overlapping epitopes specific scFv can be 
distinguished: 
1. scFvs recognizing Aβ1-10 N-terminal domain 
2. scFvs recognizing Aβ1-40/42 C-terminal domain. The IVEM analysis shows that 
only A1 recognizes very weakly (in terms of LacZ activation) Aβ1-28, This is 
probably because it recognizes one epitope spanning partially this region. 
In a simplistic way, we can consider the second category of scFvs as recognizing the C-
terminal (28-42) part of Aβ; but, in the light of the complex folding of Aβ peptide, it is 
more correct to say that the portion 28-42 of Aβ is essential for anti-Aβ binding. The 
distribution of Aβ epitopes recognized surely is not casual, showing a clear enrichment in 
two clusters (fig.4). It is very interesting to note that scFvs derived from the naïve 
SPLINT library recognize in a higher proportion the C-terminal part of Aβ, while the 
pool of scFv from the immune SPLINT library are enriched in N-terminal binders (fig.4). 
 
 
 
Fig.4 Scheme of two principal epitopes recognized by SPLINT-selected anti-Aβ scFvs. 
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The absence, or the lower overall representation of same epitope specificity might be due 
by different reasons: 
1. Lack of scFvs, in naïve SPLINT libraries, recognizing particular epitopes, as 
notably the N-terminal epitope (library hypothesis); 
2. Difficult exposure of non recognized epitopes on LexA-Aβ bait, motivated by its 
folding or by its aggregation into the yeast cytoplasm and nucleus 
(conformational hypothesis).  
Probably both the hypotheses contribute to the observed epitope distribution.  
The libraries naïve and immune are not equally representative in terms of epitope pattern 
recognition. In particular, as above-observed, a large part of immune scFvs recognizes N-
term of Aβ: >90% of total, considering the high redundancy of this library. This result is 
in accordance with the immunization protocols performed in humans and in animals, and 
suggests that immunization with Aβ peptide provides a “directed evolution” of V regions, 
biasing their binding specificity toward N-terminal Aβ residues. 
After immunization with Aβ peptide, most of the B-cells produce antibodies which 
recognized epitopes reside in the amino-terminal region of the peptide (Schenk D, et al, 
2004). 
“After immunization with Aβ, the peptide is processed by antigen-presenting cells in the periphery and then 
presented to T and B cells. Epitope mapping of these events following Aβ immunization in AD patients 
indicates that the predominance of T-cell epitopes lies in the central to carboxy-terminal region of the Aβ 
peptide. This agrees with the dominant Aβ T-cell epitope region identified in nontreated AD and control 
elderly individuals. By contrast, most of the B-cell or antibody producing epitopes detected from 
immunized patients reside in the amino-terminal region of the peptide. The latter point is reinforced by the 
observation that most anti-Aβ mouse monoclonal antibodies that have been produced are directed to the 
first 16 amino acids of the peptide. (Schenk D, et al, 2004).” 
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However, in the SPLINT libraries, because of the recombinant random assembly of VL 
and VH genes, do not reproduce the original VL-VH pairing observed in vivo, thus the 
particular combinations of VL and VH determine the binding properties of these SPLINT 
selected scFvs. Therefore, it is noteworthy that scFvs selected from immune SPLINT 
library show the observed and above-discussed epitope specificity.  
 
In order to explain the non-random distribution of epitopes recognized by SPLINT-
selected scFvs, we hypothesized also a conformational exclusion of some epitopes on the 
surface of the peptide (‘conformational hypothesis’). A lot of structural data described 
models of Aβ42 peptide, in which its N-terminal part (Aβ1-10) is unstructured thus, the 
remaining portion of Aβ is crucial for the formation of β-structures (Petkova A., et al, 
2002). Hypothesizing similar conformation for Aβ, as C-terminal portion of LexA-Aβ 
fusion protein, Aβ1-10 and Aβ28-42 could be the most exposed regions, available for 
interactions with scFvs. 
 
 
Fig.5 Structural model of Aβ40 monomer (modified from Petkova et al, 2002) and 
hypothesis of conformational epitopes exposure.   
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Aβ baits - scFv interactions: differential activation of reporter genes 
As discussed above, different scFvs anti-Aβ determine distinct activation of the reporter 
systems (His3 and LacZ). In the light of IVEM results, we can observe that the best 
activators of the reporter LacZ gene for Aβ baits are scFvs Im1, Im3, Im32 and Im47 
(specific for N-terminal epitope). Thus, scFvs specific for the C-terminal or recognizing 
conformations of whole peptide, gave a lower and slower reaction in the β-Gal assay; this 
is not a peculiarity of naïve scFvs because also Im8 and Im18 (C-terminal specific) show 
similar properties.  
These observations could be in accordance with above-hypothesized conformations in 
vivo of Aβ42 bait (even if the peptide is fused with lexA as C-terminal fusion protein). β-
structured (and probably aggregated) Aβ, interacting with the C-terminal specific scFvs, 
could interfere to the assembly of functional transcription machinery. Thus, the N-
terminal specific scFvs, interacting with epitopes of Aβ baits not showing steric 
hindrance problems, could favour activation of reporter genes and give healthy phenotype 
in yeast cells. 
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4. Sequence analysis of scFvs clones 
As above discussed, we have selected a panel of 18 different anti-Aβ scFv clones from 
naïve and immune SPLINT libraries. DNA sequence of each scFv clone shows the 
recombinant format VL-linker-VH. In particular, two Nuclear Localization Signals (NLS 
1 and 2) are flanking the 5’ and 3’of each scFv clone (5’_NLS1-VL-linker-VH-NLS2_3’) 
in pLinker220 or in pMV1 plasmids used in IACT technology; moreover, scFv DNA is 
fused at 3’ with the sequence of the Activation Domain (AD) VP16.  
DNA clones were sequenced using specific sense and antisense primers for sequencing 
reactions. 
For the analysis, scFv nucleotide sequences were translated and the conserved Variable 
regions (VL and VH) of antibodies were analyzed. 
 
We performed multi-alignment analyses of scFvs aminoacidic sequences by ClustalW 
software.  
The aim of this analysis was the following: 
1. comparative analysis of the naïve variable regions versus the immune variable 
regions of the isolated scFvs  
2. identification of “consensus sequences for the binding site”, in the 
Complementary Determining Regions (CDRs) 
 Clustal W alignments allowed the identification of CDR regions in accordance to 
Kabat numbering scheme for variable regions of immunoglobulins superfamily.  
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ScFvs protein sequences were analyzed by ClustalW program version 1.83 (available 
online on the website of the European Bioinformatics Institute (EBI-EMBL): 
http://www.ebi.ac.uk/clustalw) that automatically align many sequences with a profile-
based progressive alignment procedure. 
ClustalW output files are:  
1. score tables, obtained by pairwise alignments (all sequences are compared to each 
other); 
2. multiple sequence alignments, showing aligned text of the sequences and their 
aminoacidic identities, similarities and gaps; 
3. cladogram or phylogram tree, constructed describing the “progressive groupings” 
of the sequences by similarity. 
In order to have a complete characterization of scFvs sequences we performed 
CLUSTAL W analysis on the following subgroups: 
- all complete sequences: scFvs naïve and scFvs immune; 
- only scFvs naïve; 
- only scFvs immune; 
- only VH of all scFvs; 
- only VL of all scFvs. 
 
Here we show exemplifying ClustalW analysis output files of 15 out of all 18 scFvs 
sequences, starting from the “score tables” obtained by pairwise alignments. 
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We show only exemplifying scores concerning the sequence of scFv Im1 compared with 
each other scFv sequence: for instance, the comparison between Im1 and Im3 (first row) 
gives the score of 79 (calculated on the basis of aminoacidic identities, similarities and 
gaps) that is a good score of similarity. The highest score of similarity, equal to 96, is 
obtained comparing Im1 and Im47: in fact, analyzing their sequences, they show only 6 
different aminoacids. 
 
 
The second output file generated by ClustalW is the multiple sequence alignment, 
showing aligned text of the sequences and their aminoacidic identities (indicated with * ), 
similarities (indicated with : and . ) and gaps (indicated with − ). In the fig.1 we show the 
exemplifying alignment of the first 55-60 residues of VL regions of the 15 analyzed 
scFvs. 
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Fig.1 Multiple sequence alignment output file: the green box points out an example of 
identities ( * ), the box points out (with only one aminoacid different between all scFvs) 
an example of strong similarity ( : ). 
 
 
The Cladogram or Phylogram trees, at the end of the output file, are representations of a 
complex Guide Tree that lists all the distances between the sequences, the number of 
alignment positions used for each, the sequences joined at each alignment step and the 
branch lengths (data not shown).  
We used the third output file generated by Clustal W analysis in the format of the 
Cladogram tree, only to have a validated representation of the distribution and the 
“derivation” of clusterized subgroups and individual scFvs. 
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Fig.2 multiple alignment of 6 scFvs immune and 9 scFvs naïve; variable regions VL and 
VH are highlighted in blue and yellow respectively, CDRs are boxed in red. 
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The comparison of all sequences gives a first general overview on the diversity or 
similarity among the scFvs. Multiple alignments show critical residues that are highly 
conserved and the regions with the highest variability corresponding to the CDRs (see 
fig. 2).  
Between Naïve and Immune subgroups, the latter shows the highest degree of identities 
(supplemented fig.1). 
The Cladogram visualizes the distances between all sequences. All scFvs (except Im8) 
derived from immune SPLINT, clusterize in a subgroup that is highly conserved (fig.3). 
This result may be in accordance with an oligoclonal response obtained by the 
immunization.  
 
 
Fig.3 A large part of scFvs immune (blue box) clusterize in a subgroup highly conserved. 
 
 
Differential analysis of VL and VH regions of the scFvs provides a further level of 
analysis. We focused on the analysis of the 11 scFvs (A1, A13, A18, A19, B2, Im1, Im3, 
Im8, Im18, Im32 and Im47) that were better characterized in vitro and by IVEM.  
The highest variability in VL and VH regions is in CDRs, therefore their sequence 
analysis is highly relevant. All VH regions of the examined immune scFvs (except Im8) 
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are highly similar; CDRs-H2 are identical (GRIDPANGNTKYDPKFQG) and CDRs H1 
are highly conserved (KDTYMH, except Im32 that has KDTYIH). Interestingly, the VH 
region of scFv A18, even though selected from the naïve SPLINT library, is very similar 
to an immune scFv, being its CDRs H1 and H2 identical to the above-mentioned 
sequences.   
ScFvs Im1 and Im47 show identical CDR H3 (ARSNYGFAY) as well as Im18 and Im32 
(NAATGPWFAY) explaining the sub-clusterization visualized in cladogram of VH 
regions (fig.5)  
VH regions of naïve scFvs and their CDRs, except A18, show high variability in 
comparison to immune scFvs. 
Table : CDRs of the VH regions of analyzed scFvs 
ScFv 
 
CDR H1 CDR H2 CDR H3 
Im1 KDTYMH GRIDPANGNTKYDPKFQG ARSNYGFAY 
Im47 KDTYMH GRIDPANGNTKYDPKFQG ARSNYGFAY 
Im3 KDTYMH GRIDPANGNTKYDPKFQG ASSSYAMDY 
Im32 KDTYIH GRIDPANGNTKYDPKFQG NAATGPWFAY 
Im18 KDTYMH GRIDPANGNTKYDPKFQG NAATGPWFAY 
Im8 TSYWMH GAIYPGNSDTSYNQKFKG TREGDYDGGY 
B2 TSSWMH GETHPNSGNTNYNEKFKG ARWGYNYLYAMDY 
A18 KDTYMH GRIDPANGNTKYDPKFQG ARSLDGYLDS 
A13 SSYWIE GEILPGSGSTNYNEKFKG ARRGNLYYYVMDY 
A19 TSYVMH GYINPYNDGTKYNEKFKG ARGEDGYSSFDY 
A1 TDHAIH GYISHGDGDIKYNENFKG KRSTAADFDS 
 
 
Fig.4 The Cladogram of the VH regions of 11 different analyzed scFvs. 
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Fig.5 The VH regions from naïve scFv A18 and the VH regions from the scFvs isolated 
from the immune SPLINT (box blue) (except Im8), clusterize in one distinct subgroup 
(green box). 
 
 
Cluster distribution of VL regions is different in comparison to cluster distribution of VH 
regions. VL of immune scFvs, for instance, clusterize in two different and distant 
subgroups: (Im1, 47, 32) and (Im3, 18, 8) (fig.7). VL region of Im8, similarly to its VH 
region, is the sequence less related to other immune scFvs.  
Identities and similarities of CDRs sequences explain the distances of the branches of the 
cladogram tree. CDRs from Im1, Im47 and Im32 VL regions are highly related; in 
particular, CDRL1 (RASESVDNYGISFMN) and CDRL2 (YAASNQGS) are identical in 
Im1 and Im47 and their CDRL3 are highly conserved (QQSKEVPxT). CDRs L1-2-3 of 
Im32 are closely related to Im1 and Im47. CDRs from Im3 and Im18 VL regions are 
highly similar to a specific consensus (CDR L1: RSSQSLxHSNGNTxLH CDR L2: 
YxIxNRFS; CDR L3: SQxTHxPLT). 
 
VL regions from naïve scFvs show a high diversity; A1, A13, A18 and B2 cluster 
appears to be derived from the same node generating the branch of Im1,47,32, confirming 
the different distribution of the VL regions comparing the VH regions (fig.7).  
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Table : CDRs of the VL regions of analyzed scFvs 
ScFv 
 
CDR L1 CDR L2 CDR L3 
Im1 RASESVDNYGISFMN YAASNQGS QQSKEVPFT 
Im47 RASESVDNYGISFMN YAASNQGS QQSKEVPLT 
Im32 RASESVDSYGNSFMH YCASNLES QQSNEDPLT 
Im3 RSSQSLVHSNGNTYLH YKISNRFS SQSTHVPLT 
Im18 RSSQSLIHSNGNTHLH YRITNRFS SQNTHLPLT 
Im8 RSSKSLLYKDGKTYLN YLMSTRAS QQLVEYPLT 
B2 RASSSVSSSYLH YSTSNLAS QQYSGYPWT 
A18 SASSSSVCYMH YDTSKLAS QQWNSNPLT 
A13 HASQSFNAWLS YKASNSHT QQGQSFPLT 
A19 KASQSVSNDVA YYASNRYT QQGQSYPLT 
A1 HAGQNINVWLS YKASNLYT QQGRSYPRT 
 
 
 
Fig.6 Cladogram of the VL regions of 11 different analyzed scFvs. 
 
 
 
 
Fig.7 The VL regions from immune scFvs (blue boxes) clusterize in two different and 
distant subgroups: (Im1, 47, 32) (green box) and (Im3, 18, 8) (yellow box). 
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Detailed analysis of the CDRs confirms high similarities among the immune scFvs and 
the different cluster distribution of VL and VH regions.   
Only scFvs Im1 and Im47 seem to derive from the same original paring of VL and VH 
regions; all the other scFvs, as expected, present different VL-VH pairing.  
 
In the following figure, the cladogram generated by alignment of complete sequences of 
the above-mentioned 11 scFvs, allows to identify two functionally related subgroups, 
defined on the basis of the source of the library (immune scFvs) or of the binding 
properties of the isolated scFvs (C-terminal specific scFv).  
 
 
We were unable to identify any consensus sequence in the analyzed scFv for the Aβ 
binding sites, not even linked to epitope specificity (C-terminal versus N-terminal). In 
fact, CDRs from C-terminal specific scFvs are highly diverse; moreover, B2, naïve scFv 
N-terminal specific, does not show a high similarity with Im1, Im3, Im32 and Im47 (that 
are also N-terminal specific); in addition, CDRs sequences of the immune scFv Im18 (C-
terminal specific) are highly similar to that of immune N-terminal specific scFvs. 
Further characterizations of the scFvs sequences will focus on the comparison between 
the available VL and VH sequences and other scFvs or anti-Aβ antibodies. 
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5. Production of scFvs as recombinant proteins in E.coli 
ScFvs were expressed as recombinant proteins in E.coli using two different protocols 
optimized for periplasmic or for cytoplasmic expression. Periplasmic expression allows 
the purification of scFvs in native conditions from periplasmic space of E.coli; the 
production yields are very poor in comparison with the cytoplasmic production of 
recombinant proteins, especially that from inclusion bodies. SPLINT selected scFvs, are 
readily folded and stable in the yeast cytoplasm thus are good candidates for the 
cytoplasmic expression in E.coli. 
ScFvs cDNAs were subcloned from yeast expression vector into prokaryotic expression 
vectors. In particular we used, for the expression in the E.coli periplasm, the plasmid 
pDAN3 (kindly provided by Prof. Sblattero, University of Trieste) and, for the expression 
in the E.coli cytoplasm, we modified the plasmid pETM13 (kindly provided by Dott. 
Covaceuszach, Lay Line Genomics, Trieste). One advantage of the latter system is that in 
many cases the target protein accumulates in the cytoplasm to such high levels that it 
constitutes a high percentage of the total cell protein. Therefore, it is relatively 
straightforward to isolate the protein in few chromatographic steps by conventional 
methods. 
 
5.1 Periplasmic expression 
The phagemid pDAN3 (fig.1) allows the expression of scFv under the control of a LacZ 
promoter inducible by IPTG (isopropyl β-D-thiogalactoside) with the secretion of the 
recombinant protein in the periplasmic space being directed through a PelB leader 
sequence at the N-terminus of the scFv; the expressed scFv carried also two peptide tags 
(SV5 and His6) at the C-terminus. 
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Fig.1 pDAN3 vector used for the periplasmic expression of scFvs in HB2151 E.coli 
strain. 
 
A general protocol provides that transformed HB2151 E.coli were IPTG induced for 4h; 
the scFvs were purified from the isolated periplasmic fraction by affinity chromatography 
with NiNTA™ Agarose resin.  
The yields of the purified scFvs are highly variable but generally are very low. The 
following table resumes the obtained final concentrations of purified scFvs and the total 
amount of protein per initial volume of culture. scFv αTL111 is a SPLINT derived 
unrelated scFv used as a control. 
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 Concentration 
of purified  
scFv 
Amount of scFv for ml 
of starting culture 
scFv A1 170 ng/μl 425 ng/ml 
scFv A13 85 ng/μl 213 ng/ml 
scFv A18 175 ng/μl 438 ng/ml 
scFv A19 400 ng/μl 1000 ng/ml 
scFv B2 170 ng/μl 425 ng/ml 
scFv Im1 85 ng/μl 213 ng/ml 
scFv Im3 500 ng/μl 1250 ng/ml 
scFv Im8 85 ng/μl 213 ng/ml 
scFv Im18 75 ng/μl 188 ng/ml 
scFv Im32 80 ng/μl 200 ng/ml 
scFv Im47 85 ng/μl 213 ng/ml 
scFv αTL111 500 ng/μl 1250 ng/ml 
 
 
A very common problem in the NiNTA preparations of heterologously expressed His-
tagged proteins is the presence of E.coli SlyD, a prolyl isomerise that specifically binds 
divalent metal ions which can result in significant contamination of the purification step.  
 
 
Fig.2. Analysis of the purified periplasmic preparation of scFvs by PAGE and Blue 
Comassie staining. It is noteworthy the different concentration of scFvs for the same 
loaded volume (αTL is used as reference), the presence of degradation products and high 
M.W. contaminants (correspondent to SlyD E.coli protein) in the scFvA1 and scFvB2 
preparations.  
 
 
Å ~30kDa
 138
The very low amounts of purified protein do not allow easily further steps of purification 
and analysis.  
 
Fig.3 Representative analitical Superdex-75 gel filtration chromatograms of scFv A19, 
periplasmic purified, showing the prevalent peak (*) correspondent to the monomeric 
protein, and the secondary peak correspondent to the dimeric aggregated scFv (**). 100 
μg/analysis of NiNTA purified scFv were used for this assay.  
 
 
5.2 Cytoplasmic expression 
The low yields of scFvs obtained from periplasmic expression system have induced us to 
optimize a cytoplasmic expression protocol, that was kindly provided by Dr. Paoletti 
(SISSA, Trieste).  
In many cases and in several host systems, the recombinant proteins accumulate in cells 
as insoluble aggregates, so-called inclusion bodies. The proteins expressed as inclusion 
bodies are mostly inactive and denatured. The formation of inclusion bodies is a frequent 
consequence of high-level protein production in the cytoplasm. It is not possible to 
generalize or predict which proteins are produced as inclusion bodies. 
Production of recombinant proteins as inclusion bodies has several advantages: 
*
**
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· The recombinant protein deposited as inclusion bodies can be 50% or more of the total 
cellular protein. 
· Inclusion bodies often contain almost exclusively the over-expressed protein. 
· In the form of inclusion bodies the protein is protected from proteolytic degradation 
resulting in higher yield. 
· Expression as inclusion bodies will protect the cell against the toxicity of the 
recombinant protein since inclusion bodies have no biological activity. 
· Inclusion bodies can be accumulated in the cytoplasm to a much higher level than when 
produced in soluble form. 
 
For the expression of the scFv in the cytoplasm of E.coli we choose the largely used 
system vector-host pETM13 - BL21(DE3)pLysS E.coli. pETM13 uses the promoter of 
T7 bacteriophage and BL21(DE3)pLysS is an E.coli strain able to produce T7 RNA 
polymerase after IPTG induction. 
The plasmid pETM13 was modified by site-specific mutagenesis (removing BssHII 
restriction site at the 2251nt of original pETM13, inside lacI gene) and by adaptation of 
the pDAN3 polylinker for scFv cloning (NotI-BssHII-scFv-NheI-NcoI) and a new vector 
named pGio1 was obtained (fig.4).  
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Fig.4 pGIO1, derivative of pETM13 vector was used for the cytoplamic expression of 
scFvs in BL21 E.coli strains. 
 
Culture of BL21(DE3)pLysS carrying the scFv expressing plasmids pGio1 was induced 
with 1mM IPTG.  
To obtain soluble scFv, the washed inclusion bodies are dissolved in denaturing agents 
and the released scFv is then refolded by gradual removal of the denaturing reagents by 
dialysis. Refolding is initiated by reducing concentration of denaturant used to solubilize 
inclusion bodies. Protein refolding is not a single reaction and competes with other 
reactions, such as misfolding and aggregation, leading to inactive proteins. Rate of 
refolding and other reactions is determined both by the procedure to reduce denaturant 
concentration and the solvent condition. 
The procedure that has been used to solubilize inclusion bodies and to refold scFv was 
individually optimized for each anti-Aβ scFv, requiring a slightly different procedure 
which must be empirically determined. The cytoplasmic expression and purification of 
anti-Aβ scFvs were kindly performed by Dr. Michela Visintin (LayLineGenomics, 
Trieste). 
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The purification of the refolded scFvs was achieved through a ion exchange 
chromatography. Purified scFvs were also analyzed by Gel Filtration in Superdex75 
columns, in order to recover only the fractions corresponding to the monomeric proteins.  
 
 
 
Fig.5 Representative cation exchange chromatography for refolded scFv A13 (performed 
on HiTrap SP column) from one cytoplasmic preparation, and analysis of scFv A13 (in 
the recovered fractions) by PAGE and Blue Comassie staining. This representative 
cytoplasmic preparation shows the high yield of production; the single peak high and 
tight, in the ion-exchange chromatography plot, indicates the pureness of preparation and 
the good rate of refolding.  
 
 
The following table resumes the obtained final concentrations of purified scFvs, from 
inclusion bodies, and the total amount of protein per initial volume of culture.  
Å ~30kDa
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 Concentration 
of purified  
scFv 
Amount of scFv for ml 
of starting culture 
scFv A1 8.7 μg/μl 8.8 μg/ml 
scFv A13 4.5 μg/μl 3.3 μg/ml 
scFv A18 0.6 μg/μl 0.3 μg/ml 
scFv A19 4.0 μg/μl 3.0 μg/ml 
scFv B2 0.16 μg/μl 0.17 μg/ml 
scFv Im1 1.9 μg/μl 0.95 μg/ml 
scFv Im3 5.45 μg/μl 2.72 μg/ml 
scFv Im8 0.2 μg/μl 0.4 μg/ml 
scFv Im18 2.1 μg/μl 1.58 μg/ml 
scFv Im32 0.75 μg/μl 0.38 μg/ml 
scFv Im47 3.38 μg/μl 4.5 μg/ml 
 
 
The yields of purified scFvs by cytoplasmic expression were significantly higher (up to 
~20 fold more for scFvs A1 and Im47) than those obtained by perisplamic expression, 
even though highly variable for different scFvs. Only scFv B2 resulted very difficult to 
purify by cytoplasmic expression, resulting very toxic for E.coli.  
 
 PERIPLASMIC 
YIELDS 
Amount of scFv 
 for ml of starting 
culture 
CYTOPLASMIC 
YIELDS 
Amount of scFv for 
ml of starting 
culture 
scFv A1 425 ng/ml 8.8 μg/ml
scFv A13 213 ng/ml 3.3 μg/ml
scFv A18 438 ng/ml 0.3 μg/ml
scFv A19 1000 ng/ml 3.0 μg/ml
scFv B2 425 ng/ml 0.17 μg/ml
scFv Im1 213 ng/ml 0.95 μg/ml
scFv Im3 1250 ng/ml 2.72 μg/ml
scFv Im8 213 ng/ml 0.4 μg/ml
scFv Im18 188 ng/ml 1.58 μg/ml
scFv Im32 200 ng/ml 0.38 μg/ml
scFv Im47 213 ng/ml 4.5 μg/ml
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6. Expression in mammalian cells as intrabodies 
 
The selection of an antibody by IACT, on the basis of its ability to bind antigen in 
intracellular yeast enviroments, is a good and reliable predictor for the performance of an 
intrabody in mammalian cell lines (Visintin et al., 1999, 2002; Tse et al., 2002).  
For intracellular studies, intrabodies targeted to specific sub-cellular compartments, can 
act as specific functional knock-out tools. The “protein interference” approach for 
knocking out Aβ function could not be pursued with the very well established RNA 
interference (RNAi) methodology (Wall et al., 2003) mainly because: 
• Aβ peptide is a proteolitic fragment deriving from its APP (Amyloid Precursor 
Protein) precursor; RNAi can target only indirectly Aβ, through the modulation 
of APP or of β/γ secretases expression levels; 
• RNAi based approaches could not allow to discriminate between Aβ monomers 
and Aβ oligomers. 
Preliminary experiments of cytoplasmic expression in 3T3 fibroblast mouse cell line of 
SPLINT-selected scFvs anti-Aβ were performed. These experiments allow the evaluation 
of their solubility, stability and expression yeald in mammalian cell cytoplasm. Cells 
were transiently transfected with the vector scFvexcytoV5 (kindly provided by Dr. 
Visintin, Lay Line Genomics, Trieste) a modified version of scFvExpress-cyto vectors 
(Persic et al, 1997) expressing scFvs anti-Aβ (fig.1) in the cell cytoplasm.  
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Fig.1 scFvexcyto-V5 vector used for the cytoplasmic expression of scFvs anti-Aβ. DNA 
sequence coding for each scFv were cloned (BssHII-NheI) into the vector backbone; scFv 
expression in mammalian cells in under the regulation of cytomegalovirus (CMV) 
promoter (modified from Persic et al., 1997). 
 
 
Cytoplasmic expression of scFvs were detected  with an anti-V5 antibody. The scFvs 
expression were tested by Western Blot analysis of cell extracts and by 
ImmunoFluorescence at 30 h post transfection. 
A good level of expression for all scFvs tested were detected by Western Blot analysis. 
ImmunoFluorescence, indeed, demonstrated a differential distribution pattern of 
expressed recombinant proteins. Some scFvs, such as Im1, Im47, Im3 (see supplemented 
figure 2), show a diffuse expected intracellular staining, typical of soluble cytoplasmic 
proteins, but others (B2, A13, A18) display the greater the accumulation of the 
intracellular scFv in a puntiform or ‘donut-like’ pattern (supplemented fig.2) distribution 
(Persic et al, 1997). Moreover, some non tagged scFvs gives a specific localization 
staining in subcellular compartments such as ER, Golgi, secretory and endocytotic 
pathways.  This is in line with the observation of Paganetti and coworkers (2005) that 
have shown that a cytoplamic expressed scFv intrabody, raised against the EFRH epitope 
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of human APP (epitope shared with Aβ), rapidly associates, within ER, with newly 
synthetized APP that remain associated along the secretory line.  
 
In conclusion, we have observed the expression of anti-Aβ scFvs in mammalian cells. 
They are mainly soluble and well expressed. Further experiments in other mammalian 
cell lines and primary cultures are in progress. The expression of the anti-Ab scFv into 
different subcellular compartment (secretory, mitochondria, nuclear) are also in progress. 
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7. In vitro Characterization of scFvs anti-Aβ IACT-selected 
 
ScFv recombinant proteins (purified from E.coli) were tested for binding properties in the 
following in vitro tests:  
1. ELISA using coating with different aggregated forms of synthetic Aβ peptide; 
2. ELISA using NeutrAvidin plates (Pierce) with coating of N-term biotinylated Aβ 
peptides; 
3. Immunoprecipitation (IP) of synthetic monomeric or oligomeric Aβ peptide;  
4. Immunohystochemistry (IHC) and ImmunoFluorescence (IF) on human AD brain 
slices; 
5. Western blot and Dot Blot analysis of human AD brain extracts enriched in 
soluble oligomers (experiments still in progress; data not shown).  
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7.1 ELISA with coating of different aggregated forms  
of synthetic Aβ peptide 
 
Dahlgren (2002) and Blaine Stine (2003) have described the conditions for Aβ  peptide 
Oligomerization and Fibrillogenesis in vitro, as summarized in the following diagram 
(from Dahlgren et al, 2002).  
 
 
 
 
 
 
Our collaborator Anita Westlind Daniellson (Stockholm University) kindly provided 
human and murine synthetic ADDLs. Monomeric and fibrillar Aβ were obtained from 
synthetic commercial peptide resuspended in DMSO. Different aggregation status of Aβ 
peptides are confirmed by western blot analysis (fig.1).  
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Fig.1 Western blot analysis of different forms of synthetic human Aβ1-42. Aβ oligomers 
ADDLs (AβO, lane 1), Aβ monomers (AβM, lane 3) and Aβ fibrils (AβF, lane 4) were 
loaded (1μg/lane equal to ~200pmol of total Aβ42), without heating or boiling samples, 
in NuPAGE™ 4-12%. WB was performed with MAb antiAβ 4G8. Note that ADDLs 
(lane 1) consist of small as well as large oligomers, and that large insoluble fibrils (lane 
4) remains in the well of the gel. In the lane 1, “I” indicates monomers, “II” dimers, “III” 
trimers and “IV” tetramers. 
  
 
The coating of different formats of Aβ peptide in ELISA plates was performed diluting in 
PBS at the final concentration of 10μg/ml different preparations of Aβ, and incubating 
overnight at 4°C. 
Considering the complex dynamic of Aβ aggregation, we cannot exclude changes in the 
aggregation status during coating incubation; it is better to define different coating 
conditions as “mainly monomeric”, “mainly oligomeric” and “mainly fibrillar”. The most 
critical point is the maintaining of the monomeric format  
IV 
III 
II 
I 
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Fig.2 Scheme of the ELISA coating and the antibodies used for the detection. 
Synthetic Aβ peptides were coated in solid phase on the ELISA plate, and scFv proteins 
were used as primary antibodies, as described in the text.  
 
 
Different formats of Aβ coating were detected using anti-Aβ scFvs selected from naïve 
and immune SPLINT libraries. Recombinant E.coli purified anti-Aβ scFv proteins, have 
a SV5 tag at the C-terminus of VH region. ScFv-V5 can be detected using MAb or PAb 
anti-V5. The ELISA signal can be detected with a secondary antibody HRP-conjugated 
(allowing chromogenic reaction of TMB substrate) (fig.2). ScFvs are used at the 
concentration of 24μg/ml (equal to 0.8μM). As internal control, the detection of Aβ 
species was performed using the monoclonal antibody MAb 4G8 (concentration of 
1μg/ml, equal to ~7nM) and the sera of the immunized mice (dilution of sera: 1:10000).  
Different Aβ species were used in coating at the concentration of 10 μg/ml(fig.3): 
1. synthetic human Aβ monomers;  
2. synthetic human Aβ fibrils; 
3. synthetic human Aβ oligomers (hADDLs); 
4. synthetic murine Aβ oligomers (mADDLs); 
5. unrelated antigen BSA 
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Fig.3 ELISA assay of anti-Aβ scFvs against different aggregated or monomeric forms of 
synthetic Aβ peptide coated (at the concentration of 10 μg/ml) in solid phase on the plate. 
The results show, for scFvs, a notable binding against Aβ oligomers in comparison with 
MAb 4G8 and sera of immunized mice, that do not distinguish between oligomeric, 
fibrillar and monomeric forms of Aβ. Each point represents the mean (n=3). 
 
 
The results of ELISA revealed a greater binding specificity of the scFvs selected from 
SPLINT libraries for human Aβ oligomers (hADDLs). The binding properties of scFvs, 
in these ELISA conditions, appear significantly different in comparison with the binding 
specificity of both monoclonal antibody anti-Aβ and of the immunized sera. MAb 4G8 
cannot distinguish between different forms of Aβ; PAbs from the immunized mice 
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discriminate only between human and murine peptides, demonstrating the specificity of 
immunization against the human antigen (fig.3).  
All scFvs anti-Aβ SPLINT-selected, independently from the source of the SPLINT 
library by which have been selected, show the same binding behavior with the highest 
specificity against hADDLs. In terms of absolute ELISA O.D. values for hADDLs 
binding, are described in the following table 1: 
Table:1  decreasing scale of scFvs binding to hADDLs, in terms of absolute O.D. values 
scFv O.D. value 
(mean±S.E.;n=3)  
Im3 2.10 ± 0.02 
A1 2.08 ± 0.03 
Im1 1.65 ± 0.02 
B2 1.62 ± 0.02 
Im47 1.46 ± 0.02 
A18 1.19 ± 0.02 
Im18 1.04 ± 0.03 
Im32 0.56 ± 0.04 
Im8 0.39 ± 0.02 
A13 0.33 ± 0.02 
A19 0.22 ± 0.02 
Unrelated αTL 0.09 ± 0.01 
 
ELISA O.D. values of hADDLs binding are significant for all scFvs in comparison with 
the unrelated scFv (anti Thimosine-β4, derived from the naïve library: Visintin et al., 
unpublished data) as well as in comparison with the binding values obtained for other Aβ 
forms. 
Each scFv, except for Im3 and Im1, present this decreasing scale of specificity: 
hADDLs> hAβ fibrils > mADDLs > hAβ monomer (table 2). Generally, the isolated 
scFvs cannot distinguish between hAβ monomer and an unrelated antigen in coating, as 
for example BSA; therefore, the binding to Aβ monomer, in these ELISA conditions, is 
not specific with the exceptions of A1, B2 Im3 and Im47.  
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Table: 2 Comparative scale for anti-Aβ scFv specificity (Im3 and Im1, shown down): 
hADDLs > hAβ fibrils > mADDLs > hAβ monomer in terms of absolute O.D. values 
(mean) 
 
 hAβ42  
ADDLs 
hAβ42 
Fibrils  
mAβ42 
ADDLs  
hAβ42 
Monomer  
A1 2.08 0.74 0.54 0.16 
B2 1.62 0.43 0.35 0.17 
Im47 1.46 0.49 0.42 0.27 
A18 1.19 0.19 0.18 0.09 
Im18 1.04 0.74 0.23 0.13 
Im32 0.56 0.15 0.14 0.09 
Im8 0.39 0.12 0.11 0.08 
A13 0.33 0.10 0.11 0.08 
A19 0.22 0.07 0.09 0.07 
Unrelated αTL 0.09 0.07 0.07 0.07 
MAb 4G8 2.35 2.1 2.4 2.1 
 
 hAβ42  
ADDLs 
mAβ42 
ADDLs  
hAβ42 
Fibrils  
hAβ42 
Monomer  
Im3 2.10 0.74 0.51 0.27 
Im1 1.65 0.38 0.35 0.13 
 
ELISA specificity for hAβ fibrils and mADDLs binding is comparable for each anti-Aβ 
except for Im18, that presents significant higher values for human fibrils. ScFvs anti-Aβ, 
in particular A1, A18, B2, Im1, Im3, Im8, Im32 and Im47, discriminate at least three 
times better human ADDLs than other aggregated forms of Aβ.  
In conclusion, the specificity of the isolated scFvs seems to be not only preferential 
versus conformational aggregated oligomeric Aβ, but also species-specific versus human 
Aβ. The ability of our scFvs to distinguish hADDLs from mADDLs is highly relevant: 
they are very specific, if compared to other conformation specific antibodies, such as the 
polyclonal anti-oligomer elaborated by Kayed and coworkers (2003) (commercially 
available and known as A11), that recognize equally well oligomeric-specific epitopes 
common to different peptides (including Aβ, lysozime, IAPP and prions).  
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The species-specificity in vitro was different from what observed in IACT. In fact, as 
discussed above in the In Vivo Epitope Mapping (IVEM) characterization, scFvs 
recognize equally well both human and murine Aβ baits; but in this last case, we have not 
performed quantitative assays. Therefore, it is likely that the in vivo binding could be 
different from the in vitro binding in ELISA condition.   
 
 
 
7.2 ELISA with NeutrAvidin plates:  
coating with N-term biotinylated Aβ peptides 
NeutrAvidin™ protein is a deglycosilated avidin able to bind biotin-labeled molecules, 
studied generally used to minimize nonspecific adsorption. NeutrAvidin™ plates with 
high binding capacity (HBC) represent an excellent system to detect small peptides as 
Aβ. We used N-terminus biotinylated hAβ1-40 and hAβ1-42 peptides. The use of the N-
terminal biotinylated Aβ peptides allows to have the conformational structured Aβ more 
exposed, avoiding non specific interactions with the plastic of ELISA plates.  
 
Fig.4 Scheme of the ELISA coating and the antibodies used for the detection, in 
NeutrAvidin™ plates. E.coli purified recombinant anti-Aβ scFv proteins, were used as 
primary antibodies at different concentrations and detected by an anti-SV5 antibody 
HRP-conjugated. 
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NeutrAvidin™ ELISA presents higher sensibility in comparison with standard ELISA. In 
fact, low concentrations of scFvs (up to 3μg/ml instead of 24μg/ml) as well as of the 
antigen (down to 0.1μg/ml) give a significant response (figs.5 and 6).  
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Fig.5 Dose-dependent curves of five different scFvs at five different concentrations. on 
NeutrAvidin plates were coated with Aβ42-biot (1μg/ml). 
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Fig.6 ELISA results: coating with Aβ42-biot (1μg/ml and 0.1μg/ml) onto NeutrAvidin 
plates (scFvs at saturating concentrations of 25 μg/ml).  
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The binding capacity of Reacti-Bind™ NeutrAvidin™ HBC plates is of ~60 pmol of D-
biotin/well. 
The following tables resume the amounts of Aβ-biot peptide, scFvs and MAbs used in 
our experiments. 
 Aβ42 biot   
(MW 4740.4; 70μl/well) 
concentration pmoles/well 
10 μg/ml (2μM) 147 
5   μg/ml 73.5 
1   μg/ml 14.7 
0.1 μg/ml 1.47 
 
 
 
scFv   
(MW ~30000; 50 μl/well) 
concentration pmoles/well 
24  μg/ml (0.8μM) 40 
12  μg/ml 20 
6    μg/ml 10 
3    μg/ml 5 
1.5 μg/ml 2.5 
 
 
 
MAb anti Aβ  
(MW ~150000; 100 μl/well) 
concentration pmoles/well 
1 μg/ml (6.7nM) ~0.7 
 
The concentrations of 5μg/ml of Aβ-biot (70μl/well) should potentially saturate all 
NeutrAvidin binding sites in each well if the highest binding efficiency of biotinylated 
peptide to NeutrAvidin plates is obtained. We have found that the coating onto 
NeutrAvidin plates with high and saturating concentrations of Aβ-biot (5-10μg/ml) 
determines its aggregation in structures recognized by the well established polyclonal 
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antibody anti-oligomer PAb A11 (Kayed et al., 2003), that was used as a positive anti-
oligomer control. 
PAb A11 is a conformation-dependent antibody that specifically recognizes soluble Aβ 
amyloid oligomers and does not recognize low molecular weight monomers or dimers, or 
mature amyloid fibrils. 
As pointed out by Glabe, “this anti-oligomer antibody recognizes soluble oligomers from 
various amyloids including lysozyme, IAPP, a-synuclein, prion 106–126, polyQ and 
insulin. Because antibody recognition is independent of the amino acid sequence, the 
epitope is likely to be a common peptide backbone motif, such as the array of hydrogen 
bond donors and acceptors at the edge of a β-sheet or a turn motif.” (Glabe, 2006) 
 
 
We found that particular conditions of incubation of Aβ-biot peptide onto NeutrAvidin 
plates favour its oligomerization. The highest values of O.D., using PAb A11 as primary 
antibody, are obtained incubating 10μg/ml (2μM) of Aβ-biot peptide at 4°C overnight in 
F12 phenol red free medium (the same conditions used by Dahlgren and coworkers for 
the oligomerization of Aβ (100μM) in solution (Dahlgren et al., 2002)). In these 
conditions (* in fig.7) PAb A11 shows a four-fold discrimination between Aβ-biot coated 
at 10 μg/ml and Aβ-biot coated at 0.1-1 μg/ml (fig.7). 
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Fig.7 ELISA results: PAb anti-oligomer A11 binding to Aβ42-biot at different conditions 
of incubation favouring oligomerization onto NeutrAvidin plates. 
 
MAb 4G8 is not able to discriminate between different concentrations of peptide in 
ELISA (fig.8); under the oligomerization conditions discussed above (but not in normal 
coating conditions: 1 hour in coating buffer), the concentration of 0.1 μg/ml is partially 
limiting for the binding of the MAb 4G8. The significant O.D. values observed at 
0.1 μg/ml of Aβ (correspondent to 1.5 pmoles/well) with MAb 4G8 could be considered 
an index of high affinity of the antibody versus the antigen, that is presumably non 
aggregated at this concentration.   
The scFvs anti-Aβ tested in ELISA show a behavior similar to that of PAb A11, which is 
able to discriminate between Aβ-biot coated at 10 μg/ml and at 1 μg/ml. The sample of 
scFvs tested was chosen to include two scFvs representative of N-terminal binders (Im3 
and B2) and two scFvs representative of C-terminal binders (Im8 and A1) (fig.8). 
All scFvs show good affinity versus the human peptide also at concentrations of Aβ 
coating of 0.1 μg/ml (1.5 pmoles). For some scFvs, (i.e. B2), the high ELISA values at 
*
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Aβ peptide coating concentration of 0.1μg/ml could indicate not only a good affinity, but 
also less specificity for oligomers; in fact these scFvs are able to bind monomer and 
oligomers.  
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Fig.8 ELISA onto NeutrAvidin plates. Aβ42-biot peptide is coated under conditions of 
oligomerization. Binding of PAb A11, MAb 4G8 (used at equi-molar concentrations, 
~7nM) and four different scFvs anti-Aβ (0.4μM) are shown. 
 
 
In conclusion, ELISA in NeutrAvidin plates suggest that selected scFvs under study, 
recognize preferentially the same conformational oligomeric forms recognized by the 
well characterized anti-oligomer PAb A11.  
The use of NeutrAvidin plates, even not in oligomerization conditions, have allowed the 
conformational structures of Aβ peptide to be recognized by scFvs, uncovering their 
specific preference for Aβ oligomers to be characterized.  
In any event, the behaviour of scFvs in the recognition of Aβ in vitro, in comparison to 
MAbs anti-Aβ 4G8 or 6E10 (antibodies not discriminating between different aggregated 
and un-aggregated forms of Aβ) is very different.  
The ELISA results discussed in the previous section, which showed high specificity of 
scFv binding to human ADDLs, together with the present results of ELISA in 
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NeutrAvidin plates, indicate that the recognition of peculiar conformations of Aβ seems 
to be a crucial property of the SPLINT-selected anti-Aβ scFvs. Probably, the 
oligomerization of Aβ enriches in the conformational epitopes that are recognized by the 
selected scFvs under study. Concerning PAb A11, Glabe similarly suggest that “the 
epitope on the oligomers must be either conformationally distinct or greatly reduced in 
the fibril structure. In keeping with the latter, the edge of the β-sheet would be expected 
to be exposed only at the ends of fibrils; thus, the amount of this epitope would decrease 
as the average length of the fibrils increased.” (Glabe, 2004) 
 
ELISA in NeutrAvidin plates performed using biotinylated hAβ40 show that a large-part 
of scFvs cannot distinguish between Aβ42 and Aβ40. ScFv A19 recognizes two times 
more specifically Aβ40 than Aβ42 at the concentration of coating of 1μg/ml. Also N-
terminal specific scFvs, recognize better Aβ40 than Aβ42 (data not showed), probably 
because the N-term epitope is better exposed in Aβ40 peptide.  
 
Preliminary experiments of competitive ELISA in NeutrAvidin plates have been 
performed using hAβ1-16 peptide as a competitor of scFvs binding to hAβ-biot 
oligomers (fig.9). Aβ16 is not an aggregating peptide and competes significantly with 
MAb 6E10 (that recognizes the epitope Aβ3-9) for the binding to Aβ-biot in NeutrAvidin 
plates. Indeed, scFvs anti N-term (B2 and Im3) as well as anti-oligomer PAb A11 do not 
feel the inhibitory effect of Aβ16 on the binding of Aβ-biot conformational oligomers 
(fig.9).  
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These preliminary results suggest that also N-term specific scFvs could recognize 
specific conformations of Aβ, probably preferential structured in oligomers of Aβ whole 
peptide (Aβ1-42), confirming the general behaviour of most of the scFvs selected, 
independently from epitope characterized by IVEM.  
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Fig.9 Competitive ELISA: dose-effect of increasing concentrations of Aβ16 competitor 
peptide to the binding of Aβ-biot oligomers. NeutrAvidin plates are used in this 
experiment. 
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7.3 Immunoprecipitation of synthetic antigen 
ELISA results show as general characteristic of SPLINT-selected scFvs a preferential 
binding ability of particular conformations of human Aβ, particularly of oligomeric 
aggregates. 
In order to test the binding and antigen-recognition properties of the anti-Aβ scFvs under 
solution condition, they were tested for their ability to capture and remove ADDLs or Aβ 
monomers from solution by immunoprecipitation. 
It is likely that solution favours a “natural” conformation of Aβ monomers as well as Aβ 
oligomers, being both forms of Aβ soluble species (unlike insoluble Aβ fibrils).  
 
Immunoprecipitation (IP) of Aβ monomer as well of Aβ oligomers can show several 
experimental problems related to critical folding and aggregation properties of this 
peptide. It is likely that, during the steps of incubation, Aβ changes the aggregation status 
(for instance the monomers can become oligomers, and oligomers can grow into larger 
oligomers). Moreover, it was observed also a non-specific binding of Aβ oligomers to 
protein G beads. The detaching bond antigen from antibody was also a critical step; we 
have avoided brash conditions (boiling or high salts) in order to reduce changes of the 
original conformation and in the aggregation status of the peptide.  
Nonetheless, we were able to demonstrate that anti-Aβ scFvs bind ‘Aβ soluble species’ 
under solution condition.  
The general protocol of IP using scFvs (fig.10) provides a preincubation of scFvs and Aβ 
antigen, in order to allow their complex formation in solution. PAb anti-V5, bound to 
ProteinG-Sepharose™, provides the capture of scFv-Aβ complex thanks to the binding of 
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the exposed V5 tag of scFv proteins. The captured complex was finally analyzed by 
western blot (WB), in semi-denaturing conditions using NuPAGE™ gels (SDS PAGE 
gels, without boiling samples and in non reducing conditions).  
We analyzed two fractions deriving from the last step of the immunoprecipitation 
protocol: IP pellet and IP supernatant. In the final step of IP, ProteinG-antiV5 beads 
carrying the captured complex scFv−Aβ, were centrifuged and washed by subsequent 
centrifugations: the first supernatant was the ‘IP supernatant’, which is enriched in Aβ not 
specifically immunoprecipitated, and the final centrifugation pellet was the ‘IP pellet’, 
which is enriched in immunoprecipitated Aβ. Subsequently, the two fractions were 
analyzed by WB, after a gentle detach of Aβ from the IP pellet, as discussed above.  
 
We show results obtained from immunoprecipitation experiments using scFv A1 (C-
terminal binder) and scFv B2 (N-terminal binder), which are both good binders of Aβ 
oligomers in ELISA assays; moreover, as previously shown, scFv B2 can recognize both 
Aβ oligomers and Aβ monomer in ELISA experiments. 
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Immunoprecipitation of Aβ monomer in solution by scFv B2 
As shown in fig.10, scFv B2 can specifically immuno-precipitate soluble synthetic Aβ42 
monomer.  
 
 
Fig. 10 scFv B2 immunoprecipitates Aβ monomer from solution. ScFv B2 (350pmol) 
was initially incubated with Aβ monomer (1nmol) and separately PAb anti-V5 
(~300pmol) was incubated with ProteinG-Sepharose; the complex B2-Aβ was 
immunoprecitated by the ProtG-antiV5. IP pellets were loaded, without heating or 
boiling, in NuPAGE™. WB performed with antiAβ 4G8. Note that the band of 4.1 kDa is 
present only in the lane of WB loaded with pellet of IP (Aβ+B2).  
 
 
As shown in fig.11, in the same experiment, the scFv B2 was able to immunoprecipitate 
both Aβ monomers and Aβ oligomers: the latter are species between 30kDa and 50kDa, 
probably formed during incubation steps.  
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Fig.11 scFv B2 immunoprecipitates Aβ monomer and oligomers from solution. In the 
lane 1 was loaded  IP pellet (B2+Aβ), in the lane 2 IP pellet (Aβ alone). IP pellets were 
loaded, without heating or boiling, in NuPAGE™. WB performed with antiAβ 4G8. 
  
Immunoprecipitation of Aβ oligomers in solution by scFv B2 
As for the immunoprecipitation of ‘pre-assembled’ Aβ oligomers (ADDLs) by scFvB2, 
we found that the IP supernatant was significantly depleted in ADDLs of high molecular 
weight bands (60-180kDa). This is an indirect evidence of ADDLs binding from scFvB2, 
even if no Aβ bands in the IP pellets could be differentially detected (data not shown). 
Similarly, Lambert and coworkers (2003), characterizing the specificity of two new 
antibodies (M93 and M94) raised against Aβ oligomers, tested their ability to remove 
ADDLs from solution by immunoprecipitation and showed only WB of ADDLs-depleted 
supernatants and not of ADDLs-enriched IP pellets. 
 
In another experimental trial, changing the incubation binding scheme of ADDLs and B2 
scFv protein (as indicated in fig.12) we have obtained a specific enrichment in Aβ 
immunoreactivity, only in the IP pellet. 
We have observed in WB a separation of three Aβ immunoreactive bands (> 190kDa, 
>100kDa, ~50kDa) (fig.); in this case the IP pellet samples were not boiled, but heated at 
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70ºC before loading in NuPAGE™. The same IP samples, not boiled and not heated, 
show a totally different pattern, with immunoreactive enriched species between ~40kDa 
and ~90kDa (data not shown). Probably, even though the heating procedure changes the 
aggregation status of the immunoprecipitated ADDLs, it favours their detachment from 
ProteinG complex, allowing a better detection of the IP enriched fraction. 
 
Fig.12 scFv B2 immunoprecipitates ADDLs in solution. scFv B2 (350pmol) was initially 
incubated with PAb anti-V5 (250pmol) for ~2hrs; the complex B2-PAb antiV5 was then 
incubated with ProteinG-Sepharose for ~4hrs; finally the ADDLs (100pmol) were 
immunoprecitated by the whole complex ProtG-antiV5-B2. IP pellets were heated at 
70ºC and loaded in NuPAGE. WB performed with antiAβ 4G8.  
 
 
Immunoprecipitation of Aβ oligomers in solution by scFv A1 
According to the first IP protocol [(scFv+ADDLs) + (ProtG-antiV5)], preincubating 
ADDLs (1000pmol) with scFv A1 (400pmol), we obtained a specific enrichment in Aβ 
immunoreactivity between 40kDa and 100kDa (without heating of samples). The 
component of Aβ monomer, normally present in ADDLs preparations, appears in 
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supernatants but not in pellets, showing that is not immunoprecipitated by scFv A1 
(fig.13). 
 
 
Fig.13 scFv A1 immunoprecipitates ADDLs in solution. ScFv A1 (400pmol) was 
initially incubated with ADDLs (1nmol) and separately PAb anti-V5 (~300pmol) was 
incubated with ProteinG-Sepharose; the complex A1-ADDLs was immunoprecitated by 
the ProtG-antiV5. IP pellets were loaded, without heating or boiling, onto NuPAGE™. 
WB performed with MAb antiAβ 4G8. Lanes legend: 1) IP pellet (A1+ADDLs); 2) IP 
pellet (ADDLs alone); 3) input of ADDLs; 4) M.W. markers; 5) supernatant 
(A1+ADDLs); 6) supernatant (ADDLs alone). The arrow indicates the specific 
enrichment of 40kDa−100kDa Aβ species in the pellet of IP(ADDLs+A1). 
 
 
In conclusion, these preliminary results indicates that scFv A1 and B2 are able to bind 
different soluble species of Aβ peptides, under solution conditions. ScFv B2, respect to 
scFv A1, results also a good binder of Aβ monomers even if it is preferential binder of 
Aβ oligomers.  
The characterization of the ability of the anti-Aβ SPLINT-selected scFvs, to bind ‘Aβ 
soluble species’ in solution could be relevant for different applicative purposes as, for 
instance, pull-down of conformational critical species from biological samples and in 
vivo therapeutic targeting of pathological Aβ oligomers. 
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7.4 ImmunoHystoChemistry (IHC) and ImmunoFluorescence (IF) on 
AD human brains: recognition of in vivo-produced forms of Aβ 
 
The ability to recognize naturally produced and not only synthetic Aβ is a relevant 
characteristic for anti-Aβ antibodies, both for therapeutic and for diagnostic purposes. For 
instance, Hock and coworkers (2002, 2003) have demonstrated that in clinical protocols 
of active immunotherapy in humans, only patients with immune sera highly reactive in 
vitro versus Amyloid plaques (Tissue Amyloid Plaques Immuno Reactivity assay = 
TAPIR assay), independently of ELISA titers of anti-Aβ antibodies, show clinical 
protective effects.  
 
In addition, peculiar pathological conformations of Aβ aggregates can be detected only in 
biological samples and in tissues. Recently, Lambert and coworkers (2006) similarly to 
our observations, report that different antibodies produced against the same antigen 
(synthetic ADDLs) show differential reactivity in human AD brains, against different 
pathological Aβ assemblies. 
 
In order to verify the peculiarity of the SPLINT selected antibodies, we have tested the 
tissue immuno-reactivity of some scFvs that were previously characterized in IVEM and 
ELISA (A1, A13, A18, B2, Im1, Im3, Im8, Im18, Im32 and Im47). 
 
Sections of 40μm were prepared from Temporal Cortex of post-mortem human AD 
brains (Braak stage V-VI) and control (Braak 0-I). 
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ScFvs were used as primary antibodies and, as performed in ELISA, detected via a 
sandwich of antibodies using an intermediate MAb or PAb anti-V5 and after an 
appropriate secondary for ImmunoHystoChemistry (IHC) or ImmunoFluorescence (IF). 
A preliminary set of IHC experiments were performed with scFv A1. It was immediately 
evident that the scFv staining by this scFv was peculiar, in comparison to classic 
Amyloid plaques detected by commercial anti-Aβ antibodies as 6E10 or 4G8. In IHC, 
scFv A1 detect mainly some small cell bodies (probably microglia) and often diffuse 
halos around them (supplemented figure 3), also without formic acid (90%) pre-treatment 
of slices. The reactivity is specific if compared with control tissues, which present only 
tight cellular staining. 
 
ImmunoFluorescence (IF) was essential for colocalisation studies. 
To avoid potential stickiness problems, brain slices were preferentially pre-treated with 
formic acid 90% for antigen retrieval, and treated for autofluorescence reduction after 
antibodies incubations.  
ImmunoFluorescence on AD brains slices showed a specific staining pattern, which is 
distinct for different scFvs, in comparison to the staining of Aβ deposits obtained with 
commercial, well established anti-Aβ antibodies. We suggest that different scFvs can 
detect different Aβ oligomer structural epitopes.  
 
scFv A1 (suppl. fig. 4) shows peculiar cellular reactivity of small cells in plaque-rich 
areas, and interestingly a partial complementary staining of plaques in comparison to 
anti-Aβ MAbs 6E10 and 4G8. We postulate that scFvA1 might be specific for the early 
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stage of amyloid maturation: the supplemented fig. 4A shows that no core staining in the 
upper plaque can be noted, similarly to the reported case of anti-Aβ globular oligomers 
detecting a rim around the plaques in AD brains (Barghorn et al., 2005). As observed in 
IHC, also in IF, scFvA1 often detects pericellular diffuse immunoreactivity (suppl. 
fig.4B), not detected by classic Abs anti-Aβ; similar pericellular staining is observed by 
Lambert and coworkers (2006) using their MAbs anti-oligomer. Finally, scFvA1 can 
specifically recognize blood vessels with Amyloid deposits, especially in plaques rich 
areas in the brain from one AD patient showing greater signs of Cerebral Amyloid 
Angiopathy (CAA) (suppl. fig.4C).  
 
ScFv A13 reacts weaker than other scFvs with Aβ deposits in human AD brain slices. 
A13 detects preferentially some cell bodies (probably of astrocytes) and their pericellular 
zones in plaques rich areas (suppl. fig.5). It is possible that the fixation/staining 
conditions do not preserve the epitope recognized by scFv A13. 
 
ScFv A18 (suppl. fig.6) presents a prevalent vascular reactivity in plaque-rich areas; 
blood vessels are specifically recognized by A18 but not by PAb anti-Aβ42.  
 
ScFv B2 presents mostly strong cellular reactivity, tightly related to plaques (suppl. 
fig.7A). Similar cellular reactivity corresponding specifically to astrocytes is detected by 
one of MAbs anti-oligomer developed by Lambert and coworkers. Probably, B2 detect 
also dystrophic neuritis (suppl. fig.7B). ScFvB2 can detect also specifically blood vessel 
deposits, near Aβ plaques detected by other Abs (suppl. fig.7C). 
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ScFv Im8 (suppl. fig.8A-B) detects specific small dotted clusters of mainly pericellular 
immunoreactive deposits, spatially distinct and separate from small plaque-like 
depositions (stained with Aβ42 C-terminal specific Ab). This immunoreactive pattern is 
peculiar of Im8 but not of other scFvs. Im8 shows also secondary cellular and dystrophic-
neurites reactivity (suppl. fig.8C).  
 
ScFv Im18 (suppl. fig.9A) shows specific pericellular reactivity near large plaques 
partially distinct and separate from them. In other fields of slice, Im18 (suppl. fig.9B) 
similarly to Im32 (suppl. fig.9C) detects cellular reactivity spatially related to Aβ42 
plaques. 
 
The immunoreactive pattern of Im47 is similar to that of Im18, with stronger cellular 
reactivity (probably astrocytes) in smaller plaques zones, and distinct pericellular 
reactivity near large plaques (suppl. fig.10). Pericellular reactivity of Im47 is often 
specifically dotted, resembling oligomeric-specific staining of PAb A11 (Kayed et al 
2003) in human AD brains (suppl. fig.11) and in 3xTg AD mouse model (Oddo et al 
2006).  
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In the following table we resemble the interesting differential binding properties of scFvs 
examined in human AD brain slices, in comparison with other characterized properties. 
  IVEM 
Human 
Aβ 1-10 
ELISA1 
Human 
Aβ1-42 ADDLs 
ELISA2 
Human 
Aβ1-42 biot 
IFs 
Human 
AD brains 
A1 - +++ +++ P, pC, C, Pa, V ++ 
A13 - + +++ C, pC + 
A18 - ++ + V, C ++ 
A19 - +/- +/-   
B2 + +++ ++ C, V +++ 
Im1 + +++ ++   
Im3 + +++ +++   
Im8 - + + O, pC +++ 
Im18 - ++ ++ C, Pa, pC ++ 
Im32 + + + C + 
Im47 + +++ ++ C, O, pC +++ 
P, plaque reactivity; pC, pericellular; Pa, parenchimal; C, cellular; O, oligomeric-like 
(dotted cluster); V, vascular 
 
ScFvs show different ability to react with Aβ deposits in human AD brain slices (see last 
column in the table). This diverse staining pattern could derive not only from differential 
intrinsic properties of recognition of Aβ in vivo produced, but also from differential in 
vitro stability of scFvs during the incubation steps. Optimizations of protocols are in 
progress, as well as experiments of co-localization with other anti-oligomers, 
unfortunately not all readily available. For scFvs Im1 and Im3, preliminary results are not 
shown. 
The ability of scFv to bind Aβ in AD tissues (extra- or intracellularly) can be 
qualitatively indicated in a decreasing scale: scFv Im8, B2, Im47, Im18, A18 and A1; 
noteworthy Im8, which was not very convincing in comparison to other scFvs in ELISA, 
but results specifically immunoreactive in AD brain slices. Clearly, optimization of the 
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experimental conditions for individual antibodies might improve the labeling pattern for 
some of them (this is true for A13, not shown). 
 
Discussion 
Pericellular zones (Lacor et al 2004) and cluster deposits, spatially segregated near 
plaques (Kayed et al 2003) were previously described as targets in AD brains of two 
different anti-Aβ oligomers (respectively PAb M94 and PAb A11). Recently, also 
astrocytes have been described clearly stained by NU-6, another MAb anti-Aβ oligomers 
(Lambert et al 2006). In addition, Barghorn and coworkers (2005) have observed that 
their PAb anti-Aβ globular oligomers detect a dense rim around the plaques in AD brains, 
distinctly from thioflavine-S staining. 
As above-discussed, our scFvs are peculiarly able to stain similar deposits (intracellular, 
pericellular and extracellular), and these observations favorably support their oligomeric-
specificity. In addition, some of the scFvs are able to react specifically with blood vessels 
in association with plaques recognized by other anti-Aβ antibodies; vascular reactivity is 
of interest because it is still unknown if oligomeric forms of Aβ can deposit in blood 
vessel, and how the perivascular drainage of Aβ oligomers is involved in AD 
pathogenesis. Other peculiar reactivity of some scFvs giving, for instance, intracellular 
staining in different cell types or differential dotted pericellular or synaptic-like staining, 
deserve to be investigate. In conclusion, our scFvs, probably thanks to the in vivo 
selection strategy, allow to detect new interesting conformational oligomeric-specific 
deposits in vivo produced. 
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8. ScFvs anti-Aβ as neutralizing agents in cellular models of 
neuronal cell death and of amyloidogenesis 
 
To explore and validate a relevant biological role for the SPLINT-selected anti-Aβ scFvs, 
we tested them in two different in vitro models of externally administered Aβ oligomers 
(human ADDLs) (points 1 and 2, below) and in a novel cellular model of endogenously 
produced Aβ and cell death which links neurothrophic deficits and amyloidogenesis 
(point 3). 
Several anti Aβ scFvs were administered in vitro as purified recombinant proteins and 
were tested for the following properties: 
1. inhibition of hADDLs-induced toxicity in the SHSY5Y human neuroblastoma 
cell line; 
2. inhibition of hADDLs synaptic binding in rat hippocampal primary cells; 
3. block of Aβ aggregation and/or neutralization of Aβ toxic species in neuronal 
differentiated PC12 cells deprived of serum and NGF (overproducing Aβ peptides 
and showing their aggregation in ThioflavinT positive structures).  
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8.1. Model of ADDLs toxicity in SHSY5Y human neuroblastoma cell 
line 
To test the biological activity of scFvs for their possible ability to neutralize the toxic 
effects of Aβ oligomers, a widely accepted cellular model of Aβ toxicity was exploited: 
hADDLs externally administered to SHSY5Y human neuroblastoma cells line, following 
two different protocols of treatment, an acute and a chronic protocol. 
 
The protocol of acute toxicity provides for the administration of 2.5 μM hADDLs 
(referred to the concentration of total Aβ peptide in the ADDLs preparation) for 16hrs. 
Instead, the protocol of chronic toxicity provides for the administration of 600nM 
hADDLs for 46hrs.  
The entity of cell death was evaluated by counting the number of apoptotic nuclei 
(staining with Hoechst 33342) and by the MTT assay (a measure of mitochondrial 
activity). In our experiments the average of cell viability reduction, measured by MTT 
assay, comes to 50% in the chronic as well as in the acute protocol. The amount of 
apoptotic nuclei (mostly pycnotic) is about 20%, consistently with what observed in 
published reports (Arias et al., 2005).  
A biologically relevant anti-Aβ oligomer antibody should, in principle, neutralize the 
toxicity induced by ADDLs. The anti-oligomer polyclonal antiserum PAb A11 blocks 
acute toxicity in neuronal differentiated SHSY5Y (Kayed R et al 2003) and protects 
against chronic toxicity induced by Aβ oligomers in undifferentiated SHSY5Y cells (Ma 
Q. et al., 2006). Lambert and coworkers (2001, 2006) have described polyclonal and 
monoclonal antibodies specific for ADDLs, endowed with neutralizing properties. 
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Testing our scFvs in vitro in cellular models was therefore important to establish the 
experimental conditions for the neutralization of Aβ oligomers cell death or toxicity. 
Under the established conditions, a number of scFvs demonstrated interesting 
neutralization properties, and a systematic screen to identify the best lead candidate can 
therefore be performed.  
 
8.1a. Modulation of hADDLs acute toxicity by administration of scFvs 
In order to evaluate the neutralizing ability of scFvs, as inhibitory effects on cell death, a 
single concentration of 550nM was tested; the protocol provides the coincubation of 
2.5μM ADDLs with scFv (or with the ‘vehicle’ solution, for the negative control) for at 
least 1h before cell treatment.  
The anti-Aβ scFvs tested (scFv A1, A13, Im47) were chosen to be representative of C-
terminal and N-terminal binders.  
Microscope analysis of nuclei, by in vivo staining with Hoechst 33342, allows 
individuating an altered morphology of nuclei after apoptotic stimuli of ADDLs, in 
comparison with healthy cells. We focused on the identification and on the count of 
highly condensed pycnotic nuclei. The quantification has been performed by counting the 
number of pycnotic nuclei per fields (at least five different fields) of more wells (3-4) for 
the same experimental point. 
We obtained a significant reduction of apoptotic nuclei in the treatment of SHSY5Y cells 
with scFvs A1, scFv A13 and scFv Im47 (fig.1), in comparison with antibody-untreated 
control cells and with cells treated with an unrelated scFv (αTL111, anti-Thymosin). 
Interestingly, the toxicity of hADDLs was almost completely neutralized by scFv A1 and 
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scFv A13. The results are indicative of a highly specific neutralizing ability of scFvA1 
and scFvA13, measured by this test, in the light of the sub-stoichiometric molar ratio 
scFv:Aβ that is of 1:5 (0.55μM of scFvs and 2.5μM of ADDLs).  
These and other scFvs anti-Aβ were tested also by MTT assay, showing a partial 
protective effect (preliminary results not shown). In the experiments of acute toxicity, the 
MTT assay, in general, leads to an underestimation of the protective effect of scFvs anti-
Aβ, if compared with the quantification of condensed nuclei/field. (approximately 30% 
less). 
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Figure 1. Neutralizing effect of the anti-Aβ scFv A1, scFv A13 and scFv Im47 in acute toxicity protocol, 
after 16 hrs of apoptosis ADDLs-induced. The values of apoptotic nuclei are expressed as % of apoptotic 
nuclei in untreated cells (ADDLs treatment, no antibody) versus treated cells (ADDLs treated plus Ab pre-
treatment). SHSY5Y cells were exposed to hADDLs (2.5μM), or with hADDLs pre-incubated with anti-Aβ 
scFvs (550nM) or with the unrelated scFv (anti-Thymosin). All treatments were performed in cell culture 
medium (D-MEM F12) serum free and without phenol red. Each column represents the mean ± S.E. (bars) 
of 5 values. * Denotes statistical significance (p < 0.05) of apoptotic nuclei values versus ADDLs 
treatment. ^Denotes statistical significance (p < 0.05) of apoptotic nuclei values versus the treatment with 
the unrelated scFv.  
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8.1b. Modulation of hADDLs chronic toxicity by administration of scFvs 
The effect of anti-Aβ scFvs A1 and A13 on cells survival, in the chronic toxicity 
protocol, after 46 hrs of hADDLs (600nM) treatment, was studied in the concentration 
range between 1.5 and 600 nM (1.5nM, 15nM, 150nM, 600nM) (fig.2). The 
characterization of other anti-Aβ scFvs is in progress. 
ScFv were administered to the cell culture 2 hours before hADDLs. 
Concerning the amount of protection in terms of rescue of apoptotic nuclei, incubation 
with scFvs A1 and A13 results in a good neutralization of ADDLs toxicity, because at 
1.5nM (with a molar ratio of scFv versus ADDLs of 1:400) they are able to reduce by 
60% the number of apoptotic nuclei. Moreover, an unexpected dose-effect behavior was 
observed. In fact, the reduction of apoptotic nuclei by administration of scFvs A1 and 
A13 appears to correlate inversely with the scFvs concentration; lowest concentrations of 
scFvs exhibit a greater protection. The reason for this might be due to an unlikely non 
specific toxicity of scFvs proteins at higher concentrations for long times (46 hrs), or to 
the fact that, at higher concentrations, scFvs might lose neutralizing ability, for instance 
by aggregation.  
 178
 
 
0
20
40
60
80
100
120
CT
RL
AD
DL
s 6
00
nM
A1
3 1
.5n
M
A1
3 1
5n
M
A1
3 1
50
nM
A1
3 6
00
nM
A1
 1.
5n
M
A1
 15
nM
A1
 15
0n
M
A1
 60
0n
M
%
 o
f a
po
pt
ot
ic
 n
uc
le
i (
%
 v
s 
to
x)
 
Figure 2. Neutralizing dose-dependent effect of the anti-Aβ scFv A13 and scFv A1 in chronic toxicity 
protocol, after 46 hrs of ADDLs-induced apoptosis. The values of apoptotic nuclei are expressed as % of 
apoptotic nuclei in untreated cells (ADDLs treatment, no antibody) versus treated cells (ADDLs treated 
plus Ab pre-treatment). SHSY5Y cells were treated or not, for 2 hours with four different doses of anti-Aβ 
scFvs (1.5nM, 15nM, 150nM, 600nM); cells were afterwards exposed to hADDLs (600nM) for 46 hrs. All 
treatments were performed in cell culture medium (D-MEM F12) serum free and without phenol red. Each 
column represents the mean ± S.E. (bars) of 5 values. * Denotes statistical significance (p < 0.05) of 
apoptotic nuclei values versus ADDLs treatment.  
 
The protective role of scFvs, as determined by the reduction of apoptotic nuclei, appears 
to be more significant than that assessed by MTT viability assay (see fig.3). In addition, 
the neutralizing dose-dependent effect of the anti-Aβ scFv A13 and scFv A1 in the 
chronic toxicity protocol, as evaluated by MTT assay, showed a different trend in 
comparison with what observed by the counting of apoptotic nuclei (see fig.3). However, 
we cannot consider MTT data totally consistent with other experimental observations, 
probably due to the intrinsic limitations of the MTT assay. In fact, consistently with what 
recently reported (Hong et al., 2007), we observed that extracellularly applied Aβ 
oligomers rapidly induce the MTT formazan exocytosis (MTT-FE), with the formation of 
“needle-like” crystals at the cell surface, whereas, normally, MTT formazan is 
 * 
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accumulated only in the mithocondria of living cells. Thus, using the standard MTT assay 
procedures, the final quantitative determinations of the solubilized MTT formazan are not 
completely reliable, as they are flawed by this side-effect specifically induced by 
exogenous Aβ oligomers.  
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Fig. 3 Dose-dependent neutralizing effect of the anti-Aβ scFv A13 and scFv A1, evaluated by MTT assay, 
in chronic toxicity protocol, after 46 hrs of ADDLs-induced apoptosis.  
SHSY5Y cells were treated or not, for 2 hours with four different doses of anti-Aβ scFvs (1.5nM, 15nM, 
150nM, 600nM); cells were afterwards exposed to hADDLs (600nM) for 46 hrs. All treatments were 
performed in cell culture medium (D-MEM F12) serum free and without phenol red. 
The values are expressed as percentage of protection, calculated from the percentage of vitality in different 
experimental points: % protection = [(scFv+ADDLs) – (ADDLs)] / [(CTRL) – (ADDLs)]. 
Each point represents the mean ± S.E. (bars) of nine values, from three different experiments. The 
statistical analysis (one way ANOVA by Student-Newman-Keuls Method) confirms the significance of 
data in individual experiments (p<0.05).  
 
 
8.1c. Conclusions 
 
Experimental data obtained by administration of scFvs to SHSY5Y cell cultures show 
that scFvs A1 and A13 are effectively able to modulate ADDLs-induced toxicity, 
protecting from cell death. The reduction of toxicity is more significant if measured by 
counting of apoptotic nuclei in acute toxicity. The high anti-apoptotic action of scFvs A1 
and A13 at low concentrations in acute toxicity protocol (550nM of scFvs against 2.5μM 
of ADDLs) is suggesting of a high affinity for hADDLs and of a very specific 
neutralizing power.  
MTT assay 
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Even more surprising appears the protective role in chronic toxicity protocol: here the 
administration of as low as 1.5nM of scFvs A1 and A13 results in a significant degree of 
protection against 600nM of hADDLs.  
Recently, in cultured human cortical neuron, different concentration-dependent 
mechanisms of Aβ oligomers-induced toxicity have been suggested. In fact, 2-10 μM of 
Aβ oligomers (AβOs) induced rapid and massive neuronal death (with a time lapse that is 
dose dependent), through a stereotyped succession of cellular changes consistent with the 
activation of a mitochondrial death apoptotic pathway. At low concentrations (<1μM) 
AβOs caused chronic and subtler mitochondrial alterations but minimal cell death 
(Deshpande et al., 2006). 
A recent study, in a protocol of chronic toxicity similar to our experimental conditions 
(500nM of Aβ oligomers administered for 46 hours to SHSY5Y cells), showed that low 
concentrations of the anti-oligomer PAb A11 (2ng/ml= ~12.5pM) protect from Aβ 
oligomers-induced toxicity and prevent the activation of the glycogen synthase kinase-3β 
(GSK3β) (Ma et al., 2006).  
The observations that conformational-specific antibodies can neutralize the AβOs-
induced toxicity at concentrations largely sub-stoichiometric (with respect to total Aβ) 
could suggest for these antibodies shared mechanisms that deserve to be investigated.  
We hypothesize that scFvs anti-Aβ target specific conformational epitopes of Aβ, 
otherwise able to activate, in an unknown way, apoptotic pathways probably both 
intracellularly and extracellularly.  
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8.2. Synaptic binding of ADDLs 
ADDLs are ligands for particular proteins on neuronal cell surfaces, as demonstrated by 
experiments in long-term cultures (>21 days) of dissociated rat hippocampal neurons 
(Lambert et al., 1998). We performed an experimental paradigm, to incubate mature 
cultures of hippocampal neurons with synthetic or natural ADDLs and then probe with 
oligomeric-specific antibodies. 
ADDLs bind to these neurons with regional specificity, attaching mostly to dendrites and 
exhibiting a punctate pattern reminiscent of rafts, focal contacts, or synaptic terminals, 
co-localizing with clusters of PSD-95. Binding occurs within minutes and is localized to 
the cell surface (being detected without permeabilization of living cells). Hot spots are 
seen in hippocampal and cortical, but not cerebellar, cultures, a specificity of binding 
consistent with AD vulnerability (Lambert et al., 1998). 
The biological relevance of synaptic binding of ADDLs is today widely accepted because 
ADDLs are the most synaptotoxic Aβ species and because synaptic dysfunction, 
occurring early in AD, is considered the best pathological correlate of cognitive decline 
(Gong et al., 2003; Haass & Selkoe, 2007).   
 
Inhibition of hADDLs synaptic binding by scFvs 
The inhibition of ADDLs synaptic binding is therefore a simple, but biologically relevant, 
experiment to test neutralizing action of antibodies raised against these synaptotoxic Aβ 
species.  
We performed an experimental protocol in which ADDLs, or ADDLs preincubated with 
scFvs, are administered to primary rat hippocampal neurons. We used 300nM of 
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hADDLs, preicubated or not with 600nM of scFvs A1 or A13. The extent of ADDLs 
synaptic binding was evaluated by immunofluorescence using the anti-oligomer PAb A11 
and a MAb anti PSD-95 (see supplemented fig.12).  
Comparing areas of similar density of PSD-95 positive spots, focusing mainly on 
dendrites, we performed a qualitative analysis of A11-positive spots density. Quantitative 
analyses are in progress using MethaMorph and ImageJ (NIH) software.  
Our qualitative analysis confirms that synaptic binding can be significantly reduced by 
prior incubation of ADDLs with scFv A13 and with scFv A1 (see supplemented fig.13). 
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8.3. Nerve growth factor deprivation causes activation of the amyloidogenic route 
and release of Aβ in PC12 cells: inhibitory effect of scFv A13 
 
As a further evaluation of the protective role of selected scFvs anti-Aβ, we exploited a 
new cellular model that links neurotrophic deficits and/or deprivation to the activation of 
an amyloidogenic pathway. This model is based on PC12 cells differentiated with NGF. 
PC12 cells, a clonal cell line derived from rat pheochromocytoma, respond to NGF 
treatment by undergoing mitotic arrest and differentiation into a neuronal-like phenotype 
(Greene et al., 1976). These neurons die via an apoptotic mechanism when NGF is 
withdrawn from the culture (Edwards et al., 1994). 
Recently we demonstrated that NGF deprivation causes activation of the amyloidogenic 
route and release of Aβ peptides in PC12 cells (Matrone et al., submitted paper). 
Moreover, in this cellular model, we demonstrated the causative role of endogenously 
over-produced and secreted Aβ in triggering apoptosis. In fact, apoptotic death and Aβ 
production are completely inhibited by β and γ secretase inhibitors, which also favour 
maintenance of PC12 morphology and neuritic network. On the contrary, Aβ production is 
activated by inhibitors of TrkA, the high affinity receptor of NGF.  
These findings indicate that the antiapoptotic action of NGF is tightly linked to the 
processing of the amyloid precursor protein APP, and suggest that NGF neurotrophic 
signalling deficits may have direct relevance to the onset of Alzheimer disease, via the 
activation of aberrant APP processing. Similarly, a previous study, carried out in our 
laboratory in AD11 transgenic mice, showed that NGF deprivation, via endogenous 
cerebral expression of NGF-antibodies, induced a neuropathological and behavioural 
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AD-like phenotype (Capsoni et al., 2000), providing a direct evidence linking reduced 
NGF signalling and/or activity in the brain to the activation of an amyloidogenic route 
and Alzheimer neurodegeneration (Capsoni et al., 2002).  
ScFv A13 was chosen to evaluate its ability to inhibit cell death in this PC12 cell model. 
Before describing the results obtained, I will describe the properties of this new cellular 
model. 
 
 
8.3.1 Cellular model  
a. Overproduction of endogenous Aβ peptides  
The first experimental observations showed that the progressive death of PC12 
differentiated cells, when NGF and serum were withdrawn from the culture, was 
accompanied by a parallel increase of thioflavine (ThT) binding proteins in the medium 
(figure1A-B). Notice that when the extent of ThT binding (table) was referred to the 
corresponding cell death (measured by MTT assay), the ratio (ThT/MTT) changed from a 
value of 1.0 to a value of 10 after 72 hrs of apoptosis induction (because ThT values 
increase and MTT values decrease). 
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Figure 1: Panel A shows the effect of NGF deprivation on PC12 survival evaluated by the MTT procedure. 
Viability of PC12 incubated in serum and NGF  (---♦---), deprived of serum (---■---; +NGF) and deprived 
of serum and NGF (---Δ---;−NGF) for 24, 48, or 72 hours are shown in the figure. The values were 
expressed as percentage of the values for PC12 control cells (time 0)  
Panel B reports the values of thioflavine T (ThT) binding proteins in the secreted serum-free medium of 
PC12 differentiated cells (+NGF) and in the medium deprived of serum and NGF (-NGF) for 24, 48 and 72 
hrs (+NGF, ---■---; -NGF, --Δ---). The corresponding ratio between the values for ThT and MTT assays is 
represented in the table below. The data are expressed as percentage of PC12 control cells (time 0). 
Each point represents the mean ± S.E. (bars) of nine values.  
* denotes statistical significance (p <0.05) versus time 0; ** denotes statistical significance (p < 0.001) 
versus 0 and 24 hrs of apoptosis.  
 
Th-T Th-T/MTT 
Time (hrs) 
+NGF -NGF +NGF -NGF 
0 100 100 1 1 
24 110±7.9 120±12.3 1.25±0.11 1.5±0.12 
48 112±10.1 155±17.2* 1,45±0.17 3.5±0.23* 
72 109±12.3 160±9.5 * 1.55±0.2 10.6±0.32 ** 
 
Thioflavine T (ThT) binds to proteins that undergo a β-sheet transition and cannot, 
therefore, be taken as a direct measure of Aβ production and its polymeric aggregation. 
In order to assess the actual presence of Aβ peptide(s) in ThT-positive structures present 
in the culture medium at different times after NGF withdrawal, cells were harvested and 
collected, the culture medium was centrifuged and the resulting “fibrillar” pellet was 
A B 
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dissolved in 70% formic acid and Tris 2M and analyzed by Western Blot and ELISA-
sandwich assay (Figure2).  
 
 
 
Figure 2: A) Western blot analysis of Aβ1-42 in PC12 cells and in the corresponding culture media pellets 
after 48 hours apoptosis. 10μg of total protein extracts were loaded on Tricine gels and probed with 
monoclonal anti Aβ antibody (6E10). The data are representative of three distinct experiments. 
B) Elisa assay of Aβ1-42 amount in pellets derived from culture media of NGF-differentiated PC12 deprived 
of serum or deprived of serum and NGF for 24, 48, 72 hours. The values of Aβ1-42 content are referred to 
total protein amount of each sample and are expressed as percentage of PC12 control cells (time 0). Each 
point represents the mean ± S.E. n=4. * denotes statistical significance (p < 0.05) versus time 0. 
 
Figure 2A shows a Western Blot analysis of PC12 cells and of the corresponding 
aggregates obtained from culture medium carried out with a monoclonal anti-Aβ 
antibody (6E10) after 48 hours of apoptosis induction. As it can be seen, NGF withdrawal 
induces a marked increase of Aβ antibody cross reacting polypeptides of different size in 
the cells and in the medium (-NGF) as compared to the corresponding control samples 
(+NGF). As shown in figure 2B, the amount of formic acid soluble aggregated Aβ, as 
determined by ELISA, closely parallels the amount of ThT binding proteins.  PC12 cells 
deprived of serum, but still containing NGF, release a small, constant amount of Aβ1-42 in 
the medium, but when deprived of both serum and NGF, they produced a much larger 
A B 
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amount of Aβ, that peaked at 48 hrs. It is worth noting that also the content of APP 
protein increases during the same time period of apoptosis induction, indicating that the 
larger production of Aβ is paralleled by a significant increase of its precursor (data not 
shown). The data reported also demonstrate that these fibrils, containing a large amount 
of Aβ1-42, can be only partially dissolved with a strong detergent such as 10% SDS and 
need of a treatment with 70% formic acid, generally employed to dissolve senile plaques 
from AD brains, to be completely solubilised.. In figure 3A-B are shown Elisa assay of 
samples obtained from culture medium of PC12 cells for Aβ1-42 and Aβ1-40. The medium 
was ultracentrifuged and partially solubilised in 10% SDS. The remaining pellet is totally 
dissolved in 70% formic acid. Aβ1-40 and Aβ1-42 peptides are detectable in both the 
soluble and insoluble fractions, but Aβ1-42 amount is higher than Aβ1-40. Furthermore, the 
level of Aβ1-42 detected in the insoluble fraction resulted approximately twice than that 
present in the 10% SDS solution. By contrast, Aβ1-40 levels result homogeneously 
distributed in the different fractions.  
 
 
 
Figure 3. A and B Elisa assays of Aβ1-42 and Aβ1-40, respectively, of pellets derived from culture medium 
after 48 hrs of apoptosis dissolved with 10% SDS (soluble)  and subsequently with 70% formic acid 
(insoluble). The values of Aβ 1-42 and Aβ 1-40 contents are referred to total protein of each sample and are 
the average of 3 independent experiments. *denotes statistical significance (p < 0.05) of SDS 10% soluble 
fraction versus +NGF; ^denotes statistical significance (p < 0.05) of SDS 10% insoluble fraction versus the 
corresponding SDS 10% soluble fraction. 
A B 
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Finally, the analysis of SDS 10% insoluble fraction by MALDI-TOF analysis (data not 
shown) completely validate the presence of Aβ1-42 in the medium of PC12 cells after NGF 
deprivation.  
b. Modulation of Aβ over-production 
Aβ peptides derive from APP precursor by its cleavage by beta and gamma secretases. In 
our model, as shown in figure 4, inhibitors of β and γ secretases largely block not only 
the increase of thioflavine binding proteins but, very significantly, also PC12 cell death, 
underlining the tight correlation between NGF deprivation, pathological APP processing 
and cell death of PC12 cells. γ and β-secretase inhibitors, separately added, are able to 
exert a strong but partial inhibition, while, together, they fully restore cell viability and 
reduce fibril production to control levels. Moreover, the overall morphology and neuritic 
network of PC12 cells is maintained when β and γ secretase inhibitors are added in the 
serum free medium deprived of NGF (data not shown). 
 
Figure 4. Effect of γ and β secretase inhibitors on PC12cell survival and ThT release, evaluated by MTT 
and ThT assay in NGF-differentiated PC12 cells after 48 hrs of NGF withdrawal. The values of MTT (white 
bars) and ThT (black bars) are expressed as % of control cells. PC12 differentiated cells deprived of serum 
(+NGF) and serum and NGF (-NGF) were exposed to γ and β secretase inhibitors. All the values are 
expressed as percentage of control cells (+NGF). Each column represents the mean ± S.E. (bars) of 6 
values. * Denotes statistical significance (p < 0.05) of ThT values versus –NGF. ^Denotes statistical 
significance (p < 0.05) of MTT values versus –NGF.  
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In order to start dissecting the involvement of NGF signalling, through the NGF tyrosine 
kinase TrkA receptor in the Aβ production and in cell death, both parameters were 
assessed after incubation with a Trk-A inhibitor, K252-a (Berg et al., 1993). As shown in 
figure 2C, after 2 hrs of incubation, 100 nM K252-a induce 60% of cell death and the 
additional incubation with NGF (50ng/ml) fails to revert this effect, confirming a 
significant inhibition of Trk-A receptor signalling. Moreover, after 2 hrs of incubation 
with K252-a, the extent of thioflavine binding structures increases by 50%, a value 
identical to that observed in PC12 cells undergoing apoptosis after NGF withdrawal. 
Finally, the combined treatment with β and γ secretase inhibitors, totally blocks cell death 
and thioflavine binding production, further indicating that the NGF-high affinity receptor 
is involved in controlling APP processing and Aβ production.  
 
Figure 5. Effect of 100 nM K-252a on cell viability and ThT binding and the effect of γ and β secretase 
inhibitors on the proapoptotic action of K-252a. After 2 hrs of incubation with K-252a, cells were washed 
three times and re-exposed to NGF 50ng/ml for 48 hrs in some samples and to γ and β secretase inhibitors 
for 48 hrs. All the values were expressed as percentage of control values (+NGF) and represents the mean 
± S.E. (bars) of 5 values. * Denotes statistical significance (p < 0.05) of ThT assay versus K-252a –NGF 
(black bars) and ^denotes statistical significance (p<0.05) of MTT assay versus K-252a –NGF (white bars). 
 
c. Conclusions 
The studies here reported demonstrate that apoptosis following NGF withdrawal is 
accompanied by activation of an amyloidogenic route with overproduction and release of 
Aβ and its aggregation into thioflavineT-positive structures.  
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The free and organized overproduced Aβ structures can be quantified and are easily 
detectable by the thioflavine binding procedure. ELISA as well as Western blot assays 
demonstrate that these polymers contain large amounts of Aβ in a ratio relatively 
comparable to that observed by the thioflavine measure.  
The finding that inhibition of the Aβ production by a combined treatment with β and γ 
secretase specific inhibitors is accompanied by a parallel inhibition of apoptosis, further 
underlines the tight correlation between NGF withdrawal and APP processing with Aβ 
formation. This conclusion is also supported by the finding that treatment with a TrK-A 
inhibitor, K-252a, causes a marked reduction of cell survival and an increase of Aβ 
production that is fully counteracted by a combined treatment with the two secretase 
inhibitors. Previous studies have shown that cortical or cerebellar granule neurons 
undergoing apoptosis produce Aβ peptides (LeBlanc, 1995; Romano et al, 2003) and the 
latter affect healthy neurons thus generating a sort of autocrine toxic loop (Marques et al., 
2003). The present study further demonstrates that this toxic loop may also be operative 
in PC12 differentiated cells, and provides evidence for a direct causal link between NGF 
withdrawal, APP abnormal processing and Aβ toxicity, as suggested by the antiapoptotic 
action of γ and β secretase inhibitors and of the anti-Aβ antibodies. 
 
8.3.2 Antibodies treatments: the protective role of scFv A13 
In order to assess whether the Aβ peptides, and in particular their particular conformation 
or oligomeric aggregation, produced after NGF removal, play a role in the cell death 
process, NGF-deprived PC12 cells were treated with scFv A13 and with MAb 4G8 as a 
reference.  
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The well established MAb 4G8, recognizes the linear epitope aa18-22 of Aβ, regardless 
of its quaternary state (monomeric, oligomeric or fibrillar); scFv A13, as discussed 
above, similarly to the other SPLINT-selected scFvs anti-Aβ, recognizes a 
conformational epitope (C-terminal), preferentially exposed in Aβ oligomeric aggregates. 
In addition, in the previously described cellular bioassays (ADDLs-induced toxicity in 
SHSY5Y cells, and synaptic binding of ADDLs in hippocampal primary cultures), scFv 
A13 resulted one of the best candidates among the panel of scFvs anti-Aβ tested.  
The effect of the anti-Aβ scFv A13 on cells survival and ThT “release” after 48 hrs of 
NGF deprivation was studied in the concentration range between 1 and 2 nM (Figure 6) 
(concentrations established so that the molar ratio of scFv versus total Aβ (measured by 
ELISA assay) was between 1:5 and 1:3). 
scFv A13, at 1.5 nM, almost totally rescues the cells from apoptotic death, and inhibits 
Th-T “release”, in comparison with similar concentrations of an unrelated scFv (anti-
thymosin αTL111).  
 
Figure 6. Effect of scFv A13 on PC12 cells deprived for 48hrs of serum and NGF evaluated by the MTT 
(white bars) and ThT (black bars) procedure, in the dose range from 1 to 2 nM. The values were expressed 
as percentage of the corresponding PC12 control cells (+NGF) 
Each point represents the mean ± S.E. (bars) of nine values. *denotes statistical significance (p < 0.05) 
versus ThT values versus -NGF; ^ denotes statistical significance (p < 0.05) versus MTT values versus -
NGF .  
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Both anti-Aβ antibodies scFv A13 and MAb 4G8 largely inhibit both fibril production 
and PC12 cell death (figure 7). It is noteworthy that the conformationally selective 
antibody scFv A13 is protective at concentrations (1nM) lower than those at which MAb 
4G8 is effective (6.7 nM). 
 
 
Figure 7. Inhibitory effect of the anti Aβ scFv A13 recombinant antibody and of the anti-Aβ MAb 4G8 on 
cell viability and Aβ production in NGF-differentiated PC12 cells after 48 hrs of apoptosis. The values of 
MTT (white bars) and ThT (black bars) are expressed as % of control cells. PC12 differentiated cells 
deprived of serum and NGF (-NGF) were exposed to scFv A13 (1.5nM) or to an unrelated scFv (anti-
Thymosin) (1.5nM) or to MAb 4G8 (6.7nM). All the values are expressed as percentage of control cells 
(+NGF). Each column represents the mean ± S.E. (bars) of 6 values. * Denotes statistical significance (p < 
0.05) of ThT values versus –NGF. ^Denotes statistical significance (p < 0.05) versus of MTT values 
versus–NGF.  
 
 
The reduction of Aβ production after the treatment with this antibody became more 
evident by Western Blot and Elisa assay (figure 8A-B). Western Blot (figure 8A) shows 
that the treatment with scFv A13 induces a marked decrease of Aβ-antibody cross-
reacting polypeptides in the medium of NGF-deprived cells (−NGF, after 48 hours of 
NGF withdrawal) as compared to the corresponding control samples (+NGF). We 
observed a significant reduction of Aβ-immunoreactivity at 30-60 kDa; moreover, the 
medium of A13-treated cells (−NGF) does not show more the bands higher than 60 kDa 
and lower than 30 kDa, included the faint band at 4kDa (probable Aβ monomer). 
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Similarly, ELISA assay (figure 8B), used to measure the amounts of Aβ1-42 in pellets 
derived from culture media (SDS soluble and insoluble), shows that scFv A13 determines 
a total reduction of Aβ1-42 in NGF-deprived cells (from ~8pg/mg of  total proteins, 
down to ~1.5pg/mg of total proteins) at the levels of control cells (+NGF).  
 
 
Figure 8: A) Western blot analysis for Aβ in the culture medium of PC12 control cells and after 48 hours 
apoptosis exposed or not to scFv A13 antibody (1.5nM). 10 μg of total protein extracts were loaded on 
Tricine gels and probed with monoclonal anti Aβ antibody (6E10). The data are representative of three 
distinct experiments. 
B) ELISA assay of Aβ1-42 amount in pellets derived from culture media of NGF differentiated PC12 
deprived of serum or deprived of serum and NGF for 48 hours and treated with or without scFv A13 
antibody (1.5nM). The values of Aβ1-42 content are referred to total protein amount of each sample and are 
expressed as percentage of PC12 control cells (+NGF). Each point represents the mean ± S.E. n=3. * 
denotes statistical significance (p < 0.05) versus +NGF, **denotes statistical significance (p < 0.001) 
versus -NGF.  
 
The complete rescue from apoptosis and the overall reduction of Aβ species and Th-T 
positive structures, after 48 hours of NGF deprivation, can suggest for scFv A13 some 
mechanisms of neuroprotection. ScFv A13 can probably recognize Aβ and/or early Aβ 
oligomers, avoiding their superior aggregation and/or neutralizing them as activators, via 
an autocrine toxic loop, of an amyloidogenic route that can trigger apoptosis through the 
overproduction and aggregation of Aβ peptides.  
A B 
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The scFv A13 is protective at concentrations (1nM) lower than those at which MAb 4G8 
is effective (6.7nM): one hypothesis could be that scFv A13 neutralizes early, low 
concentrated but conformationally critic Aβ species only partially recognized by MAb 
4G8, in the medium of NGF-deprived cells. We could hypothesize also a preferential 
intracellular internalization of scFv A13, in the light of a new mechanism of action 
recently suggested for anti-Aβ antibodies (Tampellini et al., 2007). 
Investigating the mechanism of action of scFv A13, can help the discovery of a new link 
between reduced NGF signalling and/or activity, and the activation of an amyloidogenic 
route. 
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DISCUSSION 
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1. Anti-Aβ scFvs: SPLINT libraries as a good source of unique 
recombinant antibodies against a relevant antigen in AD pathology 
 
Targeting Aβ pathological species, in particular Aβ oligomers, is one of the primary hot-
topics of actual research in AD and antibodies represent elective tools to target, with 
different purposes, this relevant antigen. 
Here, we discussed the novel generation of a panel of 18 recombinant anti-Aβ antibodies, 
in the format of single chain fragments (scFvs), using the novel approach of Intracellular 
Antibody Capture Technology (IACT) developed in our laboratory (Visintin et al, 1999, 
2002, 2004). Anti-Aβ scFvs were selected from recently derived libraries, Single Pot 
Libraries of INTrabodies (SPLINT) (Visintin et al., 2004a), that are repertoires of 
recombinant scFvs engineered by amplifications and assemblies of VH and VL genes of 
immunoglobulins of different source. In these libraries, each scFv clone derives from a 
random VH-VL pairing of natural VH and VL immunoglobulin regions. 
Two different SPLINT libraries were used in this work:  
• a naïve library derived from a non-immunized source of natural VH and VL 
mouse regions genes (Visintin et al, 2004a); this library, of complexity of ~107 
different scFv clones, was constructed and kindly provided by Dr Visintin, 
(LayLineGenomics, Trieste); 
• an immune library derived from a source of natural V genes from spleen 
lymphocytes of mice immunized with human Aβ42 (Meli et al, 2005, 2006). The 
construction of this immune library, of complexity of ~106 different scFv clones, 
was here described for the first time. 
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Antibody libraries can be engineered in vitro, displaying a complexity comparable to that 
of the natural immune system of mammals, so that theoretically their repertoire is 
complete and every imaginable antibody may be derived. In general, the larger the 
library, the higher the chance is to isolate specific antibodies with good binding 
characteristics (in terms of affinity) (Perelson & Oster, 1979; Griffiths et al., 1994). It has 
been shown that libraries containing about 107 independent clones are sufficient to yield 
antibodies to proteins with affinities in the low micromolar range (similar to those 
obtained in a primary immune response in vivo), while larger antibody libraries of 109 –
1010 clones yielded specific antibodies with affinities in the nanomolar range (similar to 
those obtained after a secondary immune response) (Griffiths et al., 1994; Vaughan et al., 
1996; Sheets et al., 1998).  
As discussed, the immune library, even though smaller by a factor of 10 in comparison 
with the naïve library (106 versus 107), has been a good source of specific scFv antiAβ 
because of the immunization enrichment. 
In addition, regarding the SPLINT libraries, as discussed by Visintin and coworkers 
(2004a), the real diversity of the library could be higher than the number of yeast 
transformants (106), which provides the nominal “cellular” diversity: this peculiarity 
could be achieved by yeast cells that, after transformation, can express more than one 
scFv. The final diversity may or may not result after further recombination events and 
after segregation of different scFvs in daughter cells. This latter event, could easily 
contribute to an increase of the real diversity by a factor ≥10 leading therefore, under the 
selective pressure of IACT, to the selective isolation of antigen-specific scFv fragments. 
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Even though we have not yet performed affinity measurements for anti-Aβ scFvs, we 
know from previous studies in our group that affinities of other scFvs selected from naïve 
SPLINT libraries are in the range of nM. 
 
The naïve library is an un-biased source of scFvs and results an excellent source of 
antibodies against a wide panel of different antigens tested (Visintin et al, 2004a) and 
also, as demonstrated in this thesis, against Aβ42. The specificity of preferential epitope 
(N-terminal) recognized by scFvs selected from the immune library suggests that Aβ 
immunization could be a good strategy to improve, in a biased way, a library of 
recombinant scFvs against this antigen. 
Sequence analysis confirms the high similarities between scFvs selected from the 
Immune library, suggesting a selective enrichment of VL and VH natural regions 
amplified from lymphocytes of active-immunized mice, resembling a real mechanism of 
oligoclonal response of the immune system to the Aβ antigen. A single functional 
consensus sequence that might represent a fingerprint of the CDR sequences against Aβ 
has not been identified. In any case, this work provides the first systematic sequence data 
on the antibodies generated against Aβ. 
It is noteworthy that, even though scFvs anti-Aβ have been selected as stable intracellular 
binders, they maintain the ability to bind Aβ species in vitro in different conditions, from 
all the in vitro tests incubations to the cell cultures treatments, suggesting a significant 
stability and solubility. Even though we have not yet performed chemico-physical and 
thermodynamic stability characterization of the anti-Aβ scFvs proteins, high stability and 
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solubility are characteristics improved by the conditions of intracellular expression and 
selection employed with the IACT technology. 
In all of the in vitro characterizations of the scFv binding ability, we have not verified a 
distinctive advantage for scFvs selected from the immune library in comparison to scFvs 
deriving from the naïve library, even with two ‘naïve’ scFvs (A1 and A13) showing 
interesting biological properties in cellular bioassays. 
The biological relevance of scFvs have been demonstrated in vitro by experiments using 
them as recombinant proteins externally administered, in different cellular models.  
Results show a good ability of scFvs A13 and A1 to reduce significantly the synaptic 
binding of synthetic ADDLs to the neuritic processes of hippocampal neurons. ScFvs A1 
and A13 (at very low concentrations 1.5nM) are also able to reduce cell death ADDLs-
induced in SHSY5Y cells.  
ScFv A13, in a cellular model (PC12 neuronal differentiated cells) of endogenous 
overproduction, secretion and aggregation of Aβ after NGF deprivation, protects PC12 
cells from neuronal apoptosis and significantly reduces Aβ42 and the ThT positive 
structures accumulation in the medium. ScFv A13 have been used ~10 fold less 
concentrated than the “gold-standard” MAb 4G8 (Matrone et al, submitted paper). The 
molecular mechanisms of action of this neuroprotective activity of A13 are under 
investigation, but probably scFv A13 acts as blocker of early “malicious” Aβ oligomers, 
significantly reducing their toxicity but also reducing their further aggregation in large 
ThT positive fibrils.  
In conclusion, we have described the isolation and characterization both in vitro and in 
vivo of a large panel of oligomeric-specific anti-Aβ scFvs, taking advantage of the 
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IACT/SPLINT technology. The ability to recognize in vivo produced Aβ species and also 
to neutralize them is directly related to the selection strategy (IACT), that enriches in 
selective binders of in vivo (in the yeast cytoplasm) folded and probably aggregated Aβ 
bait.  
 
 
2. Conformation specificity of anti-Aβ SPLINT-selected scFvs 
 
Different results obtained with several experimental approaches suggest that anti-Aβ 
scFvs selected from SPLINT libraries show conformation specificity and preferential 
binding ability versus Aβ oligomers. 
The in vivo data obtained from SPLINT scFvs selection in yeast, in particular the IVEM 
(in vivo epitope mapping) results, suggested also a reliable conformational hypothesis in 
order to explain the lack of recognized epitopes in the central part of Aβ peptide. The 
conformational hypothesis is consistently supported by strictly related studies in yeast, as 
below discussed. 
The results from the first ELISA assay, performed with different Aβ species directly 
coated in solid phase, showed that SPLINT-selected scFvs were specifically able to 
recognize human Aβ42 oligomers 3-5 fold better than humanAβ42 fibrils, and up to 10-
20 fold better than human Aβ42 monomers.  
Subsequently, the more sensitive NeutrAvidin ELISA assay showed that scFvs anti-Aβ 
recognizes conformational structural epitopes probably more exposed in Aβ42 oligomers; 
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Aβ oligomers in this assay were also recognized by the well established PAb A11 anti-
oligomer antibody (Kayed et al., 2003).  
Immunoprecipitation results showed that the two anti-Aβ scFvs (A1 and B2) can 
differentially bind Aβ42 soluble species under solution conditions which could favour the 
native folding conformations of Aβ monomers and oligomers.  
The data obtained by the recognition of in vivo produced Aβ, in human AD brains, 
suggested also a specificity of anti-Aβ scFvs for Aβ deposits, in line with previous 
experimental reports of other anti-oligomer antibodies tissue-immunoreactivity. 
Moreover, in AD brains the ability of different scFvs to recognize various 
immunoreactive structures (cells, pericellular, intracellular and extracellular deposits, 
blood vessels) and to show distinct labeling patterns, suggested a peculiarity of each 
scFv, in spite of their common ability to recognize Aβ antigen in biochemical assays in 
vitro. This interesting ability of SPLINT-selected anti-Aβ scFvs could be strictly linked 
to the peculiarity not only of Aβ itself as misfolded antigen, but also of the complex 
‘scenario’ in the pathological tissues. In fact, it is known that Aβ, in vivo can interact with 
a variety of cofactors including metals, glycosaminoglycans, glycoproteins such as serum 
amyloid P and apolipoprotein E, and constituents of basement membranes such as 
perlecan, laminin, and agrin (Alexandrescu, 2005). These “pathological chaperones” have 
effects that range from mediating the rate of amyloid fibril formation to increasing the 
stability of amyloid deposits, and may contribute to the different “immunoreactivity 
properties” of Aβ deposits in human brains (and in general of Aβ aggregates in biological 
samples). Because of in the literature are not yet available complete data on the Aβ 
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oligomeric immunoreactivity in human and animal tissues, scFvs anti-Aβ SPLINT-
selected could be a relevant tool to characterize this interesting aspect of AD pathology.  
It is likely that the presence of ‘chaperones’ bound to Aβ in biological samples (as brain 
extracts) could preserve particular conformations of Aβ immunoreactive species when 
analyzed by Immunoblot procedures. As observed in the preliminary DotBlot and 
WesternBlot analysis, some scFvs SPLINT-selected show weak reactivity versus Aβ 
species in these assays. In particular, scFvs can recognize only natural Aβ oligomers 
(from AD brain extracts) but not synthetic Aβ preparations well recognized in other in 
vitro assays. Consistently with experimental observations of others (Kayed et al., 2003), 
it is likely that immunoblot (IB) procedures do not preserve native conformations of Aβ 
oligomers, especially if synthetic, even if they are considered SDS stable species. 
Changes in the native conformation of Aβ oligomers in IB analysis could compromise the 
detection ability of conformational specific antibodies as observed with the well 
established polyclonal anti-oligomer PAb A11 (Kayed et al., 2003), and with the SPLINT 
selected scFvs.  
In the above-discussed cellular bioassays it is likely that the neuroprotective actions of 
scFvs A1 and A13 are related to their ability to target pathological assembled species, 
through the recognition of specific conformational epitopes. 
ScFv A1 and A13 are significantly able to neutralize the toxicity induced by externally 
administered ADDLs. We have observed that scFvs A1 and A13, used at concentrations 
largely sub-stoichiometric (with respect to the concentrations of total Aβ), similarly to the 
conformational-specific polyclonal antibody PAb A11 (Ma et al. 2006), could be able to 
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neutralize the Aβ oligomers-induced toxicity, suggesting for these antibodies shared 
mechanisms. 
In addition, it is likely that, in the above-described model of amyloidogenesis in PC12 
cells, the ability of scFv A13 to block Aβ aggregation and cell death could be related to 
the specific targeting of spontaneously misfolded and early endogenously produced Aβ 
peptide. 
 
 
3. IACT selection from SPLINT libraries: might Aβ-bait determine 
conformation specificity of selected scFvs? 
The success of the selection campaign in isolating a large number of scFv fragments with 
biased specificity for Aβ oligomers was largely unanticipated. The high proportion of 
conformation-specific anti-Aβ isolated leads to postulate that the Aβ bait itself might be 
the basis for the high enrichment of anti-Aβ oligomers in the selected panel of scFv. If so, 
how could the Aβ bait have influenced and biased the downstream antibody selection 
process? 
 
3.1 Experimental reports supporting Aβ folding and aggregation in yeast 
cells 
Different studies have demonstrated that Aβ bait and Aβ prey can interact in two hybrid 
system (Hughes 1998). It has been demonstrated also that this ability to interact is related 
to crucial residues (Festy et al 2001) related to the structure of Aβ. So, it has been 
supposed that Aβ can aggregate with specifically structured scaffold in yeast two hybrid 
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system. Moreover, aggregation for prion endogenous proteins and for other aggregating 
protein ectopically expressed (synuclein, huntigtin) has been very well demonstrated in 
yeast cell cytoplasm and mediated by specific chaperone proteins. Recently also the 
modulation of Aβ oligomerization in yeast cytoplasm have been related to the activity of 
chaperone proteins (Bagriantsev and Liebman, 2006) 
 
3.1a Beta-amyloid in two-hybrid system 
Two-hybrid system as a model to study the interaction of β-amyloid peptide monomers 
was explored for the first time by Hughes and coworkers (Hughes et al., 1996). 
Afterwards, several interactors of Aβ were successfully found through two-hybrid system  
(Yan et al., 1997; Hughes et al., 1998). Moreover, Festy and coworkers (2001) showed 
that Aβ-Aβ interactions in two-hybrid can be disrupted by several mutations in the Aβ 
sequence.  
All these studies were preparatory to our approach of IACT selection, providing the 
rationale feasibility basis for the aim of using the Aβ bait to select for anti-Aβ 
oligomeric-specific antibodies. The results of planned experiments were successful 
beyond expectations. At the same time, they supported the hypotheses of a 
conformational structure of the Aβ bait. 
The first finding that mutations in Aβ sequence (F19 F20 > T19 T20) compromise Aβ-Aβ 
interactions (Hughes et al. 1996) were consistent with in vitro observations made by 
others: in fact, previously reported data showed that a well preserved hydrophobic core 
around aminoacids 17–24 was important for the formation of β-sheet structure and 
amyloid properties (Hilbich et al., 1992). 
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Interestingly, Festy and coworkers (2001) designed by molecular modeling and tested by 
the two-hybrid approach, series of mutations spread all over the sequence of Aβ1-42 and 
changing the distribution of hydrophobicity and/or the spatial hindrance. By molecular 
design consistently with experimental models, the sequence of the amyloid peptide can 
be split into four clusters, two hydrophilic (1-16 and 22-28) and two hydrophobic (17-21 
and 29-42). Screening of mutations demonstrated that the C-domain (residues 29-40 
(42)), the median domain (residues 17-22) and the N-domain (1-16) are all crucial for 
interaction. This demonstrated that almost all fragments of the amyloid peptide except an 
intermediate loop (residues 23-28) are important for the native interaction. The native 
fold of Aβ could be stabilized in Aβ–Aβ complexes. It is likely that the secondary 
structure of Aβ (probably β-sheet) showing a high susceptibility to mutations, should 
have a low stability; thus, the formation of tertiary structures (Aβ-Aβ complexes) could 
be strongly favored.  
 
These data supported a conformational hypothesis of Aβ in vivo, in the two-hybrid format 
in the yeast nucleus, even though Aβ is the C-terminal fragment of the larger fusion 
protein LexA-Aβ bait.  
  
3.1b Beta-amyloid oligomerization in yeast cells 
Recently, Bagriantsev and Liebman (2006) described a new yeast model system focused 
on the initial stages of Aβ42 oligomerization, not related to the two-hybrid system. They 
exploited as reporter protein, the yeast translational termination factor Sup35p; this is 
also a protein that can form self-propagating infectious amyloid aggregates, arising 
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spontaneously in the cell, and manifest a prion phenotype referred to as [PSI+] (Glover et 
al., 1997). The N-terminal part of Sup35p is responsible for the aggregation, and was 
substituted by Aβ42 from the authors in the functional fusion protein AβMRF, that 
maintain the C-terminal RF (release factor) functional domain, performing translation 
termination. The easily scored activity of Sup35p's MRF domain was impaired in 
AβMRF fusions because the Aβ42 causes the fusion to form SDSstable low-n oligomers 
(dimers, trimers, tetramers), similarly to the wild type Sup35p. Using this model system, 
they found that oligomerization of the fusion protein is stimulated by millimolar 
concentrations of the yeast prion curing agent guanidine. Surprisingly, deletion of the 
chaperone Hsp104 (a known target for guanidine) inhibited oligomerization of the fusion 
protein. Furthermore, they demonstrated that Hsp104 interacts with the Aβ42-fusion 
protein and appears to protect it from disaggregation and degradation. 
 
This experimental approach gives three relevant considerations: 
− Aβ42-fusion proteins can oligomerize in the yeast cytoplasm; 
− the chaperone machinery of yeast cell can participate also in the oligomerization 
process of Aβ42-MRF; 
− oligomerization of Aβ42-MRF can be chemically modulated (by guanidine) 
exactly as for yeast ‘natural’ prions. 
 
These general conclusions from an experimental system, distinct from, but related to the 
IACT system, used in this thesis, provide an additional framework to interpret and 
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discuss the success of our approach in generating a high proportion of anti-Aβ oligomers 
scFvs antibody fragments. 
 
3.2 Beta-Amyloid in IACT system 
On the basis of the experimental reports discussed before, regarding the use of Aβ bait in 
two hybrid system and the oligomerization of Aβ in yeast cells, it is likely that also in 
IACT system, Aβ42 bait is conformationally structured and/or oligomeric.  
Regarding the mechanisms of oligomerization we can postulate two hypotheses not 
mutually exclusive: 
• a mechanism of Aβ oligomerization favoured by Aβ itself and/or chaperone-
mediated in the yeast cytoplasm and/or nucleus; 
• a mechanism of Aβ oligomerization favoured in the L40 yeast nucleus by the 
multiple LexA binding operators, hypothesizing interactions between adjacent 
LexA-Aβ fusion proteins. 
 
3.2a Is Aβ bait conformationally structured? 
In IACT system, similarly to the above described two hybrid systems, Aβ is expressed as 
a C-terminal fusion of LexA DNA binding domain.  
On the basis of “In Vivo Epitope Mapping” (IVEM) results, we suggested that, for 
conformational reasons, some epitopes of the Aβ bait are not easily accessible. 
Consequently, during the SPLINT selection of anti-Aβ scFvs, there is an enrichment of 
epitope-specific scFvs for the C-terminus and the N-terminus of Aβ42, epitopes that 
should be more exposed. In particular, the N-terminus is preferentially recognized by 
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scFvs selected from the immune library, a biased repertoire of recombinant antibodies 
enriched in N-terminal binders. It is likely that the central part (a.a. 10-28) of the Aβ bait 
used in the IACT system could be “hidden”, and difficultly recognized by the SPLINT-
selected scFvs. These observations could be indirect evidences for the Aβ folding in yeast 
nucleus. 
By the IVEM approach, we studied the interactions of scFvs selected against Aβ42, with 
other Aβ baits (both human and murine) that are deletion mutants of the whole Aβ: Aβ40, 
Aβ28, Aβ17, Aβ10.  
Essentially, a large part of scFvs selected against Aβ42 from the naïve SPLINT library 
and a smaller part of scFvs selected against Aβ42 from the SPLINT immune library, can 
recognize only Aβ42 or Aβ40. We called these scFvs “C-terminal-specific” but they 
could potentially recognize conformational epitopes not displayed by the shorter deletion 
mutants of Aβ. On the contrary, scFvs recognizing Aβ10, recognize the N-terminal 
epitope in all the deletion mutants of Aβ baits.  
Several structural models suggest that the N-terminus of Aβ, especially the region 1-10, 
is unstructured (Petkova et al., 2002). On the other hand, the N-terminal part of Aβ seems 
to play a role in the aggregation of Aβ42 peptides (also reported in the above-mentioned 
two hybrid system (Festy al al., 2001)) and a recent experimental report showed that, by 
using antibodies raised against Aβ1-15, the N-terminus of Aβ plays a conformation-
specific role in the preferential recognition of Aβ42 oligomers and fibrils, but not of 
Aβ42 monomers (Moretto et al., 2007). The ELISA results discussed in this thesis 
confirmed that the conformation-specificity versus Aβ oligomers is a common behaviour 
of anti-Aβ scFvs SPLINT-selected, not related to the epitope-specificity. On the basis of 
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these results, it is likely that the fusion with LexA favours structural conformations of the 
N-terminus of Aβ. 
 
Finally, the scFvs described in this thesis were originally selected against the human 
Aβ42 bait; however, they cannot distinguish between human and murine baits in vivo (by 
IVEM), in spite of the in vitro ELISA results that showed their ability to discriminate 
significantly from human and murine ADDLs. This could indicate that the folding in vivo 
is different from the folding in vitro, as well as the exposure of particular conformational 
epitopes. 
 
 
3.2b Aβ bait oligomerization 
The oligomerization of Aβ-bait in yeast is a fascinating hypothesis that could explain the 
specificity and the preferential binding of IACT-selected anti-Aβ scFvs to Aβ oligomers, 
obtained in different in vitro assays. In the opposite scenario, in absence of bait 
aggregation, scFvs could be selected against structural epitopes (see above) that in vitro 
could be favourably exposed in oligomeric assemblies. 
Some data, discussed above, support the Aβ bait oligomerization hypothesis: 
− Aβ fusion proteins can oligomerize in the yeast cytoplasm (Bagriantsev, 
2006); 
− Aβ bait and Aβ prey can interact in vivo in the yeast nucleus (Hughes et al., 
1996; Festy et al., 2001). 
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In addition, we have obtained one preliminary experimental evidence in favour of the 
Aβ42 bait oligomerization. Protein extracts from L40 yeast expressing the Aβ42 bait, 
analyzed by Western Blot in NuPAGE show a laddered pattern of immunoreactive 
species positive to the anti-Aβ MAb 4G8. As indicated in the figure 1 the pattern could 
be in accordance with the dimerization (band at 58 kDa) or the multimerization of the 
LexA-Aβ bait (fig.1) 
 
 
 
Fig.1 Western Blot analysis of protein extracts from L40yeast expressing the LexA-Aβ42 
bait, analyzed by in NuPAGE: samples not reduced and not boiled. Note not only the 
monomeric form of the fusion protein but also the dimeric form and other specific high 
molecular weight aggregates, that are probably oligomers. WB: anti-Aβ MAb 4G8  
 
As discussed above, two general hypotheses, probably not mutually exclusive, can 
explain the mechanisms triggering Aβ42 bait oligomerization: i) a mechanism favoured 
by Aβ itself and/or chaperone-mediated in the yeast cytoplasm and/or nucleus; ii) a 
mechanism favoured by the multiple LexA binding operators, in the L40 yeast nucleus. 
Regarding the first hypothesis, in yeast cell, Aβ-Aβ interaction could happen both in the 
cytoplasm and/or in the nucleus.  
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If LexA-Aβ oligomers are assembled in the cytoplasm, the nuclear pores could act as a 
‘filters’ for high molecular weight aggregates, when the fusion proteins are translocated 
into the nucleus.  
However, we cannot exclude that Aβ oligomers in vivo produced in the yeast nucleus 
and/or cytoplasm could be also assembled with yeast endogenous proteins and with 
cleavage products of LexA-Aβ bait (normally, LexA repressor undergoes a self-cleavage 
reaction (Luo et al., 2001)). 
The second general hypothesis could suggest that Aβ-Aβ interactions are favored by 
LexA operators in the L40 yeast nucleus.  
LexA protein as binder of DNA operator box is a dimer, as well as observed for other 
regulative proteins in different operator systems (Mohana-Borges et al, 2000). The 
structure of LexA dimer could be per se not sufficiently explanatory of the dimerization 
of Aβ, for structural reasons related to the molecular distances of the two C-terminals in 
models of LexA dimers (Aβ is a C-terminal fusion of LexA). However, we may 
hypothesize that Aβ fusions of different, but adjacent, dimers of LexA could interact and 
aggregate. Reporter genes in L40 are under control of multiple LexA binding operators 
(4LexA operator control His3, 8LexA operator control LacZ), and interactions between 
adjacent LexA might be possible (see fig.2).  
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Fig.2 Model of LexA dimer bound to DNA operator (lexAop) (top left), and ‘linear’ 
model of oligomerization in the yeast nucleus (bottom right). 
In the grey box: genotype of L40 yeast strain; in bold the different LexAop, functioning 
as upstream activation sequence (UAS) of the repoter genes (HIS3 and lacZ). 
 
The formation of oligomers of Aβ bait fusion proteins in vivo, is a fascinating hypothesis 
supporting a direct role of the bait in biasing the selection of conformationally oligomeric 
specific scFvs from naïve and immune SPLINT libraries. Different scFvs could interact 
with specific pattern of Aβ oligomeric baits, binding their different epitopes in the 
nucleus or in the cytoplasm, and determining different phenotypic IACT selections. 
Several experimental data are in accordance with Aβ oligomerization:  
1. Some observations supporting the conformation structure of Aβ bait are in 
agreement with Aβ oligomerization, as preferential epitope recognition by scFvs. 
It is likely that the N-terminus and the C-terminus of Aβ are more exposed in the 
oligomeric forms of Aβ baits; 
2. Oligomeric conformations of the Aβ42 bait could determine in the IACT system a 
difficult assembly of functional transcription machinery. As commented in the 
IVEM section, β-structured and probably aggregated Aβ, interacting with the C-
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terminal specific scFvs, could interfere with the assembly of functional 
transcription machinery. On the contrary, the N-terminal specific scFvs, 
interacting with epitopes of Aβ baits not showing steric hindrance problems, 
could favour activation of reporter genes and give healthy phenotype in yeast 
cells; 
3. Finally, in IACT-based SPLINT selections using Aβ-bait, the observed 
differential activation of the two reporter gene systems HIS3 and lacZ can be 
explained by another mechanism. The Aβ bait could show a different degree of 
oligomerization onto the two multi-binding sites operators that control the 
reporter genes (4 LexA operators for HIS3 gene and 8 LexA operators for LacZ 
gene, respectively), determining differential interaction and reporter gene 
activation. For instance, the scFv Im8 shows high specificity for the HIS3 reporter 
gene activation assay but shows a weak activation of the lacZ gene. A large 
number of scFvs show a similar behaviour in the secondary screening. Normally, 
in IACT screenings, these clones are excluded because HIS3 reporter gene is 
leaky in comparison to LacZ, but the case of Aβ bait could be particular in the 
light of the above-mentioned hypothesis.  
 
In conclusion, the preliminary results of Aβ42 bait yeast extracts and the experimental 
observations obtained from IACT screenings of the SPLINT selected anti-Aβ scFvs, 
together with the experimental reports of other authors in related yeast systems (Hughes 
et al., 1996; Festy et al., 2001; Bagriantsev, 2006) support the hypothesis of Aβ bait 
oligomerization in yeast using the IACT system. 
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The conformation of Aβ bait and its probable oligomeric nature in vivo (in yeast) might 
determine the unique characteristic of the selection strategy used for the isolation of 
scFvs under study. Therefore, the IACT strategy appears to be particularly suitable for 
the selection of oligomeric specific anti-Aβ antibodies, as demonstrated by the a priori 
unexpected large number of conformation-specific scFvs SPLINT-selected. 
 
4. Future perspectives 
Conformation specific scFvs anti-Aβ, developed in the experimental work described in 
this PhD thesis, show relevant features to several kinds of in vitro cell biology studies as 
well as to the in vivo therapeutic use. 
In the present state of knowledge we propose to exploit our unique experimental tool and 
strategy (intrabodies) to gain a better understanding of basic Aβ oligomerization in AD 
pathogenesis and, on this basis, to develop novel therapeutic approaches.  
1) The use of anti-Aβ scFvs as new tool of study: intrabodies 
The intracellular expression of antibodies for spatio-temporal interference with 
pathological protein function has been pioneered and developed by our group (Cattaneo 
& Biocca, 1997, Visintin et al, 1999, 2002).  
Using the selected anti-Aβ scFvs, we propose a fine and precise dissection of the 
intracellular formation and trafficking of Aβ, in particular of Aβ oligomers, exploiting 
also the engineering of scFvs intrabodies for synaptic targeting and neurosecretion.  
In these studies, scFvs can act as specific functional knock-out tools, both intracellularly 
and extracellularly, if secreted. The effects of this functional knock-out, especially if 
oligomeric-specific, could be evaluated at different levels:  
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 • modulation of neuronal survival; 
 • modulation of synaptic activity and plasticity; 
 • modulation of gene expression and protein synthesis/modifications of specific 
targets synaptic  
2) The use of scFvs as new “therapeutics” in animal models. 
We propose different routes for the pharmacological delivery of scFvs anti-Aβ to central 
nervous system. 
The first is the passive immunization through peripheral or intranasal administration of 
scFvs purified proteins. The latter could be supported by the positive experience in our 
group obtained with the nasal delivery of NGF in the CNS of AD11 mice (Capsoni et al, 
2002; De Rosa et al, 2005).  
The second is represented by the exploitation (especially by intranasal administration) of 
new systems of delivery, using viral vectors or engineered cells secreting the anti-Aβ 
scFvs; these systems can deliver quantifiable amounts of scFv protein directly to central 
nervous system (CNS), modulating synaptotoxicity of Aβ oligomers.  
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Supplemented figures 
 
 
 
Supplemented figure1. CLUSTAL W multiple alignment of 6 scFvs immune and 9 scFvs naïve; variable regions VL and 
VH are highlighted in blue and yellow respectively, CDRs are boxed in red.
 scFv Im1  scFv Im3  scFv Im47
  scFv A13   scFv A18   scFv B2
Supplemented figure2.
Immunofluorescence microscopy of the anti-Aβ scFv fragments transiently transfected in 3T3 
cells. scFvs cloned in the vector scFv-excytoV5 were expressed in the cell cytoplasm. Cells were 
reacted with the anti-V5 tag monoclonal antibody, followed by incubation with an anti-mouse 
AlexaFluor488.
Some scFvs, such as Im1, Im47, Im3 show a diffuse expected intracellular staining, typical of 
soluble cytoplasmic proteins, but others (A13, A18, B2) display the accumulation of the 
intracellular scFv in a puntiform or 'donut-like' pattern distribution.
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Supplemented figure 3. Immunohystochemistry of temporal cortex sections (40µm) prepared 
from severe Alzheimer’s (Braak V-VI) and control (Braak 0-I) brains; the anti-Aβ scFvA1 and 
mAb 4G8 were used as primary antibodies. Sections were not pre-treated with formic acid.
ScFvA1 shows high cellular reactivity (panel B); pericellular and extracellular deposits 
detected by scFvA1 (panel B) are different from Aβ plaques detected by mAb 4G8 (panel A). 
The diffuse staining of scFvA1 could suggest a recognition of soluble non-fibrillar Aβ 
oligomers.   
Scale bar 20µm in magnifications 20x, 50 µm in magnif. 10x, 100µm in magnif. 5x.  
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Supplemented figure 4. Immunofluorescence of temporal cortex sections (40µm) prepared from 
severe Alzheimer’s (Braak V-VI)  brains; the anti-Aβ scFvA1, mAb 6E10 and pAb anti-Aβ42 were 
used as primary antibodies. Sections were pre-treated with formic acid (90%).
Panel A. scFv A1 shows intense cellular reactivity in plaque-rich areas, and interestingly a partial 
complementary staining of plaques in comparison to anti-Aβ MAbs 6E10. We postulate that 
scFvA1 might be specific for the early stage of amyloid maturation: the figure shows no core 
staining of scFvA1 in the upper plaque. 
Panel B. scFvA1 often detects pericellular diffuse immunoreactivity (indicated by the arrow), not 
detected by classic Abs anti-Aβ. 
Panel C. scFvA1 can specifically recognize blood vessels with Amyloid deposits, especially in 
plaques rich areas in the brain from one AD patient showing greater signs of Cerebral Amyloid 
Angiopathy (CAA).  
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Supplemented Figure 5. Prevalent cellular reactivity of scFvA13 in plaques rich areas
of temporal cortex sections (40µm) prepared from human AD brains.  
Supplemented Figure 6. Specific vascular reactivity of scFvA18 in plaques rich areas
of temporal cortex sections (40µm) prepared from human AD brains. 
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Scale bar 10µm, magnif.40X 
Supplemented figure 7. ScFv B2 presents mostly strong cellular reactivity (similar to astrocytes), 
tightly related to plaques (panel A). Probably, B2 detect also dystrophic neurites (panel B). ScFvB2 
can detect also specifically blood vessel deposits, near Aβ plaques detected by other Abs (panel C). 
Temporal cortex sections (40µm) prepared from human AD brains. 
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Supplemented figure 8. ScFv Im8 (panel A and B) detects specific small dotted clusters of mainly 
pericellular immunoreactive deposits, spatially distinct and separate from small plaque-like 
depositions (stained with Aβ42 C-terminal specific pAb). Im8 shows also secondary cellular and 
dystrophic neurites reactivity (panel C). Temporal cortex sections (40µm) prepared from human 
AD brains.
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ScFv Im18 (red), pAb antiAβ (green),
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Supplemented figure 9. ScFv Im18 (panel A) shows specific pericellular reactivity near large 
plaques partially distinct and separate from them. In other fields of slice, Im18 (panel B) similarly 
to Im32 (panel C) detects cellular reactivity spatially related to Aβ42 plaques. Temporal cortex 
sections (40µm) prepared from human AD brains.
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Supplemented figure 10. The immunoreactive pattern of Im47 shows stronger cellular reactivity 
(probably astrocytes) in smaller plaques zones (panel A), and distinct pericellular reactivity near 
large plaques (panel B). Pericellular reactivity of Im47 is often specifically dotted, resembling 
oligomeric-specific staining of pAb A11 (see below suppl. Fig.11). Temporal cortex sections (40µm) 
prepared from human AD brains.
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Supplemented figure 11. Pericellular reactivity of the oligomeric-specific pAb A11 (Kayed et al., 
2003). TCounter-staining of nuclei with DAPI. emporal cortex sections (40µm) prepared from 
human AD brains. Scale bar 10µm, magnification 40X.  
RED channel = ADDLs GREEN channel = PSD-95
Supplemented figure 12. Synthetic ADDLs bind neurons with punctate specificity. 
Primary rat hippocampal neurons treated with ADDLs (300nM) were double immunolabeled 
for ADDLs (red), using the anti-oligomer PAb A11, and for PSD-95 (green) using a mAb anti-
PSD95. Dendritic clusters of ADDL-immunoreactive puncta colocalized partially with PSD-
95. Comparing areas of similar density of PSD-95 positive spots, focusing mainly on 
dendrites, we performed a qualitative analysis of A11-positive spots density.
Scale bar 5µm.
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Supplemented figure 13. ADDLs synaptic binding can be modulated by the SPLINT-selected 
anti-Aβ scFvs A1 and A13. 
300nM of ADDLs alone (panel A), or  preincubated with 600nM of anti-Aβ scFvs (panel B and 
C), were administered to primary rat hyppocampal neurons. 
Our qualitative analysis confirms that ADDLs synaptic binding (punctate pattern showed in the 
middle boxes of the panels A, B and C) can be significantly reduced by the pre-incubation with 
scFv A1 (panel B) or with scFv A13 (panel C). 
Two representative fields per treatment are showed. The double immunolabeling for ADDLs 
(red) and for PSD-95 (green) was obtained using respectively the anti-oligomer PAb A11 and a 
mAb anti-PSD95. 
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